













































































Current and future challenges

INSIGHTS




Linda Montanari, Luis Royuela, Ines Hasselberg  
and Liesbeth Vandam
Current and future challenges
I Legal notice
This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. 
The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained 
in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s 
partners, any EU Member State or any agency or institution of the European Union.
Luxembourg: Publications Office of the European Union, 2021
Print ISBN 978-92-9497-590-4 ISSN 1606-1683 doi:10.2810/00706 TD-XD-21-001-EN-C 
PDF ISBN 978-92-9497-591-1 ISSN 2314-9264 doi:10.2810/587522 TD-XD-21-001-EN-N
© European Monitoring Centre for Drugs and Drug Addiction, 2021 
Reproduction is authorised provided the source is acknowledged.
For any use or reproduction of photos that are not under EMCDDA copyright, permission must be sought directly from 
the copyright holders.
Recommended citation: European Monitoring Centre for Drugs and Drug Addiction (2021), Prison and drugs in 
Europe: current and future challenges, Publications Office of the European Union, Luxembourg.
Printed by Bietlot in Belgium
PRINTED ON ELEMENTAL CHLORINE-FREE BLEACHED PAPER (ECF)
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
Tel. (351) 211 21 02 00 I info@emcdda.europa.eu 
emcdda.europa.eu I twitter.com/emcdda I facebook.com/emcdda
 5  Foreword
 7  Executive summary
 11  Acknowledgements
 13  CHAPTER 1
An introduction to prison and drugs in Europe
Liesbeth Vandam, Linda Montanari, Ines Hasselberg,  
Luis Royuela, Paul Turnbull and Paul Griffiths
 21  CHAPTER 2
Drug use before, during and after imprisonment
Luis Royuela, Linda Montanari, Ines Hasselberg, Viktor Mravčík, Liesbeth Vandam and  
Wayne Hall
 33  CHAPTER 3
Drug-related health problems of people in prison
Linda Montanari, Luis Royuela, Ines Hasselberg, Liesbeth Vandam and Wayne Hall
 47  CHAPTER 4
Health and social responses to drug problems in prison
Linda Montanari, Anna Tarján, Ines Hasselberg, Lara Tavoschi, Wayne Hall,  
Brendan Hughes, Liesbeth Vandam, Amber Vernooij and Heino Stöver
 69  CHAPTER 5
A focus on harm reduction interventions in prison
Linda Montanari, Anna Tarján, Ines Hasselberg, Wayne Hall, Liesbeth Vandam,  
Amber Vernooij and Heino Stöver
 79  CHAPTER 6
Available evidence and good practice addressing drug use and related harms in  
prison settings
Lara Tavoschi, Linda Montanari and Dagmar Hedrich
 99  CHAPTER 7
Supply of drugs in prison
Paul Turnbull, Linda Montanari, Luis Royuela, Brendan Hughes and Liesbeth Vandam
 111  CHAPTER 8
Current insights and future challenges
Ines Hasselberg, Linda Montanari, Liesbeth Vandam, Luis Royuela, Paul Turnbull and  
Jane Mounteney
 119  Abbreviations




It is my great pleasure to introduce this new European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) publication, Prison and Drugs in Europe, which presents a 
comprehensive overview of the field. It explores in depth issues ranging across drug use 
and drug-related problems among the prison population, the available social and health 
service responses to drug-related problems in prison, including the most recent evidence of 
effectiveness, and the drug supply and markets inside prison. It also discusses recent and 
future challenges in the prison and drugs field.
Prison and the drugs phenomenon are intertwined in complex ways. We know that people 
who are in prison, or have been imprisoned, are more likely to use or have used drugs and 
to experience drug-related problems. We also know that once in prison their drug-using 
behaviour is likely to change. In order to adequately and efficiently respond to their health 
and social needs it is vital to have a good understanding of the patterns and prevalence 
of drug use among the prison population, and their consequences, and to know which 
responses and interventions work best in prison settings and which are actually available in 
European countries. This is particularly important when we consider that it is in prison that 
many people who use drugs access social and health services for the first time. Addressing 
drug supply and distribution is also a major challenge for prison services, particularly so 
with the recent spread of new psychoactive substances in prison and the creative use of 
new technologies to transport illicit substances into these settings.
The EMCDDA has been monitoring the drug situation for the last 25 years, and the field of 
drugs and prison is a central component of the work we carry out. We anticipate that this 
report will provide an important and much-needed basis for supporting the development 
and implementation of national policy and practical interventions, in addition to stimulating 
research activities at the European level.
The importance of the prison setting for tackling drug problems is underlined in the new 
EU drugs strategy 2021-2025 and its action plan, which includes a strategic priority aimed 
at addressing the health and social needs of people who use drugs in prison settings and 
after release. The principles of equivalence and continuity of healthcare provision in prison 
are central in these documents. The key role of drug-related services for people in prison 
with drug problems is also in line with United Nations (UN) Sustainable Developmental 
Goal (SDG) 10 to reduce inequality and with UN SDG 3 to ensure healthy lives and promote 
well-being for all at all ages.
To be useful for policy and practice, information needs to be technically robust and timely. 
It is to this end that the EMCDDA has developed a methodological framework to monitor 
drugs and prison, including monitoring tools such as the European questionnaire on drug 
use among people in prison. These efforts aim to harmonise data collection in Europe, to 
support the exchange of best practice and lessons learnt, to strengthen drug monitoring 
and to support European countries in their responses to current and future challenges. 
Importantly, this publication has only been possible with contributions from a range of 
partners and experts, to whom we are indebted, including members of the Reitox network 
of national focal points and the EMCDDA Scientific Committee, international prison experts, 
prison professionals and people with lived experience as well as scientific colleagues at the 
EMCDDA.
In a nutshell, we hope that, by highlighting the contemporary opportunities and challenges 
associated with responding to the complex world that constitutes drugs and prison at this 
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time, this study will represent an important step towards providing better care for the many 
people that experience both drug problems and imprisonment and the communities they 
return to and, ultimately, will contribute to a healthier and safer Europe for all. In this spirit I 






On any given day, around 856 000 people are in prison in Europe. People in prison are 
substantially more likely to have used drugs, to use drugs regularly and to experience 
drug-related problems than their peers in the community. This is so, although there are 
significant differences between countries, and it is especially marked in the case of women. 
Yet, available data on the prevalence of drug use among people in prison, on people’s need 
for addiction care services, on the availability of such services in prison and on the drug 
supply to prisons remain scarce, and many challenges remain with regard to harmonisation 
and comparability between countries, despite some progress being made in recent years. 
A better understanding of these issues is necessary to inform policy decisions, needs 
assessment, service planning and drug treatment organisation in prison.
This European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Insights report 
provides a comprehensive overview of the current knowledge and latest developments 
in the field of drug use and prison in the 30 countries reporting to the EMCDDA up to the 
end of 2020: the 27 EU Member States, Norway, Turkey and the United Kingdom. It also 
identifies important gaps in our knowledge, challenges for better provision of interventions 
and implications for policy and practice. The report provides an overview of the current 
situation in the field of drugs and prison in the following areas: drug use and drug-related 
problems among the prison population; the availability of drug-related services in prison; 
the evidence available for effective interventions in the prison setting; drug supply and 
supply reduction interventions; and future challenges relating to prison and drugs.
I Key findings
People in prison report high levels of lifetime prevalence of substance use before 
imprisonment and increased levels of consumption, especially of heroin, cocaine and 
amphetamines, compared with the general population. Although many people will 
stop injecting drugs when they enter prison, for those that continue, the use and reuse 
of contaminated equipment is not uncommon, contributing to an increased risk of 
transmission of infectious diseases in these settings.
The lifetime prevalence of substance use before and during imprisonment varies by 
country and is influenced by differences in prison organisation, drug policy and drug use 
prevalence in the community, as well as differences in survey methodology. Women in 
prison are reported to be particularly vulnerable and at risk of problematic drug use. 
A particular challenge in recent years has been the increasing use of new psychoactive 
substances in prison, particularly synthetic cannabinoids. The initial undetectability of 
these substances in routine urine testing is thought to be a main contributing factor.
People in prison have poorer physical and mental health and social well-being than their 
peers in the community and a lower life expectancy. They also have higher rates of 
infection of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and tuberculosis. Mortality 
among people with prison experience is higher than that in the general population, due to 
several risk factors in this population, including drug use and injecting drug use. For those 
injecting opioids, the risk of dying from a drug overdose increases markedly in the initial 
period after release.
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Many drug demand reduction interventions that have been demonstrated to be effective 
in the community have been implemented in prisons in Europe, often following some 
delay and with insufficient coverage, including assessment of drug use; drug information 
provision and drug prevention; pharmacological treatment, including opioid substitution 
treatment (OST); psychosocial interventions; interventions targeting drug-related infectious 
diseases; and preparation for release and social reintegration. OST in prison is available in 
Norway, Turkey, the United Kingdom and all EU Member States except Slovakia, yet in most 
European countries coverage in prison remains low.
Interventions available in prison to prevent and control infectious diseases include testing, 
HBV vaccination, treatment of HIV and hepatitis C, and education on infection risk and 
prevention. However, access to testing and treatment remains low. Other harm reduction 
interventions with proven effectiveness in the community, including needle and syringe 
programmes, condom distribution programmes and safe tattooing programmes, are 
available in only a few prisons in Europe. Interventions preparing people for release from 
prison include social interventions, referral to external services and overdose prevention 
strategies; only a limited number of countries provide naloxone to those leaving prison.
Diverting offenders with problem drug use towards rehabilitative measures and away from 
incarceration may have a number of positive effects such as preventing the damaging 
effects of detention and contributing to reducing the costs of the prison system (e.g. 
infrastructure, staff, etc.). Alternatives to prison are available in some countries in Europe, 
although approaches to diversion vary considerably and overall availability remains limited.
There is limited research on health- and drug-related interventions in prison and the 
effectiveness of some interventions is not yet clear. While the body of evidence may be 
reasonably well developed in community settings, and analogies could be made, the 
specificities of the prison environment need to be taken into account in future studies.
The prison and the community connect and intersect as people move between one and the 
other, and this is particularly so in the case of people with drug-related problems. Providing 
continuity of care as people move between prison and the community is key to achieving 
sustainable and effective treatment outcomes, and it is likely to have a significant impact on 
public health.
Compared with the early 2000s, the availability and levels of provision of health and social 
care services targeting the needs of people who use drugs in prison have improved in 
several European countries; yet, for the most part, people in prison are faced with a limited 
range of treatment options, and equity and continuity of care remain unachieved principles 
in the majority of countries in Europe. The World Health Organization recommends that 
health ministries provide and be accountable for healthcare services in prisons and that the 
management and coordination of all relevant agencies and resources contributing to the 
health and well-being of people in prison be a whole-of-government responsibility, where 
prison health services and professionals are fully independent of prison administrations 
and yet liaise effectively with them.
Health and social service responses in prison may have a significant public health impact 
on morbidity and mortality, not only for people in prison but also for the community as 
a whole. Engaging people with drug-related problems in treatment while in prison may 
reduce their drug use, their risk behaviours (including the risk of contracting infectious 
diseases) and the risk of overdose upon release.
Drug-related problems are just one of many vulnerabilities experienced by people who 
spend some part of their lives in prison. Social marginalisation and inequality are important 
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risk factors for both drug use and offending behaviour, requiring integrated multiagency 
approaches that address drug use and drug-related problems along with other important 
health and social problems.
Improving the evidence base on health interventions in prison (including their impact on 
public health) and on the needs of people in prison with drug-related problems (including 
women, lesbian, gay, bisexual and transgender people, and foreign nationals) is necessary 
to inform needs assessment, service planning and treatment organisation. It also provides 
useful information on the people with drug-related problems in the wider community.
There is a high demand for drugs in prison settings, and people in prison, their friends 
and families, and those working in prisons, as well as organised criminal groups, may 
be involved in facilitating drug supply to prisons. Routes of supply and mechanisms of 
distribution in prison are adapted to the particular circumstances of each prison and flexible 
enough to be adjusted to make use of new technologies (e.g. drones) or to overcome new 
challenges, such as increasing security measures and attempts by prison authorities to 
deter drug use. Although a variety of security measures have been implemented to prevent 
drugs from entering the prison environment, there is limited information about the impact 
of these measures.
In conclusion, while the evidence base is gradually increasing, more studies are needed 
on the outcomes of interventions targeting demand as well as supply reduction in prison 
settings. It is also important that data are comparable across countries in order to support 
regional drug monitoring, facilitate the exchange of best practice and lessons learnt, and 
assist in the development of responses that meet current and future European challenges 
in this field.
I Overview of the chapters
This publication is divided into eight chapters, which together present the reader with 
a comprehensive and in-depth analysis of prison and drugs in Europe.
Chapter 1 provides an introduction to the area of drugs and prison in Europe, including 
a description of the data sources and the regional and international initiatives around prison 
and drugs.
Chapter 2 presents epidemiological data on the drug consumption behaviours and 
patterns among people in prison in Europe. It discusses the drug and prison nexus by 
looking at prevalence data before, during and after imprisonment. The chapter unpacks the 
interconnections between drugs, drug use and prison.
Chapter 3 focuses on the general health of people who are in prison and use or have used 
drugs. Particular attention is paid to infectious diseases and psychiatric comorbidity. The 
mortality of people who use drugs in prison is also addressed, both during imprisonment 
and in the period following release. The chapter also discusses the healthcare needs of 
women with drug problems who are in prison.
Chapter 4 maps the organisation and implementation of interventions in European prisons, 
starting with a description of the main principles guiding the provision of interventions and 
policy objectives indicated in current policy strategies. It provides an overview of different 
policy and institutional frameworks for prison health and outlines the availability and 
coverage of drug treatment interventions.
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Chapter 5 focuses on harm reduction interventions in European prisons, providing 
a summary of available interventions, both directly and indirectly related to drug problems, 
in European countries.
Chapter 6 discusses the evidence for the effectiveness of drug-related interventions 
in prison and identifies the main knowledge gaps. The chapter also discusses the 
fundamental principles of healthcare provision in prison and details EU strategies 
addressing drugs and prison.
Chapter 7 focuses on the supply of drugs in prison settings. Prisons present a unique set 
of circumstances and challenges for those involved in drug markets and those trying to 
prevent drug supply. The chapter considers the main routes and methods of supplying illicit 
drugs and mechanisms of distribution inside prison and discusses the main measures 
implemented in prison to tackle them, with a particular focus on the use of drug testing.
Chapter 8 brings together key issues raised in the previous chapters with a view to 
discussing current and future challenges in the field. The main insights are presented under 
four themes: social vulnerabilities, the connection between prison and the community, 
the balance between care and control, and alternatives to imprisonment. Important 
implications for both policy and practice are outlined.
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Compared with the general population, people in prison 
report higher rates of drug use and drug-related problems. 
And people with problematic drug use have higher rates of 
offending, often linked to their drug use, and an increased 
likelihood of spending part of their lives in prison, frequently 
experiencing recurrent short periods of imprisonment. 
Drugs and crime, however, are interlinked in a complex 
nexus that is neither simple nor linear (de Andrade, 2018). 
Importantly, many repeat offenders are not involved in drug 
use and many people with problematic drug use do not 
commit non-drug-related crimes.
People who experience imprisonment represent 
a dynamic and rapidly changing population that is also in 
regular contact with the community. This means that, by 
addressing drug-related problems in prison settings, the 
health of both people living in prison and the community 
they return to can be improved, producing an overall 
societal benefit.
This EMCDDA Insights publication provides 
a comprehensive overview of current knowledge and the 
latest developments in the field of drug use and prison in 
Europe. In this way it offers an important basis for evidence-
informed policymaking, public health interventions and 
research activities. It draws on multiple sources of data to 
provide an overarching account of the epidemiology and 
the health and social service responses to drug problems 
in prison, as well as highlighting key issues in drug supply 
to prisons, in the 27 EU Member States, Norway, Turkey and 
the United Kingdom.
This introductory chapter sets the discussions in context 
while providing background data on prison populations in 
Europe and introducing the available sources of data.
I The European prison population
In 2019, there were over 11 million people in prison 
worldwide, of which over 856 000 (1) were held in the 
approximately 2 000 prisons located in the 27 EU Member 
States, Norway, Turkey and the United Kingdom (Walmsley, 
2018; Aebi and Tiago, 2020). This corresponds to a prison 
population rate of 142 people per 100 000 (number of 
people in prison per 100 000 inhabitants of the country 
or region), ranging from 50 in Finland to 329 in Turkey 
(Figure 1.1). This is substantially lower than the figures 
for the United States (450) and Russia (386) (Walmsley, 
2018). The number of people in prison decreased in most 
EMCDDA reporting countries between 2008 and 2019.
FIGURE 1.1
Prison population (per 100 000 inhabitants) in the EU 
Member States, Norway, Turkey and the United 
Kingdom, 31 January 2019
Source: Aebi and Tiago, 2020.
(1) Between 2018 and 2019 the prison population in the 27 EU Member 
States, Norway, Turkey and the United Kingdom increased by more than 
56 000. This is attributable to an increase of more than 80 000 detained 
in prison reported by Turkey, where the last available data before 2018 
were from 2016. In most of the other countries the prison population 
decreased. For more information, see Aebi and Tiago (2020). 
Prison population
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Women represent around 5 % of the prison population (around 
41 000), varying from 3 % in Bulgaria to 5 % in Cyprus. The 
prison population has an estimated mean age of 37 years, 
ranging from 33.6 years in Denmark to 41 years in Italy.
An estimated 11 % of people in prison in Europe are foreign 
nationals, with considerable national variation — from 
0.2 % in Germany to 74 % in Luxembourg. Around one 
fifth of people in prison have not received a final sentence, 
ranging from 8.4 % in Czechia to 48 % in Luxembourg.
More than half (52 %) of people in prison are sentenced 
to 5 years or more, with 37 % sentenced to between 1 and 
5 years and 11 % sentenced to less than one year. The main 
offences for which people are given prison sentences are 
property crimes such as theft and robbery (32 %), drug 
offences such as drug possession and drug trafficking 
(18 %) and homicides (12 %). Recidivism rates tend to 
be high, and a significant proportion of people in prison 
reoffend upon release and experience multiple prison 
spells. Prison overcrowding, measured by occupation per 
available prison place is reported in 12 countries.
I  Research on and monitoring of drugs and prison
I Challenges for data collection in prison
While gathering information on the health and social care 
needs of those in prison is important from an individual 
and public health perspective, undertaking research 
and monitoring in this setting is particularly challenging, 
especially when focusing on drug use behaviours and drug-
related problems.
There are multiple factors affecting the feasibility of data 
collection in prison settings, including the structural 
limitations of prison systems, the characteristics of the 
prison population and the often low priority attributed 
to it by both political and research agendas. Structural 
limitations to prison research and monitoring include 
complex and sometimes lengthy procedures to access 
prisons for research purposes, including ethical approvals 
(see box ‘Ethical research in prison’); limited physical space 
available for conducting research; restricted schedules 
conditioned by the organisation of daily life in prison; and 
the limited availability of research staff, including prison 
healthcare staff, who are sufficiently motivated and skilled 
to conduct prison research.
In the publication particular attention is paid to the 
terminology; in particular the term ‘people in prison’ is 
always used instead of ‘prisoners’, in order to avoid stigma 
and to highlight that people can experience imprisonment 
at some point of their life, but they should enjoy the same 
rights and respect as every member of the society (Tran et 
al., 2018).
There are also challenges to participation in research. 
Many people in prison have low levels of education and 
literacy, which may limit their understanding of survey 
and research questions, and the significant proportion 
of foreign nationals means that many may not have 
sufficient understanding of the official language to enable 
communication. There is also a high prevalence of mental 
health problems among people in prison. While none of 
the above represent grounds for exclusion from research 
efforts, these challenges may affect the time and resources 
demanded to collect data among such groups. In addition, 
people in prison are often moved between places of 
detention, and between prison and the community, which 
may disrupt research implementation. Issues of data 
validity are particularly important in studies requiring the 
disclosure of current or former drug use or drug-related 
activity. In this context truthful reporting may be hindered 
by both a general mistrust among the prison population 
and fears of punitive repercussions.
I Improving available evidence on prison and drugs
Efforts to overcome lack of information and obstacles to 
conducting data collection, monitoring and research in 
prison and among prison populations have been made 
at international, European and national levels. However, 
few countries in Europe have a comprehensive national 
system that captures and understands the nature of drug 
use, drug-related problems, interventions and treatment 
provided within custodial settings. In general, data at 
the European level are patchy and lack cross-national 
comparability, largely due to differences in legal, political, 
cultural and social systems.
A more complete picture would require further institutional 
efforts to improve harmonisation between different data 
sources and allow for comparisons across sources.
At international and European levels there are three main 
sources of information on prison populations and prison 
conditions: Eurostat, the Council of Europe and the World 
Prison Brief. Each source employs different methods for 
data collection and analysis, hindering efforts to use these 
data sets in comparative or complementary ways.
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Several key international organisations have made efforts 
to improve the available evidence on the needs of people 
in prison regarding health and drug-related problems, 
and the interventions targeting them, in order to provide 
policymakers with robust planning instruments.
In 2017 the World Health Organization (WHO) Health in 
Prisons Programme (WHO-HIPP) (see box ‘WHO Health 
in Prisons Programme’) launched the Health in Prisons 
European Database (HIPED), which collects information 
from countries in the WHO European region on the health 
needs of people in prison and the available interventions. 
HIPED includes drug-related information, defined in 
coordination with the EMCDDA. In addition, within 
WHO-HIPP a Worldwide Prison Health Research and 
Engagement Network (Wephren) was established in 2018. 
Wephren seeks to facilitate the exchange of expert advice 
and promote innovation in addressing healthcare and 
health inequalities facing people in prison.
At the international level, the United Nations Office on 
Drugs and Crime (UNODC) publishes analyses in the 
field of prison and drugs. It collects data on prisons from 
UN countries, with a special focus on HIV and disease 
prevention, drug treatment and best practices. In addition, 
Harm Reduction International (HRI), a non-governmental 
organisation, publishes information on drugs and prison. 
Its annual report is based on contributions from harm 
reduction practitioners, academics and advocacy groups 
from around the world (Stone and Shirley-Beavan, 2018).
Ethical research in prison
Prisons are punitive settings where people are deprived of their liberty and in this context research and monitoring 
needs to be informed and supported by the highest ethical standards (Shaw et al., 2014).
Ethics in prison research is informed by international and European guidance that draws attention to the particular 
risks of research among prison populations and provides recommendations on how to mitigate and address such 
risks. In many countries, research ethics boards or other designated authorities play a key role in providing guidance for 
ethical research, granting approval (or not) to studies based on the measures taken to ensure sound ethical research, 
and in mediating any emerging ethical disputes (Council of Europe, 1996).
The closed nature of prison institutions, the systematic control exerted on individuals, and underlying pressures from 
prison authorities and other staff pose significant challenges for privacy protection, confidentiality and voluntary (and 
well-informed) consent of research participants in prison settings (United Nations General Assembly, 2003).
Establishing sound ethical measures from the start of the research, defining how they will be implemented in each 
phase, and anticipating possible ethical challenges and how to best address them is thus of particular importance 
in prison settings. Prison research should follow high scientific standards and aim to improve knowledge and 
understanding of the prison population and the prison context. Prison researchers’ scientific independence from prison 
administration and prison control functions avoids conflicts of interest and may work to ensure that research follows 
high ethical standards (Watson and Meulen, 2019).
While people in prison are not devoid of agency, they are nevertheless constrained in their scope for action. Therefore, 
it is important that research in prison is carried out in a way that promotes its potential benefits for people in prison 
and reduces the risk that the findings are misused for the gain of some or negatively affect the research population 
(Coughlin et al., 2016).
Additionally, it is recommended that health research in prison is conducted in line with the principle of equivalence of 
care (United Nations General Assembly, 2015). It is necessary to refer to international standards and guidelines for the 
treatment of people in prison and the international and national mechanism set up to ensure the respect of human 
rights in prison. Finally, when prison research addresses drug use, it is necessary to ensure that people disclosing an 
illicit behaviour are not incurring in any additional punitive measures (Montanari et al., 2017).
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I Growing body of evidence on prison health
While research is limited, there is a growing interest in the 
health of people in prison in European countries. A number 
of systematic reviews conducted in recent years shed some 
new light on key aspects of epidemiology and healthcare in 
prisons. These include reviews focusing on problem drug 
use (Fazel et al., 2017), high-risk behaviours (Moazen et al., 
2018), communicable diseases (Dolan et al., 2016; Falla et 
al., 2018; Vroling et al., 2018; Erickson et al., 2019), active 
case finding (Tavoschi et al., 2018), and treatment of opioid 
dependence (Hedrich et al., 2012).
Nevertheless, when assessing the body of evidence, 
important limitations are apparent. There is a lack of 
comparative studies, as many are based on single-
site observations. In addition, the outcomes or health 
interventions under study are often poorly defined, 
thus jeopardising future comparative efforts. Within 
the European region, prison research activity is mainly 
concentrated in a small number of countries; overall most 
studies have been conducted outside Europe, mainly in 
the United States, which may limit the transferability of the 
findings.
To complement the findings from the peer-reviewed 
literature, some systematic reviews rely substantially on 
grey literature such as conference abstracts, national and 
sub-national reports, monitoring data from healthcare 
services or case studies (Tavoschi et al., 2018; Vroling et al., 
2018). These clearly have intrinsic limitations related to the 
validity and reliability of the findings.
I  EMCDDA framework for monitoring drugs and prison in Europe
In 2013, the EMCDDA developed a methodological 
framework to monitor drugs and prison in European 
countries in an effort to harmonise information across 
countries. The framework identifies five main monitoring 
components that are necessary to obtain a comprehensive 
overview of the drugs and prison issue: background 
information on the prison population; the epidemiology 
of drug use, the health and drug-related problems among 
people in prison; interventions available in prison; and 
drug-related adverse effects after prison release. For each 
component, the monitoring tools available and information 
gaps at European level on drugs and prison have been 
identified (Council of the European Union, 2013).
Existing information sources and findings from research, 
respectively, inform the first and last components, 
background information and drug situation (use and 
problems) of people after release from prison. The other 
components, drug epidemiology of people in prison and 
drug-related interventions, are informed by current data 
provided every year by European countries to the EMCDDA 
in the form of aggregated epidemiological data or annual 
national reports on the drugs and prison situation; and ad 
hoc EMCDDA tools, such as the European questionnaire 
on drug use among people in prison (EQDP) and the 
European facility survey questionnaire for the prison setting 
(EFSQ-P).
The EQDP is a model questionnaire for collecting 
comparable epidemiological data on drug use among 
people in prison in European countries. The EQDP is 
currently implemented, partially or the whole questionnaire, 
in ten (2) European countries; in addition, there are plans to 
extend implementation to other countries (see Chapter 2). 
The EFSQ-P is a model questionnaire that is used to collect 
information on drug-related services and interventions 
provided inside prison — it is an adaptation of the EMCDDA 
facility survey questionnaire used in the community. The 
EFSQ-P is in the final stages of development.
(2) Czechia, Greece, Spain, Latvia, Lithuania, Poland, Portugal, Romania, 
Slovenia, Croatia. 
WHO Health in Prisons Programme
In 1995 the WHO Regional Office for Europe set up 
the Health in Prisons Programme (HIPP) to encourage 
and support WHO Europe countries to address the 
higher prevalence of health problems in prison. Since 
its inception HIPP has developed to become a crucial 
international movement to promote health in prison 
settings. HIPP’s main activity is to give technical advice 
to member states on the development of prison health 
systems and their links with public health systems and 
on technical issues related to communicable diseases 
(especially HIV/AIDS, hepatitis and tuberculosis), illicit 
drug use (including substitution therapy and harm 
reduction) and mental health. A status report of the 
implementation of health interventions in prison in the 
WHO-Europe region was published in 2019 (WHO, 2019).
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I About this publication
I Sources of data and methodological considerations
This EMCDDA Insights report draws on a variety of sources 
including scientific and grey literature, official data, 
EMCDDA routine qualitative and quantitative monitoring 
data, national reports and data from European projects 
such as HA-REACT (3). The report also incorporates expert 
experiences and views collected at a technical meeting, 
‘Prison and drugs in Europe: future challenges’, hosted by 
the EMCDDA in Lisbon in January 2019.
While the diversity of sources informing this publication 
serves in many respects to enrich and present the 
complexity of the situation in European prisons, there are 
also a number of limitations that need to be considered, 
and caution is required when interpreting results, especially 
from a comparative perspective.
Data on drug use and drug markets in prison are 
particularly scarce and, in some countries, limited to 
anecdotal information. There is also a paucity of data 
and scientific literature focusing on the health of people 
in prison. Consequently, the report is based on and 
triangulates a combination of different information 
sources, varying in content, method, language, target 
population and data quality. Furthermore, collection 
methods for epidemiological data on drugs and prison 
differ by country: some draw on routine registers, mainly 
containing information collected at admission to prison, 
while others draw on cross-sectional surveys. The 
cross-sectional surveys available vary in the sampling 
procedures used.
Comparability across countries is also hindered by national 
variations in prison systems, drug legislation and health 
and social care systems. To substantiate some information, 
findings from research conducted in non-European 
countries, particularly the United States, are used. Despite 
the availability and high quality of the research conducted 
in the United States, there are substantial differences 
between that country and European countries in their 
prison and healthcare systems, meaning that the findings 
are not necessarily transferable.
Finally, the scarcity of available data, allied to the lack of 
comparability of data from previous years, means that it is 
not possible to look at trends before 2010. These problems 
also limit what can be said about the present. Further 
(3) In developing this report, efforts were made to draw on research studies 
and data collection that were approved by appropriate ethical boards. 
However, as research ethics procedures vary greatly across countries it 
has not always been possible to check conformity with research ethics.
research and efforts towards harmonising data collection 
across countries are needed to provide stronger evidence 
for interventions.
While acknowledging these limitations, this publication 
aims to provide an important and much needed insight on 
a topic and population that are both frequently neglected, 
despite meriting significant attention from policymakers in 
the fields of social care and public health.
I Note on the use of data and Brexit
Despite the report being published in 2021, after the exit 
of the United Kingdom from the European Union, UK data, 
including epidemiological data for 2019 and information on 
drug-related interventions up to 2020, are included when 
available as they refer to the period pre-Brexit.
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This chapter provides an overview of the epidemiology 
of drug use and drug-related problems among people 
in prison in Europe and provides information to support 
those engaged in needs assessment, service planning and 
treatment organisation. It first aims to help the reader to 
unpack the interconnections between prison and drug use, 
before presenting epidemiological data on the prevalence, 
behaviour and patterns of drug use among people in prison 
before, during and after incarceration.
I  The interconnection between prison and drugs
People in prison are substantially more likely to have used 
drugs, to use drugs regularly and to experience drug-
related problems than their peers in the community. These 
are the findings of studies carried out across the world, 
despite significant differences between countries (Fazel et 
al., 2017).
Worldwide, it is estimated that of those in prison, 30 % of 
men and 51 % of women have a drug use disorder (Fazel 
et al., 2017). At the European level, studies have shown 
that between 30 % and 75 % of people with problematic 
drug use have been in prison at some time in their life 
(Ravndal and Amundsen, 2010). The high prevalence of 
drug use among people in prison reflects, and is reflected 
in, a number of social factors discussed below (de Andrade, 
2018).
Drugs, drug use and prison experiences are interlinked in 
various ways, as illustrated in Figure 2.1.
FIGURE 2.1
Interconnections between drugs, drug use and prison
First, many people are in prison for committing drug law 
offences, but these people do not necessarily have a history 
of drug use themselves; these offences include drug 
trafficking or drug production offences. In 2019, there were 
over 850 000 people in prison across Europe, of which 
18 % received a final sentence for offences related to the 
use, possession or supply of illicit drugs (Aebi and Tiago, 
2020).
The second interconnection between drugs and prison 
refers to people who use drugs and are in prison for 
offences related to their drug use, for example those 
committed to support or fund their dependence or crimes 
committed under the influence of drugs (Gaffney et al., 
2010; Gjersing and Bretteville-Jensen, 2019). Although the 
nature of the drugs-crime link is likely to be complex and 
multifactorial, it is well documented that those dependent 
on illicit substances are responsible for a disproportionate 
number of crimes, particularly crimes committed for 
financial gain (acquisitive crimes). Involvement in income-
generating crime may, to a large extent, reflect users’ need 
to obtain funds to support their drug use (Pierce et al., 
2015).
People in prison for 
oences committed 
to support their 
drug use 
 
People in prison for 
drug law oences
People who use drugs 
and are in prison for 
oences not directly 
related to drug use
 
CHAPTER 2
Drug use before, during and after 
imprisonment
Luis Royuela, Linda Montanari, Ines Hasselberg, Viktor Mravčík,  
Liesbeth Vandam and Wayne Hall
INSIGHTS I Prison and drugs in Europe: current and future challenges
22
FIGURE 2.2
Share of prison population sentenced for drug 
offences in the EU Member States, Norway, Turkey and 








Source: Aebi and Tiago, 2020.
A third interconnection between drug use and prison 
refers to people who use drugs and are in prison, but not 
necessarily for offences related to their drug use. It reflects 
how offending and drug use may have common risk factors, 
such as social marginalisation, economic deprivation, 
school dropout, unemployment, childhood neglect and 
abuse, and parents with histories of substance use or 
mental health disorders (Stevens et al., 2005; EMCDDA, 
2012; de Andrade, 2018).
A meta-analysis of studies on the relation between drugs 
and crime concluded that the likelihood of committing 
crimes of any type is up to eight times greater for people 
who use drugs than for those who do not; it also found 
a difference in the strength of the association between 
types of drugs. The odds of offending were highest among 
those using crack cocaine (about 6 times greater), followed 
by heroin (about 3 times greater) and cocaine (about 
2.5 times greater). A statistical association between 
recreational drug use, including cannabis, and offending 
was also found, although it was substantially weaker 
(Goldstein, 1985; Bennett et al., 2008).
I Drug use before imprisonment
The prevalence of substance use before imprisonment is 
generally high among the prison population worldwide, 
despite considerable variations between countries (Fazel 
et al., 2017). At the European level, a recent systematic 
review of studies conducted in 12 countries shows that 
the lifetime prevalence of illicit drug use on entry to prison 
was on average 61 %, with the variation between studies 
ranging from 30 % to 93 % (van de Baan et al., 2021). 
Cannabis was the substance most frequently reported, 
followed by cocaine, although some studies reported the 
highest prevalence of use for crack/cocaine.
EMCDDA and national monitoring data (based either on 
cross-sectional surveys or on routine data) from 15 European 
countries, reported between 2010 and 2019 (Figure 2.3), 
show a high prevalence of drug use in all countries, although 
differences exist. While it is useful to visualise national 
study results in a chart, methodological differences in data 
collection between countries are important and conclusions 
need to be drawn with caution (see Chapter 1).
The EMCDDA European questionnaire on drug use among people in prison
A model European questionnaire on drug use among people in prison (abbreviated as ‘EQDP’) was developed by the 
EMCDDA to provide a cross-country overview of drug use among the prison population. The EQDP includes ethical and 
methodological guidelines for carrying out research in prison.
The questionnaire includes 57 questions divided into five sections that focus on general information 
(sociodemographic, legal status); substance use outside and inside prison (time spans, frequency and age at first use); 
substance injecting and other health risks (injecting, sharing of needles and other injecting equipment, tattooing); 
health status of people in prison (HIV, hepatitis B virus, hepatitis C virus testing and status, mental health, overdose); 
and use of health and addiction services (opioid substitution treatment, harm reduction and other substance-related 
treatment) (Montanari et al., 2017).
An analysis of the prevalence of substance use among people in prison in six European countries using the EQDP 
concluded that, while limitations in data comparability remain and need to be addressed, the EQDP can provide 
comparable data that may support regional drug monitoring, facilitate the exchange of best practice and lessons learnt, 
and assist in the development of responses that meet current and future European challenges in this field.
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FIGURE 2.3
Lifetime prevalence of illicit drug use among people in prison before imprisonment in 13 EU Member States, Turkey 
and the United Kingdom in 2019 or most recent data available
Data 2019 or most recent year available. Year of data collection varies by country.




































































































































The lifetime prevalence of drug use before imprisonment 
ranges from 13 % in Romania to 87 % in Ireland for 
cannabis; 7 % in Croatia to 75 % in Ireland for cocaine; 2 % 
in Turkey and Romania to 47 % in Latvia for amphetamines; 
and 4 % in Hungary and Croatia to 29 % in Belgium for 
heroin.
Data on recent use of illicit substance before imprisonment 
show that last year prevalence of illicit substance use 
ranges from 17 % in Romania to 69 % in Ireland (for 
cannabis). Last month prevalence ranges from 1 % in 
Croatia to 54 % in the United Kingdom (Figure 2.4).
Despite differences between countries, people in prison 
report substantially higher rates of drug use prior to 
their imprisonment than are found among the general 
population (Figure 2.5).
Figure 2.5 presents the results from a recent analysis using 
the EQDP in national surveys conducted in six countries 
between 2014 and 2018 (see box ‘The EMCDDA European 
questionnaire on drug use among people in prison’).
The lifetime prevalence of illicit drug use among male 
adults (aged 15-34 years) in prison before imprisonment 
and that in the general population were compared using 
ratios: a value higher than one indicates an excess of 
lifetime drug use for people living in prison compared with 
the general population. For example, a value of 3.8 for 
men in Portugal can be interpreted as meaning that men 
entering prison in Portugal are 3.8 times more likely to have 
used cannabis than those in the general population.
The excess of drug use is reported for all substances by 
comparing people in prison with the general population. 
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It was possible to calculate ratios for cannabis, cocaine, 
amphetamines and MDMA. For other substances the low 
prevalence in the general population did not allow any 
conclusive comparisons to be made.
In the six countries included in the analysis, the lowest 
excess was reported for cannabis and the highest for 
cocaine and amphetamines. The range of ratios was as 
follows: for cannabis, from 1.3 in Czechia to 3.8 in Portugal 
among men and from 1.3 in Czechia to 6.6 in Latvia among 
women; for powder cocaine, from 4.3 in Spain to 28.9 
in Portugal among men and from 7.0 in Spain to 35.8 in 
Portugal among women; for amphetamines, from 3.9 in 
Spain to 18.0 in Portugal among men and from 7.1 in Spain 
to 84.5 in Portugal among women; and for MDMA, from 2.4 
in Czechia to 21.8 in Portugal among men and from 1.9 in 
Czechia to 26.6 in Portugal among women.
Several factors may contribute to the wide variation 
between countries in the reported prevalence of drug 
use among people in prison before their imprisonment. 
These include both underlying societal reasons and 
methodological differences between countries. The 
first element includes differences in the substances 
most prevalent in the community, the characteristics of 
people with drug problems in the community and the 
consequences of disclosing drug use to prison authorities 
(Carpentier et al., 2012). Important differences exist 
across countries and surveys in the data collection 
methods, including sampling methods, mode of survey 
administration, types of questions asked, frequency of 
the surveys and other factors described in more detail in 
Chapter 1. Different estimates of drug use among people 
in prison across countries may also reflect variations in 
the use of alternative measures to imprisonment for drug 
offences: a lower number of people in prison for drug 
offences is expected in countries where alternatives to 
imprisonment are implemented. Different levels of priority 
used by law enforcement agencies and the courts in 
prosecuting drug use offences may also affect the drug use 
characteristics of people in prison.
FIGURE 2.4
Last year and last month prevalence of any illicit drug use among people in prison before imprisonment in 14 EU 
Member States and the United Kingdom in 2019 or most recent data available
* An asterisk indicates no data available. Data for Ireland, Spain, Croatia and Lithuania refer to cannabis.  
Year of data collection varies by country.
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I Drug use while in prison
Although prohibited, the consumption of illicit substances 
is widespread in prisons (see also Chapter 7). These 
substances are often more difficult and expensive to 
access in prison than in the community, which may 
contribute to a reduction in the number of people 
using drugs inside prison, and in the frequency of use 
(Carpentier et al., 2018). Many people stop using drugs 
when they enter prison or reduce their use, while others 
continue to use but may change their drug using patterns 
and behaviour. Others may start using drugs or switch 
substances once they are in prison. Overall, the prevalence 
of drug use among people in prison generally remains 
higher than in the general population in the community. 
Studies conducted between 2004 and 2013 suggest 
that in Europe between 20 % and 45 % of people with 
experience of incarceration have used drugs while in prison 
(Carpentier et al., 2018).
EMCDDA and national monitoring data on drug use inside 
prison provided by 11 countries (4) since 2010 report that 
in Europe the last year prevalence of drug use in prisons 
(4) Data from 11 countries since 2010: Belgium, Bulgaria, Czechia, Ireland, 
Latvia, Lithuania, Poland, Portugal, Romania, Slovenia, Scotland (United 
Kingdom).
FIGURE 2.5
Excess of drug use among people in prison compared with drug use in the general population in six EU Member States, 
2014-2018
Source: EQDP 2019.
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is generally highest for cannabis (0.5-67 %), followed by 
heroin (1-29 %), cocaine (0.1-20 %) and amphetamines 
(1-8 %). Again, methodological limitations should be 
considered and careful interpretation of these data is 
necessary.
Data on drug use during imprisonment in six European 
countries using the EQDP (see box ‘The EMCDDA 
European questionnaire on drug use among people in 
prison’) show that the prevalence of ever-use of drugs 
during imprisonment is generally lower than the lifetime 
prevalence of drug use before imprisonment, with 
the highest levels reported for cannabis. Variations in 
prevalence exist between countries and substances used.
While several studies point to an overall reduction in 
drug use for many people while in prison (Young et al., 
2018), some report having initiated their drug use while 
incarcerated. A recent French study reported a substantial 
reduction in substance use inside prison: the highest 
reduction in prevalence was reported for alcohol use, 
followed by illicit drugs, and the highest increase, including 
the initiation of consumption inside prison, was observed 
for prescribed drugs and medications consumed outside 
of a medical context (Rousselet et al., 2019). A 2002 study 
found that about 15 % of people in prison in England and 
Wales reported having started to use heroin, cocaine or 
both inside prison, compared with 9 % for crack cocaine, 
6 % for cannabis and 2 % for amphetamines (Boys et al., 
2002). Research conducted in a Lithuanian women’s prison 
found that 4 % of those in prison who use drugs started to 
use drugs while in prison (Narkauskaite et al., 2010).
Some people may start using additional drugs when they 
are in prison. A Belgian study found that more than one 
third of people in prison who use drugs started to use an 
additional drug during detention, with heroin the most 
reported new substance (Todts et al., 2008).
Prison wastewater studies have been used to complement 
prison survey data. Wastewater-based drug epidemiology 
allows researchers to estimate the quantity of drugs 
consumed by a community by measuring the levels of 
illicit drugs and their metabolites excreted in urine and 
detectable in the sewerage system. Two prison wastewater 
studies have been conducted in Europe, one in a Spanish 
prison and the other in three French prisons. Both studies 
report high levels of drug residues in prison wastewater. The 
French study estimated an average daily consumption of 
0.5-3 cannabis joints per person, and between 90 mg and 
282 mg of pure cocaine per 1 000 individuals, depending 
on the sampling site. Issues to consider when interpreting 
wastewater data in prison include sampling methods, 
degradation of target molecules, molecule quantification, 
data on metabolism and estimation of the number of 
individual users (Postigo et al., 2011; Néfau et al., 2017).
During imprisonment patterns of drug use may also 
change as people adapt to the prison setting. People who 
use drugs may use new substances when their drug of 
choice is not available in prison, or they may change to 
a substance that is more easily used in the prison setting 
(e.g. easier to conceal, with a sedating rather stimulating 
effect) (Singleton, 2008). People in prison tend to prefer 
to use drugs that are less likely to be detected by drug 
testing, either because they are detectable in the blood 
for a shorter time (e.g. heroin, rather than cannabis) or 
because they are generally not included in routine urine 
drug testing (e.g. synthetic cannabinoids) (Stöver and 
Weilandt, 2007; EMCDDA, 2018). In general, central 
nervous system depressant substances, including 
hypnotics and sedatives, are preferred because their 
effects are also easy to hide and their consequences easier 
to manage in the confined setting of a prison (Bullock, 
2003). The need to increase the efficiency of the drug, due 
to its scarcity in prison, may also encourage some people 
who use drugs to adopt more harmful patterns of drug use, 
such as injecting, while in prison (Niveau and Ritter, 2008).
I  Use of new psychoactive substances in prison
The use of new psychoactive substances became an 
emerging issue in prisons in a number of European 
countries in 2014-2015, although the use of synthetic 
cannabinoids was first picked up in England and Wales in 
2010-2011 (User Voice, 2016). The initial undetectability 
of new psychoactive substances in routine urine testing 
is thought to be a main reason for their increased use in 
prison, particularly for synthetic cannabinoids.
An exploratory study conducted in European countries in 
2017 found signs of new psychoactive substance use in 
prison in 22 countries (Figure 2.6). Synthetic cannabinoids 
were the new psychoactive substances most often reported. 
Other new psychoactive substances commonly used in 
prison were synthetic cathinones, synthetic opioids and new 
benzodiazepines (EMCDDA, 2018).
The prevalence of synthetic cannabinoid use in prison in 
15 European countries with available data ranged from 2 % 
in Portugal to 30 % in some prisons in England (EMCDDA, 
2018). Random urine testing conducted in German 
prisons and forensic hospitals in 2018 resulted in 38 % 
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of positive tests for new psychoactive substances, mainly 
synthetic cannabinoids, a decrease compared with 60 % 
in 2015 (EMCDDA, 2018). In the other countries reporting 
trend information on new psychoactive substance use in 
prison, no clear changes have been reported since their 
appearance in the drug market in prison.
A wide range of physical and mental health harms (such as 
psychosis, disorientation, suicidal ideation, aggressiveness 
to others or self-harm) has been associated with acute 
intoxication by, and chronic consumption of, synthetic 
cannabinoids (EMCDDA, 2018). Nevertheless, there 
are a number of reasons why people who use drugs in 
prison may choose to use these substances. Synthetic 
cannabinoids are easily accessible and most of them 
are not detectable by urine analysis, because they are 
chemically diverse and difficult to identify analytically, and 
they are often more potent and cheaper than cannabis, 
producing intoxication at lower doses for a lower cost. 
They can also be supplied in smaller quantities that are 
easier (than cannabis) to conceal and to take into prison 
(see Chapter 7). In English prisons the use of synthetic 
cannabinoids was associated with an increased number 
of health problems experienced by people in prison 
and a disruption in the functioning of the prison system 
(EMCDDA, 2018).
I  Injecting drug use before and during imprisonment
Data on the prevalence of injecting drug use in prison are 
particularly difficult to collect, in part because of the greater 
stigma attached to injection practices. Data are available 
in only a few countries and different methodologies have 
been used for obtaining them. Therefore, caution is required 
when making international comparisons of injecting drug 
use in prison.
The lifetime prevalence of injecting drug use before 
imprisonment is substantially higher among people in 
prison than in the general population in most countries 
(Azbel and Altice, 2018). Survey data collected in 10 
European countries since 2010 show that between 6 % of 
people in prison in Poland and 48 % in Lithuania reported 
having injected drugs before imprisonment (Figure 2.7). 
These proportions are substantially higher than the 
estimates of prevalence of drug injection in the European 
adult population (0.3 %).
The high prevalence of injecting drug use is confirmed by 
studies of people who use drugs with prison experience 
(Ravndal and Amundsen, 2010). A recent study, drawing 
on data collected in various community settings in 17 
European countries between 2006 and 2015, found that 
between 20 % and 80 % of people who inject drugs have 
had prison experience (Stone et al., 2018).
Qualitative studies suggest that some people inject 
drugs inside prison because injection maximises the 
psychoactive effects of expensive drugs that are in short 
supply, or because they are initiated to injection by others 
in prison (Gore et al., 1995; Peña-Orellana et al., 2011; 
EMCDDA, 2012). Based on surveys conducted between 
2010 and 2019 in ten European countries, the prevalence 
of injecting illicit drugs during imprisonment ranges from 
0.7 % in Hungary to 22.2 % in Germany (Figure 2.7).
Sterile equipment for safe injection is rarely available inside 
prison. People in prison may reuse syringes (Treloar et al., 
2016) or use syringes that are crafted from items available 
in prison.
There are few data available on the sharing of injection 
equipment in prison. EMCDDA and national monitoring 
data from four countries indicate that, of the people 
who inject drugs in prison, the proportion who share 
injection equipment while in prison may range from 27 % 
in Luxembourg to 65 % in Czechia. These are likely to be 
underestimates, considering that in most countries there is 
FIGURE 2.6
Reported use of new psychoactive substances (NPS) 
in prison, 2018
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no freely available clean injecting equipment in prison (see 
Chapter 5).
I  Drug use after release from prison
Understanding drug use after release from prison is 
important from a public health and a criminal justice 
perspective. Yet, there are not many data available, and 
the few existing studies mostly focus on the United States 
and Australia. Although these studies provide relevant 
information, their findings are not necessarily applicable to 
the European context.
Again, the findings of the existing studies vary greatly 
because of differences in the methods used, recruitment 
and actual prevalence. Most studies report some reduction 
in drug use, including injecting, in the first year after release 
from prison, although in some studies no change or even 
an increase in drug use is reported (Larney et al., 2018).
There is, however, some evidence of an association 
between recent incarceration and risky injecting drug 
use immediately after release from prison, involving an 
increased risk of sharing injecting equipment (Larney et 
al., 2018). The period following release from prison is also 
important because of the high risk of fatal overdose (see 
Chapter 3).
While addiction plays an important role, other reasons 
for continuing drug use and drug injection after release 
from prison may include poor social support, exposure to 
and availability of drugs, influence of drug-using peers, 
difficulties in social reintegration, barriers to accessing drug 
treatment and inadequate treatment offers (Binswanger et 
al., 2007).
I  Conclusions
The prevalence of drug use and drug-related problems 
among people in prison is high in Europe and worldwide, 
and people who are or have been in prison are more likely 
FIGURE 2.7
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than their peers in the community to experience drug-
related problems. Offending and drug use share a number 
of risk factors that, although not easily disentangled, reveal 
how drug use is often just one of many vulnerabilities 
among people in prison.
There are differences between countries in drug use 
prevalence and behaviour that reflect variations in the 
national prevalence of drug use, prison systems, methods of 
data collection, social and cultural contexts, legal frameworks 
and national policies, among other factors. Nevertheless, 
all of the above underlines the importance of developing 
evidence-based interventions that address drug use and the 
related healthcare needs among people in prison.
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This chapter focuses on the general health of people 
who are in prison and use or have used drugs. Particular 
attention is devoted to infectious diseases and psychiatric 
comorbidity. The mortality of people who use drugs in 
prison is also addressed, both during imprisonment and in 
the period following release. Particular attention is paid to 
the needs of women with drug problems who are in prison.
Whether they use drugs or not, people in prison have 
generally poorer physical and mental health and social 
well-being than their peers in the community. People 
in prison suffer from higher rates of acute and chronic 
physical and mental illness and have greater levels of 
disability and lower life expectancy than their peers in the 
community. They report high rates of communicable and 
non-communicable diseases, including cardiovascular 
diseases, cancer, diabetes and chronic respiratory 
diseases. They experience disproportionally high levels of 
sexual health problems, suicide attempts, self-harm and 
mental health and substance use problems, including 
alcohol, tobacco and illicit drug use disorders (Barry et al., 
2010; Plugge et al., 2014).
People in prison also have lower survival rates than the 
overall population outside prison. According to a US study 
on cancer in people in prison, the median survival time from 
diagnosis of people living in prison was 21 months, which 
compared with 54 months for those living in the community 
(Mathew et al., 2005). Health problems in people in prison 
mirror and most often magnify those of people in the wider 
community, in part because there is a significant overlap 
of risk factors for poor health and imprisonment but also 
because prison conditions can negatively affect already 
impaired health.
Overcrowding is a significant challenge in prison today. 
According to the latest official survey statistics across 
Europe, 12 countries report a median occupancy rate of 
over 100 % (Aebi and Tiago, 2020). Overcrowding increases 
stress and tension in people in prison, as well as in 
prison staff, and the poor and unsanitary conditions often 
resulting from overcrowding adversely affect the health of 
people in prison (Møller et al., 2007; Rouillon et al., 2004).
Specific groups of people in prison may have health 
and social needs that should be taken into account. 
The particular needs of groups such as women, foreign 
nationals, lesbian, gay, bisexual and transgender (LGBT) 
people and older people, may be exacerbated when 
combined with drug-related problems (see Chapter 7).
Overall, health conditions directly or indirectly related to 
drug use in people in prison include infectious diseases, 
psychiatric comorbidity, and mortality after release from 
prison.
I  Infectious diseases among people who inject drugs
On entering prison, people who use drugs have higher 
rates of infections, such as HIV, hepatitis B virus (HBV), 
hepatitis C virus (HCV), syphilis, gonorrhoea, chlamydia 
and tuberculosis (TB) than the general population (Dolan 
et al., 2016). The increased prevalence of blood-borne 
virus infections among people in prison compared with 
those in the community is, in large part, associated with 
the over-representation of people who inject drugs; a large 
proportion of people in prison have contracted infectious 
diseases through drug injection and the sharing of injecting 
equipment outside prison (Azbel and Altice, 2018).
People in prison may also contract infectious diseases 
during incarceration. Prisons are high-risk settings for the 
transmission of blood-borne viruses because, in addition 
to higher rates of blood-borne viruses among the prison 
population, people in prison may be more vulnerable to 
risk behaviours such as sharing needles and syringes in 
the absence of ready access to clean injecting equipment; 
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having unprotected sex in the absence of access to 
condoms; and undergoing unsafe tattoo practices.
These risks are further increased by prison overcrowding; 
the coexistence of many people in a small space may 
facilitate sharing of syringes and unsafe sex and may 
increase stress and related aggressiveness with an 
increased risk of violent contact and transmission. This may 
be combined with suboptimal health and social services 
provision (Jürgens et al., 2011; Garcia-Guerrero and Marco 
2012).
Worldwide the prevalence of HIV, HCV and HBV and 
co-infections is higher among people in prison than in the 
general population. A recent study estimated that, on any 
given day, of the 11 million people in prison across the 
world in 2014, 3.8 % were affected by HIV, 15.1 % by HCV, 
4.8 % by HBV and 2.8 % by active TB (Dolan et al., 2016).
The excess prevalence of infectious diseases compared 
with the general population is higher among those with 
a history of drug injection and among women in European 
prisons (Tarján et al., 2019). Nevertheless, large differences 
in the prevalence of infectious diseases among people 
in prison are reported between countries because of 
variations in prevalence of infectious diseases in the 
general population; prevalence of high-risk drug use 
and injecting drug use; how prison health is organised; 
and methods used and recruitment for measuring the 
prevalence of infectious diseases.
I Prevalence of HIV in people in prison
A history of incarceration and substance use disorders 
are risk factors for HIV transmission. A meta-analysis of 
studies conducted in 196 countries between 2005 and 
2015 estimated that the prevalence of HIV-positive people 
in prison ranged from 1 % to 16 % of the global prison 
population, depending on the region. Among people who 
inject drugs, the prevalence is higher, up to almost 20 % in 
some countries (Dolan et al., 2016).
In Europe, HIV prevalence among all people in prison 
in 24 countries reporting data ranges from 0 % in the 
Netherlands to 13 % of people in prison in Estonia. 
A number of countries primarily in eastern Europe, 
including Estonia (13 %) and Latvia (7 %) report high 
prevalence rates of HIV. This is likely to be due to a number 
of factors, including a high prevalence of people who 
inject drugs in the community as well as the limited 
coverage and capacity of harm reduction programmes. 
Among the group of people in prison with a drug use 
history, the HIV prevalence in 12 countries that report 
data ranges from close to 0 % in Czechia to 34 % in Spain 
(Figure 3.1) (Tarján et al., 2019).
I Prevalence of HCV and HBV in people in prison
At the global level, rates of HCV infection in people in prison 
are high, ranging from 1 % to 21 %, and exceeding 10 % in 
most world regions (Dolan et al., 2016). Among people in 
prison who inject drugs worldwide, HCV prevalence ranges 
from 8 % to 95 %. A systematic review of 128 studies on 
the incidence and prevalence of HCV in prison from 39 
countries worldwide reported a pooled estimate of 64 % 
HCV prevalence among people in prison with an injecting 
drug use history (Larney et al., 2014).
Data from 19 countries for the years 2009-2017 show 
a prevalence of HCV among people in prison ranging from 
less than 1 % in Slovenia to 42 % in Finland (Figure 3.1); 
among people who are in prison and have a drug use 
history, the prevalence reported in 12 countries ranges from 
3 % in Slovenia to 97 % in Sweden (Tarján et al., 2019).
Rates of HBV in prison populations are lower than those 
for other infectious diseases. Worldwide the prevalence 
of HBV infection in people in prison is estimated to range 
from 1 % to 24 % of all people in prison depending on the 
country (Dolan et al., 2016). In Europe, HBV prevalence 
among all people in prison reported from 15 countries 
ranges from close to 0 % in Slovakia and Slovenia to 16 % 
in Czechia. Among people with a drug use history, HBV 
prevalence reported by nine countries ranges from close to 
0 % in Hungary to 81 % in Sweden (Figure 3.1) (Tarján et al., 
2019).
I Prevalence of tuberculosis in people in prison
The prevalence of TB in people in prison far exceeds that 
reported in the general population (Aerts et al., 2006; Dolan 
et al., 2016). Worldwide it is estimated to range from 2 % 
to 8%, but data are more limited than for other infectious 
diseases. In Europe, data on TB prevalence (active and 
latent) is limited. This is an important gap in knowledge, 
as it has been estimated that the risk of acquiring TB is at 
least 10 times higher among people in prison than in the 
general population (Baussano et al., 2010).
The available data indicate that the prevalence of TB varies 
between 0.8 % and 6 % of all people in prison for the six 
countries reporting on it (Figure 3.1). Only Luxembourg 
reported data specific to the prevalence of TB among 
people who inject drugs in prison (0 %) (Tarján et al., 2019).
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I Incidence of infectious diseases in people in prison
While many people who inject drugs in prison may have 
contracted infectious diseases in the community before 
imprisonment, some contract them during incarceration. 
Prison settings play a role in the high prevalence of 
infectious diseases among the people who pass through 
the system.
Prisons are high-risk environments for the transmission 
of blood-borne viruses, with contextual factors such as 
overcrowding, poor physical infrastructures, limited access 
to injecting equipment, lack of condoms and lack of 
interventions for the prevention and treatment of infectious 
diseases potentially representing aggravating factors 
(Enggist et al., 2014; Silbernagl et al., 2018).
FIGURE 3.1
Prevalence of HIV, HCV, HBV and TB among the overall prison population in the EU Member States, Norway and the 
United Kingdom, 2009-2017


















































































Source: Tarján et al., 2019.
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However, there are few studies on the incidence of 
infectious diseases in prison. Spain reports a 0.03 % 
incidence of HIV-positive cases in people in prison in 2014, 
reflecting the low incidence in the general population, but 
such data are not available for other European countries.
Based on a systematic review, there is evidence of an 
association between recent incarceration and increased 
HIV and HCV acquisition among people who inject drugs 
(Stone et al., 2018). Several recent modelling analyses 
have also suggested that the incarceration of people who 
inject drugs could be a contributor to the transmission of 
infectious diseases after release from prison. The risk is 
elevated in the initial period following release, which is also 
related to the increased risk of injection during this time. 
HIV and HCV prevalence among people who inject drugs 
was found to be significantly higher among individuals 
with a history of incarceration in most of the 17 countries 
included in a 2018 study (Stone et al., 2018). Other studies 
in Canada and Australia support these findings, confirming 
the relevant public health impact of infectious diseases 
contracted in the initial period after release from prison 
(Milloy et al., 2009; Milloy et al., 2011; Winter et al., 2016; 
Stone et al., 2018; Winter and Hellard, 2018).
In 2016 and 2017, a high rate of new HIV infections in 
prison was reported in Lithuania, with more than 20 % of 
the total number of HIV-positive people in prison having 
contracted the infection inside prison (Figure 3.2). Most 
new HIV cases were among people serving their sentences 
in the same prison, which is organised in large cells hosting 
numerous people, thus increasing exposure to infectious 
diseases.
Despite of the range of health risks associated with 
incarceration, prisons can be settings for providing services 
to populations otherwise considered ‘hard to reach’ by 
community services. In particular, they may offer important 
prevention and treatment interventions to address 
infectious diseases and other drug-related problems.
I Psychiatric comorbidity
Psychiatric comorbidity can be defined as the co-
occurrence in the same person of two or more mental 
health disorders, usually a mental health disorder and 
a substance use disorder. Comorbidity particularly affects 
vulnerable groups, including prison populations (EMCDDA, 
2015).
Psychosis, personality disorders, anxiety and depression 
are all mental health disorders more common among 
people in prison than in the general population (Fazel and 
Baillargeon, 2011). A systematic review of 62 surveys of 
23 000 people in prison in 12 countries found that up to 
65 % of people in prison had a mental health disorder 
(EMCDDA, 2015).
The prevalence of comorbidity of mental health and 
substance use disorders in the prison population is 
reported to be high. In Italy, the prevalence of comorbidity 
among the overall male prison population was estimated at 
21 % (Piselli et al., 2009). In one region of Spain, psychiatric 
comorbidity was reported in approximately 85 % of people 
in prison with substance use disorders (Casares-López 
et al., 2011). In Croatia, a review study (Palijan et al., 
2009) reported figures ranging from 50 % to 80 % among 
violent offenders. Another study, conducted in England on 
a representative sample of 469 women and men in prison, 
found that a significant proportion of prisoners screened 
positive for two or more disorders (Tyler et al., 2019).
The most common mental health disorders among 
people who use drugs include personality disorders often 
associated with problem drug use (Arroyo and Ortega, 
2009), such as antisocial personality disorder, major 
depression and psychotic illnesses such as schizophrenia, 
FIGURE 3.2
HIV incidence and prevalence in people in prison, 
Lithuania, 2012-2018
All cases New cases
Number of HIV cases











Source: 2018 Lithuanian national monitoring data.
CHAPTER 3 I Drug-related health problems of people in prison
37
schizophreniform disorder, maniac episodes and delusional 
disorder. Neurodevelopmental disorders, such as attention 
deficit-hyperactivity disorder (ADHD), autism spectrum 
disorder (ASD) and intellectual disability, are suspected to 
be over-represented in prison (Young et al., 2018).
In Austria, a study conducted among people in prison 
undergoing methadone treatment reported a high 
prevalence of ADHD, which was associated with starting 
substance use at an early age. Fifty per cent of the 
study participants screened positive for childhood 
ADHD and 17 % for adult ADHD. People in prison with 
ADHD symptom status were significantly younger at 
first substance misuse, reported more drug overdoses, 
longer duration of cocaine and prescribed medication 
misuse and more in- and outpatient treatments. Early and 
effective treatment, in addition to OST could yield reduced 
concomitant consumption and higher treatment retention 
(Silbernagl et al., 2019a).
People with comorbid disorders have an elevated risk of 
suicide, one of the leading causes of premature death 
among people in prison (Silbernagl et al., 2019b; Tyler et 
al., 2019; Widinghoff et al., 2019). People in prison with 
dual diagnosis display a risk of reoffending beyond that 
of people in prison with solely substance use disorders or 
only a psychiatric disorder (Baillargeon et al., 2009), and 
the incidence of injury (including self-harm) is particularly 
elevated among people with dual diagnosis after release 
from prison (Young et al., 2018).
Table 3.1 presents key data from European epidemiological 
studies on mental health and substance use disorders from 
prison population studies published between 2006 and 
2019.
When incarcerated and left untreated, the symptoms of 
individuals suffering from comorbid disorders may lead to 
more negative consequences inside prison (Silbernagl et 
al., 2019b), and it is of central importance to identify the 
substance use and mental health needs of people in prison 
and provide them with the most appropriate evidence-
based treatment. Integrated treatment of substance use 
disorders and comorbidities during imprisonment may 
not only improve people’s mental health but also reduce 
re-incarceration risk and thus the costs to society at large 
(Silbernagl et al., 2019b).
I  Mortality during imprisonment and after release
The mortality rate among the prison population in Europe 
is generally high (Aebi and Tiago, 2020). A study on 
mortality, conducted in France on 230 people who died in 
prison in 2011, found that the death rate among people in 
prison aged 20-39 years is double the rate in the general 
population of the same age (Désesquelles et al., 2018). 
Suicide is the leading cause of death in people while 
incarcerated, accounting for around one third of all 
prison deaths (Enggist et al., 2014). In Europe, the risk of 
suicide among people in prison (10.5 per 10 000 prison 
population) is seven times that of the general population 
(EU average of 1.5 per 10 000 population) (Rabe, 2012).
A considerable proportion of people who commit suicide 
in prison have drug-related problems. The French study  
reports that 78 % of the deaths were due to a violent cause, 
11 % of which were attributed to intentional or accidental 
drug overdose or intoxication (Désesquelles et al., 2018). 
Meta-analyses suggest that drug-related problems 
are a risk factor for suicide both in prison (Fazel and 
Baillargeon, 2011) and among people who use drugs in the 
community (Darke and Ross, 2002).
In England, a study investigating 172 prison suicides in 
1999-2000 found that self-poisoning (overdose) was 
reported in 3 % of cases, and it was not among the most 
common ways of committing suicide. In this study people 
who were dependent on drugs and committed suicide did 
so early in their sentence and were twice as likely to do so 
in the first week in prison when compared with people in 
prison without drug problems.
Since 2013, the appearance of new psychoactive 
substances in prison in several European countries 
has been associated with deaths. Despite difficulties in 
determining the cause, deaths in prison directly or indirectly 
related to the use of new psychoactive substances have 
been reported in Germany, Latvia, Poland and the United 
Kingdom. In England and Wales, between June 2013 
and September 2016, there were 79 cases in which the 
person was known or strongly suspected to have taken 
new psychoactive substances before death or where use of 
such substances was a key issue during imprisonment. Of 
these, 56 were self-inflicted (EMCDDA, 2018).
The ageing trend in the general and opioid-using population 
in the community is also reflected in the prison population. 
Although there are currently few data on this, ageing brings 
with it physical vulnerabilities that can exacerbate existing 
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TABLE 3.1
Prevalence of mental health and substance use disorders in the prison population in studies published between 2006 
and 2019 in the EU Member States, Iceland, Norway and the United Kingdom
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poor health conditions and the negative consequences 
of drug-related problems highly prevalent in the prison 
population (Enggist et al., 2014).
I Mortality after release from prison
The risk of mortality increases markedly when people are 
released from prison; this is so for all causes of death but in 
particular for deaths resulting from drug overdose (Bukten 
et al., 2017; Brummer et al., 2018). The risk of death by 
overdose is extremely high in the first week after release 
(and to a lesser extent in the second week) but remains 
elevated and, compared with people with no prison 
experience, remains elevated for life (Binswanger et al., 
2007) (see Figure 3.3). The risk of non-fatal overdose in the 
initial period after release from prison is also reported to be 
high. Non-fatal overdose can cause serious morbidity and 
predicts future fatal overdose (Winter et al., 2015).
Among people in prison with a history of problem opioid 
use, the increased risk of overdose is primarily related to 
relapse to use of opioids, in particular heroin, after leaving 
prison (Darke and Hall, 2003). Their markedly reduced 
opioid tolerance after a period of abstinence is a major 
factor contributing to the elevated risk, as illustrated in 
a Scottish study on drug-related deaths among people 
discharged from hospital (Merrall et al., 2013).
Studies consistently confirm this elevated risk of drug-
related death in the first weeks after release from prison. 
A review of deaths occurring after release from prison in 
Europe, Australia and the United States found that 6 out 
of 10 deaths occurring in the first 12 weeks after release 
from prison were drug-related (Merrall et al., 2010). Similar 
results are reported by a study conducted in England 
and Wales (Farrell and Marsden, 2008). An Irish study 
of 105 deaths among people using drugs with history of 
imprisonment between 1998 and 2005 found that 28 % of 
overdose deaths after prison release occurred in the first 
week from the release from prison and another 18 % in the 
first month (Lyons et al., 2010).
In Lithuania, a combined analysis of data on mortality 
and imprisonment found that, of 83 drug-related deaths 
reported in 2017, 10 % took place within 6 months of 
release from prison. The drug-related deaths mainly 
occurred in men, with a mean age of 35 years, living in the 
capital city and taking heroin and other opioids, including 
potent opioids such as fentanyl and carfentanil. However, 
the risk of a fatal overdose in the first week after release is 
higher for women than men (Farrell and Marsden, 2008).
I  Health needs of women who are in  prison and use drugs
Women in prison constitute a small proportion of prison 
populations worldwide, usually somewhere between 
3 % and 8 % of the total (van den Bergh et al., 2014; Aebi 
and Tiago, 2020). Imprisonment rates for women vary 
significantly across the globe: 3.2 per 100 000 women 
inhabitants in Africa, 6.2 in Asia, 11.3 in Oceania, and up to 
31.4 in the Americas.
Globally, the number of women and girls in prison 
increased by more than 50 % between 2000 and 2017, 
compared with a 20 % increase in men (Walmsley, 2017). 
In Europe the proportion of women in prison has remained 
TABLE 3.1 continued
Authors Country Sample size Assessment tools Reference population Type of disorder Prevalence (%)

































ADHD, attention deficit-hyperactivity disorder; ASD, autism spectrum disorder; ASI, Addiction Severity Index; ASPD, antisocial personality disorder; BSS, Beck Scale 
for Suicide Ideation; DD, dual diagnosis; DISC, Dominance, Influence, Steadiness and Compliance; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders; 
GAF, Global Assessment of Functioning; ID, intellectual disability; K-SADS, Kiddie Schedule for Affective Disorders and Schizophrenia; N/A, not applicable; OST, 
opioid substitution treatment; PTSD, post-traumatic stress disorder; SAPAS, Standardised Assessment of Personality; SUD, substance use disorder; AUDIT: (Alcohol 
Use Disorders Identification Test-(Piccinelli) Consumption); MCM III (Millon Clinical Multiaxial Inventory, 3rd edition); MINI (Mini-International Neuropsychiatric 
Interview); SCID (Structured Clinical Interview for DSM Disorders; SBQR (Suicide Behaviors Questionnaire-Revised); SCOFF (Sick, Control, One, Fat, Food); SDS 
(self-directed support).
INSIGHTS I Prison and drugs in Europe: current and future challenges
40
stable over the last few years, but overall growth in the 
prison population has resulted in an increase of the number 
of women in prison (Tournier, 2001; Aebi and Tiago, 2020).
At 31 January 2019 there were 41 114 women incarcerated 
in the 27 EU Member States, Norway, Turkey and the United 
Kingdom, representing around 5 % of the total prison 
population. Numbers and percentages vary by country. The 
highest rates per 100 000 female population were reported 
in Czechia, Latvia, Hungary, Lithuania, Slovakia and Turkey 
(Aebi and Tiago, 2020) (Figure 3.4).
Foreign nationals make up a significant share (16 %) of 
women in prison in Europe, reaching over 20 % in 12 
countries, eight of which report a higher proportion of 
foreign nationals among women in prison than among men 
in prison (Aebi and Tiago, 2020).
The lower figures for women in prison compared with men 
reflect the fact that women tend to commit fewer and 
different types of crimes (Braithwaite, 1989; Gottfredson 
and Hirschi, 1990; Akers, 2009; Robert, 2009), and, 
according to some studies, some judges give more lenient 
sentences to women because of the high social cost of 
imprisoning them, as women provide the majority of unpaid 
household labour and child care (Steffensmeier et al., 
1993; Cho and Tasca, 2019).
Women also tend to be sentenced for different crimes 
than men (Aebi and Tiago, 2020). When they go to prison, 
women are mainly sentenced for non-violent crimes, 
including drug law offences (Borrill, 2003; Fazel et al., 
2017).
Worldwide the proportion of women in prison for drug-
related offences is higher than the proportion of men in 
prison for such offences (UNODC, 2018). In Europe, out of 
all women in prison the proportion of those incarcerated 
for drug-related offences varies considerably, from 5 % in 
Bulgaria to approximately 25 % in Denmark, Finland and 
Sweden, 33 % in Italy and 40 % in Spain (UNODC, 2018). 
Women are reported to play less dominant roles in drug 
trafficking, often occupying the lowest level of the drug 
supply chain. There are, however, recent indications of 
involvement of women in higher levels of supply chains 
(UNODC, 2018).
Some women are imprisoned for crimes indirectly related 
to drug use, such as robbery and theft committed to 
support their drug use (Gjersing and Bretteville-Jensen, 
FIGURE 3.3
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2019), while others with a history of drug use are 
sentenced for crimes unrelated to drug use or supply (Aebi 
and Tiago, 2020).
Women in prison have complex social and health profiles 
and have often received scarce or inadequate healthcare 
before imprisonment (van den Bergh et al., 2014). Many 
have experienced multiple traumas since childhood 
in contexts of social disadvantage (Fuentes, 2014). 
A substantial proportion have experienced physical, 
sexual and emotional abuse before being imprisoned, 
and many suffer from severe personality and behavioural 
disorders and/or have a history of self-harm, abuse and 
abandonment.
Compared with men in prison and with women in the 
general population, women in prison have high rates of 
mental health problems, including post-traumatic stress 
disorders, depression and self-harm (Tyler et al., 2019). 
They also report high rates of sexually transmitted and 
other infectious diseases, reproductive health problems 
(e.g. cervical cancer), dental problems, obesity and 
other non-communicable diseases (Plugge et al., 2009). 
Substance use problems are also frequently reported 
among women in prison, although for many that is 
a secondary disorder following a previous mental health 
problem (EMCDDA, 2015), and it often represents a way to 
alleviate and/or self-medicate past traumas of violence and 
abuse (Friestad et al., 2014: Braitman and Kelley, 2016). 
A recent analysis of the available data on drug use at 
reception to prison found that drug use disorders are highly 
prevalent among people in prison and are more prevalent 
among women than men (Fazel et al., 2017). Based on 
data from 10 countries (Australia, Austria, England, France, 
Germany, Iceland, Ireland, the Netherlands, New Zealand, 
United States), the study reported a pooled estimate of 
drug use disorders in the year before entering prison of 
51 % among women and 30 % among men. In a systematic 
review with data from 12 European countries, the rates of 
lifetime prevalence of any illicit drug use before prison were 
estimated at 62 % in women in prison and 41 % in men in 
prison (van de Baan, 2018).
A recent analysis of data from the EQDP from six European 
countries compares lifetime prevalence of drug use 
before prison among men and women in prison and in 
the community: it shows a higher excess of drug use 
prevalence among women than men (see Chapter 2).
The reasons for this higher excess in the prevalence of drug 
use among women in prison are likely to be related to the 
high proportion of women going to prison for drug-related 
offences (although not all of them are using drugs) and the 
high level of vulnerability of women who commit crimes 
and are sentenced to prison (van den Bergh et al., 2014; 
Wattanaporn and Holtfreter, 2014). Overall, few women are 
sentenced to prison but those who are imprisoned often 
present complex social and (physical and mental) health 
profiles.
The patterns of drug use among incarcerated women are 
similar to those reported by men in prison. The majority 
of women in prison have used cannabis in their lifetimes. 
Prevalence is also high for other illicit substance use, such 
as heroin (from 19 % in Spain to 49 % in Latvia), cocaine 
(from 21 % in Lithuania and Czechia to 41 % in Latvia), and 
amphetamines (from 17 % in Portugal to 64 % in Slovenia) 
(data from the 2019 EQDP).
Women in prison report higher rates of infectious diseases, 
including HIV/AIDS, hepatitis B, hepatitis C and syphilis, 
than men in prison and the general female population, 
as they are more likely to participate in risky behaviours, 
including sex work and injecting drug use. Many cases of 
sexually transmitted infection remain undetected because 
they are asymptomatic. Some of these infections in women 
may have serious long-term health consequences such 
as ectopic pregnancy, infertility and chronic pelvic pain. 
Sexually transmitted diseases are a major factor in the 
spread of HIV, as they enhance transmission and diminish 
the body’s general resistance (Dolan et al., 2016).
Compared with women in the general population and 
with men who use drugs in prison, women with prison 
experience show higher rates of suicide both inside and 
FIGURE 3.4 
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outside prison and report higher rates of self-harm inside 
prison, regardless of whether or not they are using drugs 
(Farrell and Marsden, 2008; Douglas et al., 2009).
The impact of imprisonment on women may be especially 
damaging. As reported in a British briefing, women in 
prison are far more likely than men to be primary carers of 
children, who are often placed in foster care when women 
are imprisoned (Prison Reform Trust, 2015). Once in prison, 
women tend to be more isolated than men and receive 
fewer visits (Prison Reform Trust, 2015). Because there are 
fewer prison institutions for women, they may serve their 
sentences away from their area of residence, hindering 
family visits and contributing to their isolation. This lack 
of facilities may also result in overcrowding (Observatoire 
International de Prisons — Section Française, 2019).
Women who use drugs and have been in prison also are at 
a high risk of drug-related death after release from prison. 
A study on drug-related mortality after release from prison 
in the United States found that among people who had 
been in prison the overdose mortality rate was more than 
50 % higher among women than men (236 v. 154 per 
100 000 person-years) (Binswanger et al., 2013).
Although it is also reported for men, studies suggest that, 
on leaving prison, women with drug-related problems 
by comparison suffer more serious long-term social 
consequences of their prison experiences (INCB, 2018). 
Women are less likely than men to receive support in 
their return to the family or the community, and they 
may be socially isolated and socially and economically 
disadvantaged, losing their accommodation and facing 
additional difficulties when searching for work (Douglas et 
al., 2009).
I Conclusions
While prison conditions can negatively affect the already 
impaired health of people who use drugs, prisons are 
also settings that may facilitate the provision of health 
services; it is often in prison that people, who are otherwise 
considered hard to reach by health services in the 
community, are offered prevention, treatment and harm 
reduction services to address their drug use and drug-
related problems. Interventions in prison may also play 
a key role upon release in facilitating the continuation of 
treatment and in preventing drug-related deaths. These 
interventions (see Chapters 4 and 5) may have a significant 
impact on morbidity, mortality, public health and recidivism, 
which not only benefits people in prison but also delivers 
a community dividend.
A better understanding of the full extent and complexity 
of drug use among people in prison is needed in order to 
inform the development of evidence-based policies and 
interventions that address the needs of people in prison. 
Yet, the scarcity of studies and data on the subject poses 
a challenge, which is accentuated when discussing data 
across countries.
There is a need to improve the epidemiological data on 
drug-related health problems among people in prison in 
order to ensure the availability of reliable and comparable 
data across countries. Examples of improvements in this 
field include the methodological framework for monitoring 
drugs and prison in Europe and the development of the 
EQDP. Further studies and data collection initiatives in this 
area would greatly contribute to the body of evidence on 
the needs of the prison population; this is key for the sound 
planning and provision of services that may affect the 
health and social conditions of people in prison.
In addition, a better understanding of the intersections of 
the risk factors associated with drug use and with criminal 
behaviour may allow for the development of services and 
interventions that address multiple risk behaviours.
I References
I  Aebi, M. F. and Tiago, M. M. (2020), Council of Europe annual 
penal statistics SPACE I: prison populations survey 2019, Council 
of Europe, Strasbourg.
I  Aerts, A., Hauer, B., Wanlin, M. and Veen, J. (2006), ‘Tuberculosis 
and tuberculosis control in European prisons’, International 
Journal of Tuberculosis and Lung Disease 10(11), pp. 1215-1223.
I  Akers, R. L. (2009), Social learning and social structure: a general 
theory of crime and deviance, Routledge, New York.
I  Arroyo, J. M. and Ortega, E. (2009), ‘Los trastornos de personalidad 
en reclusos como factor de distorsión del clima social de la 
prisión’, Revista Española de Sanidad Penitenciaria 11(1), pp. 3-7.
I  Azbel, L. and Altice, F. L. (2018), ‘Drug use, HIV, and the high-risk 
environment of prisons’, in Kinner, S. A. and Rich, J. D. J. (eds.), 
Drug use in prisoners: epidemiology, implications and policy 
responses, Oxford University Press, New York, pp. 99-115.
I  Baillargeon, J., Binswanger, I. A., Penn, J. V., Williams, B. A. 
and Murray, O. J. (2009), ‘Psychiatric disorders and repeat 
incarcerations: the revolving prison door’, American Journal of 
Psychiatry doi:110.1176/appi.ajp.2008.08030416.
CHAPTER 3 I Drug-related health problems of people in prison
43
I  Barry, J. M., Darker, C. D., Thomas, D. E., Allwright, S. P. A. and 
O’Dowd, T. (2010), ‘Primary medical care in Irish prisons’, BMC 
Health Services Research 10, 74.
I  Baussano, I., Williams, B. G., Nunn, P., Beggiato, M., Fedeli, U. and 
Scano, F. (2010), ‘Tuberculosis incidence in prisons: a systematic 
review’, PLoS Medicine 7(12), e1000381, doi:10.1371/journal.
pmed.1000381.
I  Binswanger, I. A., Stern, M. F., Deyo, Heagerty, P. J., Cheadle, A., 
Elmore, J. G. and Koepsell, T. D. (2007), ‘Release from prison: 
a high risk of death for former inmates’, New England Journal of 
Medicine 356(2), pp. 157-165.
I  Borrill, J., Maden, A., Martin, A., Weaver, T., Stimson, G., Farrell, M. 
and Barnes, T. (2003), Differential substance misuse treatment 
needs of women, ethnic minorities and young offenders in prison: 
prevalence of substance misuse and treatment needs, Home 
Office Online Report 33/03, Home Office, London.
I  Braithwaite, J. (1989), Crime, shame and reintegration, Cambridge 
University Press.
I  Braitman, A. L. and Kelley, M. L. (2016), ‘Initiation and retention in 
couples outpatient treatment for parents with drug and alcohol 
use disorders’, Experimental and Clinical Psychopharmacology 
24(3), p. 174.
I  Brummer, J., Møller, L. and Enggist, S. (2018), ‘Preventing 
drug-related death in recently released prisoners’, in Kinner, S. A. 
and Rich, J. D. J. (eds.), Drug use in prisoners: epidemiology, 
implications and policy responses, Oxford University Press, New 
York, pp. 247-262.
I  Bukten, A., Stavseth, M. R., Skurtveit, S., Tverdal, A., Strang, J. and 
Clausen, T. (2017), ‘High risk of overdose death following release 
from prison: variations in mortality during a 15-year observation 
period’, Addiction 112(8), pp. 1432-1439.
I  Casares-López, M. J., González-Menéndez, A., Bobes-Bascarán, 
M. T., Secades, R., Martínez-Cordero, A. and Bobes, J. (2011), 
‘Necesidad de evaluación de la patología dual en contexto 
penitenciario’, Adicciones 23(1), pp. 37-44.
I  Chang, Z., Larsson, H., Lichtenstein, P. and Fazel, S. (2015), 
‘Psychiatric disorders and violent reoffending: a national cohort 
study of convicted prisoners in Sweden’, Lancet Psychiatry 2(10), 
pp. 891-900.
I  Cho, A. and Tasca, M. (2019), ‘Disparities in women’s prison 
sentences: exploring the nexus between motherhood, drug 
offense, and sentence length’, Feminist Criminology 14(4), pp. 
420-440.
I  Colins, O., Vermeiren, R., Vahl, P., Markus, M., Broekaert, E. and 
Doreleijers, T. (2011), ‘Psychiatric disorder in detained male 
adolescents as risk factor for serious recidivism’, Canadian 
Journal of Psychiatry 56(1), pp. 44-50.
I  Darke, S. and Hall, W. (2003), ‘Heroin overdose: research and 
evidence-based intervention’, Journal of Urban Health 80(2), pp. 
189-200.
I  Darke, S. and Ross, J. (2002), ‘Suicide among heroin users: rates, 
risk factors and methods’, Addiction 97(11), pp. 1383-1394.
I  Désesquelles, A., Kensey, A. and Meslé, F. (2018), ‘Circonstances 
et causes des décès des personnes écrouées en France: le poids 
écrasant des morts violentes’, Population 73(4), pp. 757-786.
I  Dolan, K., Wirtz, A. L., Moazen, B., Ndeffo-mbah, M., Galvani, A., 
Kinner, S. A., Courtney, R., et al. (2016), ‘Global burden of HIV, viral 
hepatitis, and tuberculosis in prisoners and detainees’, Lancet 
388(10049), pp. 1089-1102.
I  Douglas, N., Plugge, E. and Fitzpatrick, R. (2009), ‘The impact of 
imprisonment on health: what do women prisoners say?’, Journal 
of Epidemiology and Community Health 63(9), pp. 749-754.
I  Einarsson, E., Sigurdsson, J. F., Gudjonsson, G. H., Newton, A. K. 
and Bragason, O. O. (2009), ‘Screening for attention-deficit 
hyperactivity disorder and co-morbid mental disorders among 
prison inmates, Nordic Journal of Psychiatry 63(5), pp. 361-367.
I  Elonheimo, H., Niemelä, S., Parkkola, K., Multimäki, P., Helenius, H., 
Nuutila, A. M. and Sourander, A. (2007), ‘Police-registered offenses 
and psychiatric disorders among young males: the Finnish 
“from a boy to a man” birth cohort study’, Social Psychiatry and 
Psychiatric Epidemiology 42(6), pp. 477–84.
I  EMCDDA (2015), Comorbidity of substance use and mental 
disorders in Europe, EMCDDA Insights 19, Publication Office of the 
European Union, Luxembourg.
I  EMCDDA (2018), New psychoactive substances in prison, Rapid 
Communications, Publications Office of the European Union, 
Luxembourg.
I  Enggist, S., Møller, L., Galea, G. and Udesen, C. (2014), Prisons 
and health, World Health Organization Regional Office for Europe, 
Copenhagen.
I  Farrell, M. and Marsden, J. (2008), ‘Acute risk of drug-related death 
among newly released prisoners in England and Wales’, Addiction 
103(2), pp. 251-255.
I  Fazel, S. and Baillargeon, J. (2011), ‘The health of prisoners’, 
Lancet 377(9769), pp. 956-965.
I  Fazel, S., Bains, P. and Doll, H. (2006), ‘Substance abuse and 
dependence in prisoners: a systematic review’, Addiction 101(2), 
pp. 181-191.
I  Fazel, S., Yoon, I. A. and Hayes, A. J. (2017), ‘Substance use 
disorders in prisoners: an updated systematic review and meta-
regression analysis in recently incarcerated men and women’, 
Addiction 112(10), pp. 1725-1739.
I  Friestad, C., Åse-Bente, R. and Kjelsberg, E. (2014), ‘Adverse 
childhood experiences among women prisoners: relationships to 
suicide attempts and drug abuse’, International Journal of Social 
Psychiatry 60(1), pp. 40-46.
I  Fuentes, C. M. (2014), ‘Nobody’s child: the role of trauma and 
interpersonal violence in women’s pathways to incarceration and 
resultant service needs’, Medical Anthropology Quarterly 28(1), pp. 
85-104.
I  Garcia-Guerrero, J. and Marco, A. (2012), ‘Overcrowding in 
prisons and its impact on health’, Revista Espanola de Sanidad 
Penitenciaria 14(3), pp. 106-113.
INSIGHTS I Prison and drugs in Europe: current and future challenges
44
I  Gjersing, L. and Bretteville-Jensen, A. L. (2019), ‘Drug policy 
changes and the possible impact on incarcerations in a cohort of 
street- and low threshold service recruited illegal substance users’, 
paper presented at Lisbon Addictions, 23-24 October, Lisbon.
I  Gottfredson, M. R. and Hirschi, T. (1990), A general theory of crime, 
Stanford University Press, Stanford, MA.
I  Harsch, S., Bergk, J. E., Steinert, T., Keller, F. and Jockusch, U. 
(2006), ‘Prevalence of mental disorders among sexual offenders in 
forensic psychiatry and prison’, International Journal of Law and 
Psychiatry 29(5), pp. 443–49.
I  INCB (International Narcotics Control Board) (2018), Report of the 
International Narcotics Control Board for 2017, INCB, Vienna.
I  Jürgens, R., Nowak, M. and Day, M. (2011), ‘HIV and incarceration: 
prisons and detention’, Journal of the International AIDS Society 
14(1), p. 26.
I  Larney, S., Gisev, N., Farrell, M., Dobbins, T., Burns, L., Gibson, A., 
Kimber, J. and Degenhardt, L. (2014), ‘Opioid substitution therapy 
as a strategy to reduce deaths in prison: retrospective cohort 
study’, BMJ Open 4, e004666.
I  Lukasiewicz, M., Blecha, L., Falissard, B., Neveu, X., Benyamina, A., 
Reynaud, M. and Gasquet, I. (2009), ‘Dual diagnosis: prevalence, 
risk factors, and relationship with suicide risk in a nationwide 
sample of French prisoners’, Alcoholism, Clinical and Experimental 
Research 33(1), pp. 160–68.
I  Lyons, S., Walsh, S., Lynn, E. and Long, J. (2010), ‘Drug-related 
deaths among recently released prisoners in Ireland, 1998 to 
2005’, International Journal of Prisoner Health 6(1), pp. 26-32.
I  Mathew, P., Elting, L., Cooksley, C., Owen, S. and Lin, J. (2005), 
‘Cancer in an incarcerated population’, Cancer 104(10), pp. 2197-
2204.
I  Merrall, E. L. C., Kariminia, A., Binswanger, I. A., Hobbs, M. S., Farrell, 
M., Marsden, J., Hutchinson, S. J. and Bird, S. M. (2010), ‘Meta-
analysis of drug-related deaths soon after release from prison’, 
Addiction 105(9), pp. 1545-1554.
I  Merrall, E. L. C., Bird, S. M. and Hutchinson, S. J. (2013), ‘A record-
linkage study of drug-related death and suicide after hospital 
discharge among drug-treatment clients in Scotland, 1996-2006’, 
Addiction 108(2), pp. 377-384.
I  Milloy, M. S., Buxton, J., Wood, E., Li, K., Montaner, J. S. G. and Kerr, 
T. (2009), ‘Elevated HIV risk behaviour among recently incarcerated 
injection drug users in a Canadian setting: a longitudinal analysis’, 
BMC Public Health 9(1), pp. 156.
I  Milloy, M. J., Kerr, T., Buxton, J., Rhodes, T., Guillemi,, S., Hogg, 
R., Montaner, J. and Wood, E. (2011), ‘Dose-response effect of 
incarceration events on nonadherence to HIV antiretroviral therapy 
among injection drug users’, Journal of Infectious Diseases 
203(9), pp. 1215-1221.
I  Møller, L., Stöver, H., Jürgens, R., Gatherer, A. and Nikogosian, H. 
(2007), Health in prisons: a WHO guide to the essentials in prison 
health, World Health Organization Regional Office for Europe, 
Copenhagen.
I  Observatoire International de Prisons — Section Française (2019), 
Femmes détenues: les oubliées, Dedans Dehors No 106 (https://
oip.org/publication/femmes-detenues/).
I  Palijan, T. Ž., Mužinić, L. and Radeljak, S. (2009), ‘Psychiatric 
comorbidity in forensic psychiatry’, Psychiatria Danubina 21(3), 
pp. 429-436.
I  Piselli, M., Elisei, S., Murgia, N., Quartesan, R. and Abram, K. M. 
(2009), ‘Co-occurring psychiatric and substance use disorders 
among male detainees in Italy’, International Journal of Law and 
Psychiatry 32(2), pp. 101-107.
I  Plugge, E., Elwood Martin, R. and Hayton, P. (2014), 
‘Noncommunicable diseases and prisoners’, in: Enggist, S., Moller, 
L. and Galea, G. (editors), Prisoners and Health, World Health 
Organization, Geneva.
I  Plugge, E., Yudkin, P. and Douglas, N. (2009), ‘Changes in women’s 
use of illicit drugs following imprisonment’, Addiction 104(2), pp. 
215-222.
I  Prison Reform Trust (2015), Why focus on reducing women’s 
imprisonment?, Prison Reform Trust Briefing, Prison Reform Trust, 
London.
I  Rabe, K. (2012), ‘Prison structure, inmate mortality and suicide risk 
in Europe’, International Journal of Law and Psychiatry 35(3), pp. 
222-230.
I  Robert, A. (2009), ‘The contribution of “mainstream” theories to 
the explanation of female delinquency’, in Zahn, M. A. (ed.), The 
delinquent girl, Temple University Press, Philadelphia, PA., pp. 
7-29.
I  Rouillon, F., Duburcq, A., Fagnani, F. and Falissard, B. (2004), 
‘Étude épidémiologique sur la santé mentale des personnes 
détenues en prison’, Expertise psychiatrique pénale’, etude DGS.
I  Silbernagl, M., Slamanig, R., Fischer, G. and Brandt, L. (2018), 
‘Hepatitis C infection and psychiatric burden in two imprisoned 
cohorts: young offenders and opioid-maintained prisoners’, Health 
Policy 122(12), pp. 1392-1402.
I  Silbernagl, M., Slamanig, R., Stegemann, M., Sterzer, M., Mayer, L., 
Fischer, G. and Unger, A. (2019a), ‘Attention-deficit hyperactivity 
disorder symptom status in a mixed gender population of opioid-
maintained prison inmates’, European Addiction Research 25(2), 
pp. 80-92.
I  Silbernagl, M., Yanagida, T., Slamanig, R., Fischer, G. and Brandt, 
L. (2019b), ‘Comorbidity patterns among patients with opioid 
use disorder and problem gambling: ADHD status predicts class 
membership’, Journal of Dual Diagnosis 15(3), pp. 147-158.
I  Sørland, T. O. and Kjelsberg, E. (2009), ‘Mental health among 
teenage boys remanded to prisoner’, Tidsskrift for Den Norske 
Laegeforening 129(23), pp. 2472–2475.
I  Steffensmeier, D., Kramer, J. and Streifel, C. (1993), ‘Gender and 
imprisonment decisions’, Criminology 31(3), pp. 411-446.
I  Stone, J., Fraser, H., Lim, A. G., Walker, J. G., Ward, Z., Macgregor, 
L., Trickey, A., et al. (2018), ‘Incarceration history and risk of 
HIV and hepatitis C virus acquisition among people who inject 
CHAPTER 3 I Drug-related health problems of people in prison
45
drugs: a systematic review and meta-analysis’, Lancet Infectious 
Diseases 18(12), pp. 1397-1409.
I  Tarján, A., Horváth, G. and Stöver, H. (2019), European mapping 
of harm reduction interventions in prisons, revised version, Institut 
für Suchtforschung, Frankfurt University of Applied Sciences, 
Frankfurt.
I  Tournier, P. V. (2001), Council of Europe annual penal statistics 
SPACE I, survey 2000, Council of Europe, Strasbourg.
I  Tyler, N., Miles, H. L., Karadag, B. and Rogers, G. (2019), ‘An 
updated picture of the mental health needs of male and female 
prisoners in the UK: prevalence, comorbidity, and gender 
differences’, Social Psychiatry and Psychiatric Epidemiology 54(9), 
pp. 1143-1152.
I  UNODC (United Nations Office on Drugs and Crime) (2018), 
UNODC world drug report 2018, Booklet 5: Women and drugs, 
UNODC, Vienna.
I  Van de Baan, F. C., Montanari, L., Royuela, L., and Lemmens, P. H. 
H. M. (2021), ‘Prevalence of illicit drug use before imprisonment 
in Europe: results from a comprehensive literature review’, Drugs: 
Education, Prevention and Policy, 1-12. doi:10.1080/09687637.20
21.1879022.
I  Van den Bergh, B., Plugge, E. and Aguirre, I. Y. (2014), ‘Women’s 
health and the prison setting’, in Enggist, S., Møller, L., Galea, 
G. and Udesen, C. (eds.), Prisons and health, World Health 
Organization Regional Office for Europe, Copenhagen, pp. 159-
170.
I  Van Horn, J. E., Eisenberg, M. J., van Kuik, S. and van Kinderen, 
G. M. (2012), ‘[Psychopathology and recidivism among violent 
offenders with a dual diagnosis. A comparison with other 
subgroups of violent offenders]’, Tijdschrift Voor Psychiatrie 54(6), 
pp. 497–507.
I  Walmsley, R. (2017), ‘World female imprisonment list’, World 
prison brief, Institute for Crime & Justice Policy Research, London 
(https://www.prisonstudies.org).
I  Wattanaporn, K. A. and Holtfreter, K. (2014), ‘The impact of feminist 
pathways research on gender-responsive policy and practice’, 
Feminist Criminology 9(3), pp. 191-207.
I  Widinghoff, C., Berge, J., Wallinius, M., Billstedt, E., Hofvander, 
B. and Håkansson, A. (2019), ‘Gambling disorder in male violent 
offenders in the prison system: psychiatric and substance-related 
comorbidity’, Journal of Gambling Studies 35(2), pp. 485-500.
I  Winter, R. J. and Hellard, M. E. (2018), ‘Drug use in prisoners and 
hepatitis’, in Kinner, S. A. and Rich, J. D. J. (eds.), Drug use in 
prisoners: epidemiology, implications and policy responses, Oxford 
University Press, New York, pp. 132-142.
I  Winter, R. J., Stoove, M., Degenhardt, L., Hellard, M. E., Spelman, T., 
Jenkinson, R., McCarthy, D. R. and Kinner, S. A. (2015), ‘Incidence 
and predictors of non-fatal drug overdose after release from prison 
among people who inject drugs in Queensland, Australia’, Drug 
and Alcohol Dependence 153, pp. 43-49.
I  Winter, R. J., Young, J. T., Stoove, M., Agius, P. A., Hellard, M. E. and 
Kinner, S. A. (2016), ‘Resumption of injecting drug use following 
release from prison in Australia’, Drug and Alcohol Dependence 
168, pp. 104-111.
I  Young, J. T., Heffernan, E., Borschmann, R., Ogloff, J. R. P., Spittal, 
M. J., Kouyoumdjian, F. G., Preen, D. B., et al. (2018), ‘Dual 
diagnosis of mental illness and substance use disorder and injury 
in adults recently released from prison: a prospective cohort study’, 
Lancet Public Health 3(5), pp. e237-e248.
4
47
A variety of interventions are implemented in European 
prisons to address drug-related problems. Their coverage 
and availability vary across countries and across different 
prisons within the same country. This chapter maps 
the organisation and implementation of health and 
social responses to drug problems in European prisons. 
It provides a general overview of various policy and 
institutional frameworks for prison health and outlines the 
availability and coverage of drug-related interventions in 
prisons in the EU Member States, Norway, Turkey and the 
United Kingdom.
Key issues for the organisation of drug services in prison 
are outlined, and guiding principles for carrying out drug-
related interventions in prison are introduced, followed 
by an overview of governance and a description of the 
available guidance on drug-related interventions in prison.
The second part of the chapter maps the interventions in the 
reporting countries. The mapping exercise is structured along 
the phases of imprisonment — entry, stay and release — and 
the types of interventions are discussed. For each group of 
interventions, practices from three countries are outlined. 
These examples illustrate the interventions currently used 
in some European prisons, and they do not necessarily 
represent evidence-based or best practice in the field.
This chapter is based on qualitative information provided 
by the reporting countries through the EMCDDA’s network 
of national focal points and the findings of the HA-REACT 
project. Caution should be paid when interpreting 
the data on available interventions, as these mainly 
originate from expert opinion; no standard data collection 
instruments on drug-related interventions in prison were 
available when drafting this report (see Chapter 1).
As a complement to the information provided here, 
Chapter 5 will look in more detail at specific harm reduction 
interventions, and Chapter 6 provides an in-depth review of 
the evidence of effectiveness for many of the interventions 
presented here.
I  Guiding principles for the provision and organisation of drug services in prison
Two internationally recognised principles provide the 
basis for providing health treatment for people in prison: 
equivalence of care and continuity of care.
The principle of equivalence of care was highlighted in 
the 2015 Nelson Mandela Rules (United Nations General 
Assembly, 2015), which state that ‘prisoners should enjoy 
the same standards of health care that are available in the 
community, and should have access to necessary health-
care services free of charge without discrimination on the 
grounds of their legal status’ (Rule 24).
The majority of people in prison come from vulnerable 
population groups, and so the mere provision of health 
services equivalent to those available to the general 
population is unlikely to lead to the same health status. 
It may therefore be necessary to implement additional 
and targeted interventions for people in prison in order to 
achieve equivalence of health outcomes.
The principle of continuity of care focuses on maintaining 
healthcare provision for people in prison as they move in 
and out of custody. The emphasis is on the importance 
of maintaining clinical and treatment interventions when 
entering prison, during the stay and on leaving prison 
(Enggist et al., 2014; Abbott et al., 2017).
Nelson Mandela Rule 24 addresses this principle in stating 
that ‘Health-care services should be organised in close 
relationship to the general public health administration 
and in a way that ensures continuity of treatment and 
care, including for HIV, tuberculosis and other infectious 
diseases, as well as for drug dependence’.
Accordingly, healthcare services need to aim for 
health promotion and rehabilitation (Rule 25); to be 
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interdisciplinary (Rule 25); to support the independence 
of prison doctors and the application of the same ethical 
professional principles followed outside prison (Rule 32); 
to conduct a health assessment on entry to prison (Rule 
30); to be available in the event of emergency, or when 
people are sick or request treatment (Rule 31); to ensure 
confidentiality (Rule 26); to address the needs of pregnant 
women and children (Rules 28, 29); and to comply with 
and safeguard the duty of health professionals to report to 
the prison authorities any case of mistreatment, torture or 
harm due to imprisonment and harmful prison conditions 
(Rules 33, 34, 35).
The clinical independence of healthcare staff is a requirement 
for the implementation of equivalence and continuity of 
care and is essential to providing good healthcare, and 
ensuring healthcare professionalism, in correctional settings. 
The Nelson Mandela Rules address the independence of 
healthcare professionals in Rules 27 and 31.
Clinical independence can be defined as the ‘assurance 
that individual physicians have the freedom to exercise 
their professional judgment in the care and treatment of 
their patients without undue influence by outside parties 
or individuals’ (World Medical Association, 2018). This 
is of particular importance in correctional and detention 
settings, as the relationship between healthcare providers 
and patients is not based on free will (Pont et al., 2018).
Healthcare staff may, however, face several obstacles when 
providing health services in prison. They may be obliged 
to report to correctional — rather than healthcare — 
leadership or may be asked to contribute to custodial 
measures, certifying, for instance, that a particular person 
is medically fit for punishment or solitary confinement. In 
addition, patients may have limited capacity to exercise 
self-determination, such as informed consent or dissent, 
and cannot choose the physician that attends to their 
health. Overall, prison settings are often characterised 
by a general paucity of knowledge and awareness of 
healthcare ethics (Pont et al., 2018).
International and European guidance for the provision of healthcare in prison
The provision of healthcare in prison has been the subject of much international and European guidance, starting in 1948 
with the United Nations (UN) Declaration of Human Rights and its Standard Minimum Rules for the Treatment of Prisoners 
(SMR), adopted in 1955 and last revised in 2015 as the Nelson Mandela Rules. Other important international guidance 
includes the International Covenant on Civil and Political Rights, the UN Convention Against Torture, the UN Sustainable 
Development Goals (particularly SDG 16), and the many specialist recommendations and guidance developed by the World 
Medical Association, UN and World Health Organization.
While many of these rules are not legally binding on states, they have played an important role in shaping national and 
international legislation.
Within the European context, the European Prison Rules, the reports and standards of the European Committee for the 
Prevention of Torture (CPT), and the European Convention of Human Rights (ECHR) along with the European Court of Human 
Rights (ECtHR) play a significant role in guiding and improving prison standards and in protecting the rights of people in 
prison (van Zyl Smit and Snacken, 2009). The European Prison Rules were modelled on the UN SMR for the treatment of 
prisoners and devote an entire section to health in the revised 2006 version, signalling the importance of improving the 
standards of healthcare provision in prison (Easton, 2011). The CPT has an important preventive function and through its 
reports and visits it sets clear limits on what is acceptable treatment of people in prison. It also places great relevance on 
health matters (van Zyl Smit and Snacken, 2009). The ECtHR deals with individual complaints, has an adjudicative function, 
and its findings are binding (see the case Wenner v. Germany, described in Chapter 5) (Easton, 2011).
At the country level, national prevention mechanisms that monitor and ensure respect for the human rights of people deprived 
of liberty operate in countries that ratified the Optional Protocol to the Convention against Torture (United Nations General 
Assembly, 2003). In addition, a number of other parties including non-governmental organisations, such as the International 
Red Cross or Harm Reduction International, play an important role in this field. Together these mechanisms and organisations 
provide a key source of case law and principles that govern the practice of imprisonment in Europe (Easton, 2011).
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I  Governance of prison healthcare services
The governance of prison health services in Europe, for the 
most part, rests with the ministry managing prison services 
overall, typically the ministry of justice or interior, whereby 
decisions about prison health are taken by national 
prison administrations or specialised executive agencies 
depending on these ministries. In 2019, the governance 
of healthcare in prison rested with the justice ministry in 
16 countries, with the health ministry in 8 and with the 
interior ministry in two, and in the remaining four countries 
it is shared between the justice and health ministries 
(Figure 4.1). In two autonomous regions of Spain (Catalonia 
and Basque country), unlike the rest of the country, 
the responsibility for prison health is under the health 
department.
Various international organisations including the WHO 
recommend that the management and coordination of 
all relevant agencies and resources contributing to the 
health and well-being of people in prison is a whole-of-
government responsibility, whereby prison health services 
are fully independent of prison administrations and yet 
liaise effectively with them. In addition, they recommend 
that health ministries provide and are accountable for 
healthcare services in prisons and advocate for healthy 
prison conditions (WHO Europe, 2013).
These recommendations have prompted some countries 
in Europe, and elsewhere, to transfer the responsibility 
for healthcare in prison to the health ministry. The move 
aims to provide adequate healthcare by ensuring good 
governance of healthcare in prison. Several benefits 
may be expected from a change in the governance of 
prison healthcare, such as improved resources, the 
inclusion of people in prison in public health initiatives, 
the development of prison health indicators, and the 
integration of prison health data into national health 
statistics (WHO Europe, 2013).
It remains to be assessed through evaluation, however, 
whether these measures can and have contributed to 
improving the health of people in prison and how structural 
changes can be improved.
The transfer of responsibility to health ministries aims to 
better integrate prison health services into the community 
and improve the continuity of care provided to people in 
prison (Enggist et al., 2014). Where this has occurred, 
the move was often prompted by the recognition that 
prison health problems needed to be tackled more 
effectively and that improved care for people in prison 
required easier access to medical specialists. In the United 
Kingdom, the move has increased the importance given 
to treatment for drug use inside prison. Finland and the 
United Kingdom (Leaman et al., 2016) have conducted 
evaluations of the transfers (WHO Europe, 2019). In 
Sweden, the responsibility for health in prison is under 
the justice ministry, but the health ministry supervises the 
service provision. Latvia, Portugal, Romania and Slovakia 
have developed inter-ministry collaborations between the 
ministries of justice and health to ensure an approach 
to healthcare in prison that considers the needs of both 
prison security and management and prison healthcare. 
In Spain, healthcare in prison is under the responsibility 
of the interior ministry except in the Basque Country 
and Catalonia. In most of the remaining countries the 
governance of healthcare in prison falls under either the 
justice or interior ministries.
In countries where health in prison is not under the 
responsibility of the ministry of health, drug treatment 
is mainly provided by staff employed by the prison 
administration, forming multidisciplinary teams often 
including medical doctors, psychologists, psychiatrists and 
social workers. Prison administrations may collaborate with 
external, community-based treatment providers, public 
health services or non-governmental organisations (NGOs) 
to ensure the delivery of drug treatment services to people 
in prison. Personnel from public services are often allocated 
to work alongside prison staff, and external providers may 
‘reach in’ and work independently inside the prison.
FIGURE 4.1
Government institutions responsible for the 
governance of healthcare in prison in the EU Member 







Source: EMCDDA and national monitoring data; WHO Health in Prisons 
European Database.
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Such partnerships with external organisations are reported 
in most countries. Involving external service providers 
who establish client contacts during imprisonment may 
also support continuity of care after release. Germany and 
Slovenia report that external service providers, including 
NGOs, are to a large extent involved in the provision of 
harm reduction interventions in prison (Tarján et al., 2019).
I Policy documents addressing drugs and prison
Across Europe responses to drug-related problems in 
prisons are addressed in each country by one or more 
drug, health or prison-specific policy document, such as 
prison strategies, action plans and implementation plans. 
Common policy objectives include improving access to 
health and social care in prison for people with drug-related 
problems, reducing health-related problems among people 
in prison, supporting their reintegration into society and 
reducing recidivism.
A number of countries have developed guidelines for the 
implementation of responses to drug-related problems 
in prison. Furthermore, many countries in Europe define 
specific elements of drug-related service provision in 
prisons — such as harm reduction interventions, testing 
and treatment of infectious diseases and interventions 
preparing for release — in written strategies or guidelines 
(Tarján et al., 2019).
I  European guidance on interventions targeting drug use in prison
Various institutions and agencies are engaged in prison 
healthcare, and a number of guidelines on interventions 
targeting drug use in prison are available. This section 
identifies some of the most important for the European 
context.
In 2013, the UNODC identified a minimum package for HIV 
prevention in prison settings. This document is important 
when tackling drug use in prison, as it addresses specific 
harm reduction interventions such as prison-based needle 
and syringe programmes, as well as OST and other drug 
dependence treatments (UNODC et al., 2013).
More specific to Europe, the WHO Regional Office for 
Europe (WHO Europe) released its comprehensive reports 
on prison health, covering a wide range of aspects such as 
communicable and chronic diseases, mental health and 
problematic substance use in prison settings (Enggist et al., 
National strategic documents on drugs in prison in three European countries
France
In June 2019, the Ministry of Solidarity and Health and the Ministry of Justice adopted a roadmap targeting 28 priority 
actions for the period 2019-2021, based on the ‘health/prison’ strategic actions plan on health policy for inmates 
adopted in 2017. Among these actions, seven concern treatment for inmates with addictions, including monitoring, 
harm reduction, continuity of care after release and community healthcare.
Cyprus
Two main documents address drug-related interventions in the prison setting: the Prison Regulations (1997) and the 
drug action plan 2017-2020. The Prison Regulations provide for the medical examination and treatment of all people 
in prison, including treatment for drug-related problems. In addition, the treatment and social reintegration pillar of the 
drug action plan 2017-2020 includes, under priority 7 on assurance of social reintegration services, an action providing 
for reinforcing existing mechanisms for the social reintegration of people who use drugs upon their release from prison.
Norway
The Norwegian action plan addressing substance use and addiction for the years 2016-2020 recommends an 
interdisciplinary approach that aims to strengthen primary health services and outpatient psychiatric treatment in 
prisons; establish new interdisciplinary specialised treatment services in prisons when necessary; encourage increased 
use of the option to serve a sentence in an institution outside prison; consider how detoxification services for people 
in prison can be strengthened; and expand an existing pilot ‘drug programme with court control’ into a permanent 
intervention.
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2014; WHO Europe, 2019). In 2017, the EMCDDA released 
a European guide on health and social care responses to 
drug problems (EMCDDA, 2017), which identifies prisons 
as one of the key settings for implementation of targeted 
interventions to reduce and prevent drug use and drug-
related health harms. For situations where detention is 
not avoidable, a comprehensive set of evidence-based 
interventions is described, including drug dependence 
treatment, psychological treatment and provision of naloxone 
at or around release (EMCDDA, 2017). Furthermore, among 
the primary measures identified to reduce imprisonment 
(and thus drug problems inside prison) are alternatives to 
punishment, which aim to divert offenders who use drugs 
into dedicated treatment programmes. Finally, the European 
Centre for Disease Prevention and Control (ECDC) and the 
EMCDDA have published a collection of evidence-based 
public health guidance on prevention of communicable 
diseases in prison settings, which include specific prevention 
interventions targeting people who inject drugs (ECDC and 
EMCDDA, 2018).
National guidance documents dedicated to or covering 
specific aspects of prison health, such as problem drug 
use, have been developed in several EU/EEA countries 
(see overview in ECDC and EMCDDA, 2018). Among these, 
the UK National Institute for Health and Care Excellence 
(NICE) released comprehensive evidence-based guidance 
covering all aspects of health in prison (NICE, 2016) (see 
box ‘National guidelines: NICE guideline on the physical 
health of people in prison’).
I  Drug-related interventions in prison: an overview
Interventions for people in prison with drug-related 
problems can be categorised according to the phase of 
imprisonment in which they are delivered (prison entry, 
EU drugs strategy 2021-2025
The EU drugs strategy 2021-25 includes prison as a strategic priority, with the objective of addressing the health and 
social needs of people who use drugs in prison settings and after release (Council of the European Union, 2020).
Four priority areas are identified in the strategy. First, it will be necessary to assure equivalence and continuity of 
healthcare provision in prison and by probationary services. To that end drug treatment services, including opioid 
agonist treatment, rehabilitation and recovery for drug-using offenders as well as interventions aimed at reducing 
stigma should be provided in male and female prisons and after release, in addition to supporting social reintegration. 
Each Member States should develop an appropriate continuum of care model to allow people to access the needed 
support to achieve their personal recovery goals at prison entry and during imprisonment. Equally, people released 
from prison should be supported with healthcare and social, employment, housing and reintegration services. It is 
essential to provide continued access to evidence-based drug services, equivalent to that provided in the community.
The second priority area indicated in the strategy concerns the implementation of evidence-based measures to prevent 
and reduce drug use and its health consequences, including measures to address the risk of drug-related deaths and 
the transmission of blood-borne viruses. To that end the use of drugs and the transmission of blood-borne infections 
in prison should be prevented by implementing evidence-based preventive measures and risk and harm-reduction 
interventions, carried out by well-trained staff or peers as part of a comprehensive strategy. Providing access to testing 
and treatment for blood-borne infections and other measures that reduce the health risks associated with drug use 
should be considered for prison settings in the same way as is done in the community.
The third priority of the strategy is ’[to] provide overdose prevention and referral services to ensure continuity of care 
on release’. Overdose awareness trainings in combination with the distribution of take-home naloxone might be made 
available where possible, in order to reduce overdoses and drug-related mortality.
Finally, the availability of drugs in prisons should be restricted by disrupting the channels that supply illicit drugs 
and new psychoactive substances into prisons as a priority action. A better use of the existing instruments, such as 
cooperation with law enforcement agencies, sharing and processing information, tackling corruption, using intelligence 
and drug testing, could form the basis for effective intervention.
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stay or release), the setting of the interventions (outpatient 
or inpatient treatment) and the treatment modality (e.g. 
psychosocial counselling, pharmacological treatment). 
Figure 4.2 illustrates this categorisation and presents 
a simplified overview of the drug-related interventions that 
may be provided in prison. Different phases may overlap, 
and settings and modalities for the provision of drug 
treatment may also differ between countries and prisons. 
The remainder of this chapter is structured according to 
this general description, albeit with the omission of harm 
reduction interventions, which are covered in depth in 
Chapter 5.
A variety of drug-related interventions are available in 
European prisons including health assessment and 
detoxification on entry to prison; treatment and harm 
reduction and interventions in preparation for release and 
social reintegration (Table 4.1 and Figure 4.3). For each 
group of interventions, examples from three countries 
are presented in the text boxes (but see Chapter 5 for 
harm reduction). In most countries, interventions for 
the prevention and treatment of drug-related infectious 
diseases are available in prison along with opioid 
substitution treatment and counselling, information, 
training and education. Very few countries have needle 
and syringe programmes, programmes for take-home 
naloxone and peer interventions. A European overview of 
the availability of drug-related interventions in prison by 
number of countries providing the different interventions 
is shown in Figure 4.3. Table 4.1 maps the availability of 
various drug-related interventions in prisons in the EU 
Member States, Norway, Turkey and the United Kingdom; 
the data presented indicate whether the intervention 
is reported by the Reitox national focal point as being 
available. It is possible that interventions exist that are not 
reflected in formal guidelines or laws and therefore may not 
be officially reported.
I  Drug-related interventions on entry to prison
I Health assessment on entry to prison
Conducting a medical examination on everyone remanded 
in custody or entering prison after conviction is a core 
FIGURE 4.2
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National guidelines: NICE guideline on 
the physical health of people in prison
In 2016, NICE published an evidence-based guideline 
on the physical health of people in prison (NICE, 2016). 
The document covers the assessment, diagnosis and 
management of the physical health needs of people 
in prison. It aims to improve health and well-being in 
this population by promoting more coordinated care 
and more effective approaches in prison settings. 
While the guidance document is targeted to the UK 
health system, the evidence-based recommendations 
and practical advice may be transferable or easily 
adaptable to other European contexts. The guideline 
includes a number of implementation-oriented tools 
such as a health assessment checklist, interactive 
flowcharts describing the organisation of the prison 
health system and individual system navigation, care 
pathways and quality standards.
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TABLE 4.1
Availability of drug-related and other health and social care interventions targeting people who use drugs and are in 
prison in the EU Member States, Norway, Turkey and the United Kingdom, 2019-2020
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and standard practice in prison healthcare. The European 
Prison Rules recommend that a medical doctor and 
qualified nurse examine each person in prison as soon 
as possible after admission (Council of Europe, 2006). 
The health examination should include an assessment for 
symptoms of withdrawal from the use of drugs, alcohol 
or medication. The aim is to diagnose physical or mental 
illnesses, provide any required treatment and ensure the 
continuation of community medical treatment.
In line with the European Prison Rules, most European 
countries provide health screening for people entering 
prison, generally immediately on entry or within the first 24 
hours (Table 4.1). The clinical assessment is performed by 
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FIGURE 4.3
Drug-related and other health and social care interventions targeting people who use drugs in prison in Europe, 2019 
(number of countries given where available)
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a medical doctor, psychiatrist or psychologist to ascertain 
whether the person has a substance use disorder or mental 
health problems. This is followed by a comprehensive 
medical examination performed within a specified 
timeframe, which may vary from within the first working day 
to up to 20 working days. Some countries include a specific 
assessment of drug-related problems. Belgium, for 
instance, is piloting the screening of drug-related problems 
on entry to prison.
The medical examination may involve a thorough medical 
assessment, an evaluation of the need for any specialised 
care, and testing for blood-borne viruses, sexually 
transmitted infections and, sometimes, airborne infections 
(e.g. TB). In some countries, such as Lithuania, Austria and 
Slovakia, standardised tests, questionnaires and interviews 
are used. In other countries, drug testing is conducted in 
the event of suspected drug addiction (see the section on 
drug testing in Chapter 7). Information on medical history, 
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including drug use history and mental health disorders, is 
commonly collected. Voluntary infectious disease testing is 
also offered in most countries.
The medical consultation upon entry to prison is an 
opportunity to give information about treatment and 
prevention, raise risk awareness and distribute prevention 
materials, including hygiene kits and condoms. It may 
also include referrals to specialised drug treatment and 
care in prison. For example, in Ireland every person with 
a diagnosis of opioid addiction is offered a medically 
assisted opioid detoxification programme. In Slovenia, upon 
entry to prison, a sentence plan is prepared for each person 
on the basis of their needs and risk assessments; in this 
plan, overall needs are defined alongside the assessment 
of drug use problems.
In several countries, specific attention is given to the 
assessment of suicide risk. Although not always directly 
related to drug problems, suicide is the main cause of 
death inside prison (see Chapter 3). People in prison 
are at increased risk of suicide in the first few weeks of 
imprisonment, and this risk is higher among those who 
use drugs (Marzano et al., 2016). The importance of early 
identification of drug use in people at risk of suicide and 
referral to treatment has been acknowledged in several 
countries with an integrated treatment system aimed at 
reducing suicides.
I Detoxification
Detoxification may be available on entry to prison following 
the health assessment and at other points further along the 
prison stay. Most countries in Europe provide detoxification 
with pharmacological interventions inside prison, 
mainly with methadone and buprenorphine, although in 
some countries unspecified non-opioid drugs are used. 
Approaches to detoxification treatment (requirements, 
length, forms) differ by country. In some countries, such as 
Greece, detoxification is a requirement for entering drug 
treatment in prison.
Withdrawal symptoms are usually evaluated by a doctor 
and then managed pharmacologically. In some countries, 
people undergoing detoxification are placed in special 
prison wings (drug-free units or rehabilitation units) 
or undergo special programmes. In the Netherlands, 
special detoxification programmes for users of GHB 
(gamma-hydroxybutyrate) are available in prisons. In some 
countries, detoxification may be provided in collaboration 
with external hospitals. In Luxembourg, detoxification 
is provided in-house under the responsibility of the 
prison medical unit, but people experiencing severe 
intoxication symptoms or presenting other somatic risks 
can be transferred to external units of general hospitals 
in accordance with strict rules and procedures. The 
Luxembourgish prison system has signed conventions with 
three general hospitals, ensuring out-of-prison medical 
healthcare when required.
I  Drug-related interventions during prison stay
A range of interventions are available to people who are in 
need and who opt to enrol in some type of drug treatment 
in prison. The levels of implementation and the quality of 
interventions available vary between countries and prison 
establishments.
General principles and organisation 
of drug treatment in prison in three 
European countries
Greece
In Greece, people in prison who use drugs constitute 
a specific target group. To respond to their needs, 
treatment programmes in prison alongside specific 
support interventions in the prison setting have been 
developed in recent years, by offering services such as 
individual and group counselling sessions, information, 
motivation and awareness-raising, and self-help 
groups. Medical treatment is also available.
Hungary
There is close cooperation between Hungarian 
prisons and governmental and non-governmental 
organisations in the provision of drug treatment 
services. The responsibility for drug treatment lies with 
the Ministry of Interior and has a strong focus on drug-
related security, which is perceived as hindering the 
implementation of some harm reduction interventions.
Netherlands
Addiction treatment in prison is based on the 
principles of equivalence and continuity of care and is 
organised through collaboration between prisons and 
external addiction care services. Every prison appoints 
a contact person for drugs and addiction issues, 
who participates in regional training initiatives on the 
subject.
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Assessment on entry to prison in three European countries
Estonia
On entry, all people in prison undergo an initial health check that includes drug use screening and voluntary HIV testing 
and counselling carried out by medical personnel, performed under informed consent. Retesting is offered once a year. 
In addition, HCV testing is offered to all people upon entering prison as well as testing and, if required, vaccination 
against hepatitis B.
Spain
All people in prison are examined on entry by a doctor and a nurse, establishing a clinical history file. The risk of suicide 
is also determined. Drug use history and current use is evaluated, with regard to substances used, frequency and route 
of administration, and the presence of withdrawal symptoms. Risk behaviours, such as sharing of injecting equipment, 
sexual intercourse without protection or a prophylactic, and the application of tattoos are assessed. Assessment 
for communicable diseases covers infections such as TB, HIV, HCV, HBV and syphilis. On the basis of the results, 
appropriate treatment is determined and the person is assigned to programmes addressing their health needs, both 
mental, including drug dependence (maintenance with methadone, detoxification, etc.) and physical (treatment of TB, 
HIV or viral hepatitis infection, and vaccination against HBV).
Austria
Shortly after the start of a prison sentence all people undergo a medical examination in order to assess the state of 
their health on entering prison and to initiate treatment where necessary. This examination includes the collection 
of addiction-related or diagnostically relevant data by medical staff. An individual treatment plan is defined for each 
person in prison diagnosed with a substance use disorder. In addition, screening tests for HIV, HCV, HBV and TB are 
carried out on all people upon entry to prison.
Drug-free units
Drug-free units are available in many European countries. They are places inside prison that are free of drugs, but their 
final purpose is not drug treatment; they exist to provide an environment where people in prison remain abstinent 
from drugs and where those who do not use drugs can reside. There are no specific interventions provided apart from 
voluntary and regular urine testing to document abstinence. While this approach is implemented in some European 
countries (see Chapter 4), evidence on its effectiveness is lacking.
Nineteen countries report the availability of drug-free units in prisons. Drug-free units are residential spaces in prison 
that aim to be free of drugs, where people who do not use drugs and who do not want to use them can live in a drug-
free environment during their prison stay. Those staying in these units commit themselves to not taking drugs and 
may sign a contract to undergo regular urine drug screening to document abstinence. For example, Denmark defines 
drug-free units as ‘special contract departments’, where no treatment is provided but where people in prison who do 
not wish to serve their sentence with those who use drugs can live in a drug-free environment. In a few countries, such 
as Luxembourg, Hungary, Portugal and the United Kingdom, drug-free units have a treatment component, but often 
no drug-related interventions are provided. People in prison who accept being in drug-free zones usually benefit from 
better conditions (e.g. more outside time and visits).
Drug-related interventions during this stage of 
imprisonment include detoxification, individual and 
group psychosocial counselling, residential treatment 
(therapeutic communities), OST, education and training, 
involvement in self-help groups, and harm reduction 
interventions (see Chapter 5).
Drug treatment programmes in prison can be carried out 
as outpatient or ambulatory interventions or as inpatient 
or residential interventions. Outpatient treatment is 
generally conducted in medical clinics or common spaces 
such as activity rooms and other dedicated spaces, where 
people can start drug treatment while they are living in 
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the spaces assigned to them on entry to prison. In some 
cases, people may also attend outpatient treatment 
services outside the prison. Outpatient treatment may 
include counselling, pharmacological treatment, and 
educational and training activities. The approaches may 
differ by country, and the level of provision also varies by 
country and by prison.
Residential treatment inside prison is provided in 
special units or wings to which people with drug-related 
problems are assigned after the initial assessment or at 
another time during their prison stay. Residential drug 
treatment programmes inside prison are commonly 
abstinence-based, although in some prisons OST is also 
provided in residential settings. They operate in a similar 
manner to residential programmes in the community, 
providing group and individual treatments that are delivered 
by professional staff, with support from successfully treated 
users. Therapeutic communities in prison are the main form 
of residential treatment.
In both outpatient and inpatient treatment, people with 
drug-related problems can undergo different modalities 
of treatment according to their needs and the services 
available. Often the same approaches applied in the 
community are also implemented in prison.
In a subset of 18 European countries that report data on 
people entering drug treatment inside prison, more than 
30 000 are documented as having entered drug treatment 
in prison between 2015 and 2018. 
Most entrants to drug treatment in prison were men, who 
most commonly reported opioids as their primary problem 
drug, followed by cannabis, cocaine and other substances 
(Figure 4.4). Variations between countries in the primary 
drug reported by treatment entrants in prison mirror the 
differences in the patterns of drug use of clients entering 
treatment in specialised drug treatment facilities in the 
community and are influenced by variations in treatment 
provision inside prison and in the prison system of each 
country (EMCDDA, 2018a).
Demographic differences can be seen when data for clients 
entering treatment in prison are compared with data for 
those treated in the community. For example, 10 % of the 
clients in prison are female compared with 20 % of female 
patients entering outpatient treatment in the community; 
the large proportion of men in prison may explain this 
difference (see Chapter 2). At the same time, women in 
prison represent only 5 % of the prison population; this 
implies that, compared with men, relatively more women 
in prison enter drug treatment, which is in agreement with 
the higher prevalence of drug problems among women in 
prison compared with men (see Chapter 3).
I Therapeutic communities
In Europe, 21 countries report the availability of therapeutic 
communities in prisons. Such communities are generally 
a special form of long-term, participative, group-based 
residential treatment of drug addiction following milieu 
therapy principles (EMCDDA, 2012).
Therapeutic communities in prison may be special units 
separated from the main establishment or particular wings or 
parts of the prison; they provide structured programmes that 
include healthcare, psychological and social services, with 
the aim of preparing people for their reintegration into the 
community after their release from prison. This approach may 
Residential treatment in prison in three 
European countries
Denmark
Therapy is offered in treatment departments, which 
are completely isolated from the ordinary prison 
environment. They focus on education, training and 
social reintegration and work according to the ‘import 
model’ — a treatment model in which both private and 
public treatment institutions independent of the prison 
and probation services offer treatment for drug use 
inside prisons in close collaboration with prison staff.
Italy
Special departments in dedicated sections of prisons 
are available for individuals with medical diagnoses of 
alcoholism or drug addiction and who have reduced 
their drug use, according to defined protocols. 
Compared with the rest of the prison environment, 
conditions are less restrictive in these departments, 
and professionals from public drug addiction services 
provide the same types of treatment as those provided 
outside prison. The activities are voluntary and focus 
on prevention, harm reduction, rehabilitation and 
social reintegration.
Poland
Open-ended therapeutic interventions for drug-
dependent prisoners suffering from mental health 
disorders (dual diagnosis) are provided. These 
interventions are conducted under the prison drug 
therapy system in 23 specialist therapeutic wards.
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also include detoxification, as in Ireland, where the medical 
unit in Mountjoy Prison has 18 beds specifically allocated to 
an 8-week drug-free programme. In Germany and Portugal, 
some therapeutic communities in prison provide OST. The 
approaches are often the same as those implemented in the 
community and may differ by country and prison.
I Psychosocial counselling
Most European countries provide individual and group 
counselling to people in prison with drug-related problems, 
although coverage is generally reported to be low.
I Individual counselling
Individual counselling interventions include needs assessment 
and care planning, psychological counselling, crisis 
intervention, motivational programmes, brief interventions, 
relapse prevention and harm reduction. Among the common 
counselling and treatment approaches applied in European 
countries are motivational interviewing, cognitive-behavioural 
and socio-educational interventions (e.g. social skills training). 
In addition, support is provided to OST patients in establishing 
connections with services in the community.
Individual counselling is available in most countries. 
Counselling may be offered within broader psychological 
support (e.g. in Spain and Slovenia), as part of structured 
drug treatment programmes (e.g. in Spain, France, Poland, 
Portugal, Sweden) or infectious disease interventions 
(e.g. in Estonia) and as support for pharmacological 
treatment (e.g. in Portugal). Some programmes are highly 
structured and include intensive and individualised 
counselling approaches; they are generally provided to only 
a small number of people in prison with drug problems. 
In other cases, individual counselling interventions are 
less structured and intensive and close to educational 
interventions, predominantly offered by social workers, and 
can be delivered to a larger number of recipients.
The number of patients reached by interventions, as well 
as the modalities used and length of individual counselling, 
FIGURE 4.4
Proportion of people entering drug treatment in prison by primary problem drug in 18 European countries, 2018 (or 
most recent data available)
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varies greatly by country and by prison. In Czechia, for 
example, drug prevention counselling centres provided 
individual counselling to around 10 000 people out of the 
approximately 21 000 people in prison in the country; in 
Austria, the main external provider of services in detention 
centres gave individual counselling to around 2 500 clients 
out of 9 000 people in prison. Moreover, Croatia provided 
individual psychosocial treatment to around 450 clients 
(out of 3 300 people in prison) in 2017, and Sweden 
provided an individual cognitive-behavioural therapy 
programme to almost 1 000 clients (out of 5 770 people in 
prison) in 2017.
I Group counselling
Group counselling interventions include education, 
information and group therapy. The approaches used 
may include cognitive-behavioural therapy (American 
Psychological Association, 2017) and ‘12 steps’ 
programmes, which can complement individual 
interventions. Most countries provide group counselling 
mainly based on an abstinence-oriented approach. The 
groups use psychosocial techniques, including motivational 
therapy, coping and social skills training, behavioural 
self-control training, mutual aid, life skills and family work, 
with the objectives of addressing issues such as anxiety, 
stress, low self-esteem, conflict resolution, social skills and 
problematic family relationships.
I Peer interventions/self-help
Peer interventions and self-help programmes are available 
for people in prison who use drugs in 14 European 
countries. These interventions vary from peer education 
and information on drugs, drug-related health risks such 
as the sharing of injecting equipment, liaison with prison 
authorities and peer-led research. In addition, some 
countries also offer family support or self-help groups such 
as Narcotics Anonymous.
I Opioid substitution treatment
Across Europe, substitution treatment is the main form 
of treatment provided for opioid dependence. OST 
interventions in the community are implemented in all 
30 reporting countries, and it is estimated that in 2018 
overall (community and prison) 660 000 people received 
OST in the 27 EU Member States, Norway, Turkey and the 
United Kingdom (EMCDDA, 2019). With the exception of 
Slovakia, all European countries have implemented OST 
interventions for people in prison.
Figure 4.5 shows the year each reporting country 
introduced OST in the community and in prison. According 
to data reported to the EMCDDA, in general there is a delay 
of 8-9 years in introducing OST in prisons compared with 
its implementation in the community, but this treatment 
gap has recently narrowed in some countries. Lithuania 
was the latest country to introduce OST in prison (2018), in 
response to an outbreak of HIV in prison in 2016 and 2017.
In prisons where OST is available, those who have been 
receiving it in the community can continue to be treated 
in prison. In most but not all countries, OST can also be 
initiated in prison. In some countries, OST can be re-
Group counselling in prison in three 
European countries
Sweden
Prisons offer cognitive-behavioural therapy carried out 
in groups, using an approach originally developed in 
Canada. The programme consists of 26 sessions of 
3 hours each, held over a period of 2-3 months. After 
the programme is completed, maintenance sessions 
are provided throughout the remaining sentence. 
Sweden also offers a manual-based version of the 
12-step programme, which is carried out in groups and 
includes one basic and two extended interventions, each 
consisting of 60 sessions of 3 hours over a period of 
12 weeks.
Turkey
In Turkey, group programmes are the interventions most 
often available to people with drug addictions in prisons. 
Based on the model of the tobacco, alcohol and drug 
dependence treatment programme (SAMBA), group 
interventions provide information on tobacco, alcohol 
and drug addiction, aiming to improve knowledge and 
change motivation and behaviours; they also address 
infectious disease risks and relapse into substance use.
United Kingdom
Within the framework of activities targeting the 
emergence of new psychoactive substances in prison, 
focus groups were established in selected prisons 
to discuss issues surrounding the use of synthetic 
cannabinoids in prison; participants were also invited 
to distribute a questionnaire to other people in prison 
asking about their synthetic cannabinoid use.
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Peer-to-peer interventions in three European countries
Belgium
Peer support projects are implemented in prison to train people in prison on drug- and health-related topics. They work 
through a ‘snowball technique’ and are based on the idea that people in prison can contact peers to share important 
healthcare information.
Ireland
The Ana Liffey Drug Project is a low-threshold harm reduction programme carried out in the community, which also 
includes interventions for people in prison who are actively using drugs and experiencing associated problems. 
Services include a peer support programme that helps people in prison address their drug problems. In addition, the 
Irish Red Cross promotes a self-help programme for people in prison, focusing on health prevention, including drug use 
and drug-related problems.
United Kingdom
Several self-help groups and peer-to-peer initiatives are implemented in UK prisons. User Voice is a peer-led 
organisation providing support to people inside prison and those leaving prison concerning health and social problems, 
including drug-related problems. In 2016 User Voice published the first report on use of synthetic cannabinoid receptor 
antagonists in English prisons from a user’s perspective.
FIGURE 4.5
Cumulative number countries introducing OST in the community and in prison in the European Union, Norway, Turkey 
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Source: EMCDDA Reitox monitoring data.
initiated before the end of the sentence to reduce the risk 
of overdose upon release (Tarján et al., 2019).
The substances most frequently used in OST in prison are 
similar to those used in the community in each country. 
Most countries predominantly use methadone, but Croatia 
and France mostly use buprenorphine, and Belgium, 
Cyprus, Finland and Norway prefer a buprenorphine-
naloxone combination (Tarján et al., 2019).
Continuity of care, when entering and leaving prison, is 
a critical issue for those undergoing OST because there is 
a high risk of overdose and of transmission of HCV infection 
when treatment is disrupted (Stone, 2018). One in three 
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countries has specific guidelines addressing continuity of 
care and cooperation between OST services in prison and 
in the community (see also Chapter 5). Croatia reports 
having OST guidelines specific to the prison setting, 
and in Czechia and the United Kingdom guidelines for 
implementing drug treatment in prison include OST. Other 
countries make use of existing guidelines for providing OST 
in the community or guidelines for drug treatment in prison 
where OST is one among several options (e.g. the German 
Medical Association published guidelines for implementing 
OST that can be adopted in any setting).
Data on the proportion of people in prison who are opioid-
dependent and receiving OST are not available, as the 
extent of problem opioid use among people in prison 
is mostly unknown. However, taking the total number 
of people in prison as the denominator and calculating 
a rate based on the reported number of clients receiving 
OST (Figure 4.6) is one way of illustrating the substantial 
variations in the provision of OST in European prisons. 
These rates are, however, only a ‘proxy’, as the need for 
treatment is likely to vary between and within countries. 
There is also no European information available on the 
dosages used in the provision of OST in prison.
As shown in Figure 4.6, most countries provide OST to less 
than 10 % of the prison population. Although this is only 
an indirect indicator of treatment coverage, data suggest a 
scarce implementation of OST in prison.
OST may be implemented in some but not all prisons 
within a given country or in some regions of a country 
but not in others. In Germany, for instance, prison 
administration and related policies are the responsibility 
of the federal states, leading to regional variation in the 
availability of OST in prison. In some federal states, few 
prisons are supplied with OST resources. The lack of 
treatment or low treatment rates point to an exclusive use 
of detoxification rather than substitution treatment and 
a policy oriented strongly towards abstinence in those 
prisons (de Andrade et al., 2018).
I  Responses to new psychoactive substances in prison
The rapid emergence of novel substances has meant that 
developing supportive health intervention responses is 
challenging, in particular in the prison context (Pirona 
et al., 2017). Many European countries report a lack of 
appropriate responses to new psychoactive substances 
in prisons, while others have only anecdotal information 
available.
FIGURE 4.6
Share of prison population receiving OST in prison in 
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Source: 2018 EMCDDA Reitox monitoring data; 2016 SPACE statistics.
The Wenner case
From 1991 to 2008, Wolfgang Adam Wenner, a male 
German national living in Bavaria, received methadone 
treatment for opioid dependence. In 2008, he resumed 
illicit heroin use and committed a drug-trafficking 
offence for which he was sentenced to 6 years in 
prison. Once in prison he requested that his OST 
continues; the Bavarian judicial authorities and courts 
refused and ordered abstinence-based treatment. 
Mr Wenner continued to demand methadone, while 
consuming a number of psychoactive substances 
available on the prison’s illicit drug market. Because 
his request was not granted, he demanded that his 
health status and treatment be assessed by external 
specialists. This was also rejected. Mr Wenner resumed 
his methadone treatment when he was released 
from prison at the end of 2014. He lodged an appeal 
arguing that the two refusals infringed Article 3 of 
the European Convention on Human Rights. In its 
judgment of 1 September 2016, the European Court 
of Human Rights ruled that the refusal by the prison 
administration to provide an indicated OST during the 
prison sentence violated Article 3 of the Convention 
and the prison should have consulted independent 
experts (Wenner v. Germany, 2016; Junod et al., 2018).
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In Germany, Ireland, Hungary, Poland, Slovenia and the 
United Kingdom, information initiatives and booklets, 
workshops or training modules focusing on new 
psychoactive substance use in prisons are provided to 
prison staff (EMCDDA, 2018b). In the United Kingdom, 
a wide-ranging programme has been undertaken to 
counteract new psychoactive substance use in prison. 
Among the measures implemented are legislative changes; 
a smoking ban; the development of new drug tests; 
information campaigns for people in prison; a national 
strategy and action plan to respond to people in prison 
under the influence of new psychoactive substances; and 
a toolkit to support prison healthcare and custody staff in 
addressing the use of such drugs in prison (Public Health 
England, 2017). The toolkit is an adaptation of an existing 
toolkit on responses to new psychoactive substances in 
the community (Abdulrahim et al., 2015) and provides 
guidance on interventions targeting new psychoactive 
substance use and related problems in prison. One of its 
key principles is the delivery of support based on observed 
symptoms (‘treat what you see’).
Partnerships between prison health services and providers 
in the community have proven important in delivering 
health education and treatment interventions for new 
psychoactive substance use and related harm in prisons. 
Typically, non-injectable synthetic cannabinoids are the 
most widely used new psychoactive substance in prison 
(see Chapter 2).
I Information, education and training
Interventions providing information on drug prevention 
and risks are common in European prisons and are usually 
delivered in group settings. Most countries have education 
and training activities for people in prison and information 
and training activities for prison staff. Compared with 
previous years, more countries report the availability of 
such interventions for both staff and people in prison.
Training activities focus on two main areas: drug use 
and associated risks, and psychological and social 
development. Training objectives include raising awareness 
of drug use and related risks, learning how to deal with 
emergency situations (e.g. overdoses, effects of new 
psychoactive substance use), reducing harm (e.g. risks 
of sharing injection equipment; sexual transmission of 
infections), improving psychological skills (e.g. managing 
aggressiveness, increasing self-esteem), and achieving 
professional and occupational skills for social reintegration 
after release from prison.
The approaches adopted range from information sessions 
to selected and indicated prevention interventions. Often 
the same areas are covered in the training provided to both 
staff and people in prison, although training for staff tends 
to centre more on health and emergency interventions, 
while training for people in prison focuses more on harm 
reduction measures and the prevention of infectious 
diseases.
Opioid substitution treatment in prison 
in three European countries
Croatia
OST is available in all prisons. Informed consent 
is required to initiate treatment. Medications 
used include methadone, buprenorphine and the 
buprenorphine-naloxone combination, in accordance 
with guidelines for OST in the community. Until 2007, 
methadone was mostly used for detoxification and 
exceptionally as a maintenance treatment, but since 
then maintenance treatment has become a regular 
option for the prison-based treatment of opioid 
dependence; other medications have been introduced 
and are used for maintenance treatment.
Portugal
Pharmacological programmes include detoxification 
and maintenance programmes. Detoxification is 
available in one prison establishment. Maintenance 
programmes are available either in ‘outpatient’ settings 
(consultations within the prison clinic, out-of-prison 
consultations in a Centre for Integrated Responses) 
or, where they exist, in ‘inpatient’ settings in drug-free 
wings or prison wings that function as therapeutic 
communities.
Finland
OST is available in prison, and both buprenorphine and 
methadone are available. The Prison Health Services 
Unit is in charge of assessing the need for treatment of 
people addicted to opioids and of initiating treatment, 
based on criteria determined by the criminal sanctions 
sector. On a given day in 2019, between 100 and 
130 (out of 3 000 people in prison in the country), 
approximately 3 %, were receiving substitution 
treatment.
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I  Drug-related interventions on release from prison
Specific pre-release measures are needed for those who 
use or have used drugs. As a group, people leaving prison 
have particular health-related vulnerabilities, including 
the risk of relapse into drug use, overdose and overdose 
death, and transmission of infectious diseases (Enggist et 
al., 2014; WHO Europe et al., 2018). To ensure an easier 
transition into community treatment, cooperation between 
services operating inside the prison and health and social 
services outside in the community is especially important.
There are two important interlinked components in 
interventions for release from prison: linkage to services in 
the community in order to ensure that ongoing treatment 
for addiction and infectious diseases continues; and 
prevention of overdose deaths in the period immediately 
following release from prison.
I Throughcare and social reintegration
Continuity of care after release from prison, often called 
‘throughcare’, is an important principle for the health and 
social care of people in prison. Throughcare consists in 
ensuring continuity of care before, during and immediately 
after custody. Throughcare and referral to external service 
providers by prison or probation services can be crucial 
in preventing relapse into drug use (Patel, 2010). Most 
countries (5) report that they address the principle of 
continuity of care in their written strategies and guidelines 
for drug-related issues in prison (Tarján et al., 2019).
In countries where prison and community health services 
operate under the same roof, it is easier to achieve 
throughcare because integrated programmes operating 
inside prison can link people in prison with community 
services before their release. In some prison systems, 
there are pre-release units to facilitate referrals and ensure 
a smoother transition.
Interventions to prepare people for release from prison 
are available in all countries, although not in all prisons 
and not for all people in prison. Social reintegration is an 
important objective of prison release programmes, and they 
often focus on providing information on social benefits and 
connecting with social networks and services to support 
the return to the labour market. The interventions may be 
structured programmes, as in Luxembourg, or referrals 
to external services for different needs, as in Austria. 
Depending on the country’s organisation of health and 
social services, coordination can be established with drug, 
social and mental health services and with specific hospital 
departments, such as infectious disease departments.
I Interventions entailing early release
In many jurisdictions, undergoing drug treatment in prison 
is viewed as demonstrating commitment to rehabilitation 
and may assist people in prison in their applications 
for parole or early release. While some drug-related 
interventions may contribute in this way to early release, 
there are also a small number of drug-related interventions 
that include early release, that is, interventions in 
which both early release and drug treatment are core 
components.
The European Commission-funded Study on alternatives 
to coercive sanctions as response to drug law offences 
(5) Belgium, Bulgaria, Denmark, Germany, Ireland, Greece, Spain, France, 
Croatia, Lithuania, Luxembourg, Netherlands, Austria, Portugal, Slovenia, 
Finland, Sweden, Norway, United Kingdom (only Scotland and Northern 
Ireland; England reported that they are stated but not really implemented).
Information, training and education in 
prison in three European countries
Bulgaria
Health education programmes on prevention are 
conducted in prisons to enhance health awareness 
and promote healthy behaviour among people in 
prison. The topics most often discussed are related to 
the different types of drugs, reasons for using drugs, 
and health and social consequences of using drugs.
Latvia
In 2019, nine social reintegration programmes were 
implemented in prisons addressing the risk of specific 
criminal behaviour or opportunities to acquire specific 
social skills or abilities.
Slovenia
Workshops are organised for people in prison to raise 
awareness of the possible complications and harmful 
consequences of using new psychoactive substances. 
The aim of these programmes is to strengthen 
knowledge and skills in response to the increasing 
use of new psychoactive substances by recognising 
behaviour patterns and teaching problem-solving skills, 
strengthening work habits and responsibilities, and 
strengthening social networks.
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and drug-related crimes found that 2 out of 13 categories 
of alternatives to coercive sanctions identified in the 
European Union included some form of early release 
from prison (Kruithof et al., 2016): intermittent custody 
or release with a treatment element; and parole or early 
release with a treatment element. Alternatives to coercive 
sanctions were defined as state interventions to drug 
crimes having a rehabilitative element, namely education, 
treatment, rehabilitation, aftercare and social reintegration 
(Kruithof et al., 2016).
Intermittent custody with a treatment element includes 
interventions that involve, for instance, staying in prison 
or any other secure setting during the week and spending 
weekends in the community. This type of alternative 
to coercive sanctions is provided in Luxembourg, and 
treatment is only a possible element of the option. In 
Luxembourg, day parole is used with rehabilitation and 
social settlement in mind, whereby ‘the person sentenced 
to imprisonment is authorised to carry on work activities, 
education programs, professional training as well as to 
undertake medical treatment outside prison. The sentenced 
person is required to return back to the correctional centre 
nightly and during his spare time’ (Kruithof et al., 2016).
Parole or early release with a treatment element consists of 
temporary or permanent release from prison or detention 
under specific conditions. Treatment is considered as 
a central component of parole or early release options in 
Greece, Spain, Latvia and Poland, while in Luxembourg, 
Malta, Austria and Finland, treatment is considered 
a possible element to be included in parole or early 
release options. Belgium, Denmark, Germany, Ireland, 
France, Latvia and Romania also report the availability of 
interventions entailing early release (Table 4.1) (6).
I Conclusions
Prisons across Europe offer a variety of drug-related 
interventions on entry to prison, during imprisonment, 
and upon release into the community. Most interventions 
showing some evidence of effectiveness in the community 
have been implemented in prisons, albeit with some delay 
and limited coverage. OST, for instance, is available in the 
community in all EU Member States, Norway, Turkey and 
the United Kingdom and in prison in all but one country. 
Yet, OST is available only to a small proportion of those who 
need it in prison, and often it is offered only to people who 
(6) Sanctions consisting of drug treatment but not shortening a prison 
sentence are not included in this study.
Interventions on preparation for release 
in three European countries
Belgium
Interventions for treatment upon release are available 
in the majority of prisons in Belgium. A specific team 
in each prison is in charge of referring people who 
use drugs and people with mental health disorders to 
treatment upon release. The team includes external 
social workers who define a treatment programme 
according to the needs of the person and who contact 
external drug treatment organisations to arrange 
a referral to healthcare and treatment services upon 
release. In Brussels, a pilot project on the continuity of 
care for people on release has been in operation since 
2013. It seeks to refer people in prison to a treatment 
centre upon release so that they may continue 
substitution treatment; the prison has to provide enough 
substitution medication to cover the first 72 hours 
after release. Other pilot projects have recently been 
implemented in three other prisons in Belgium.
Germany
In the action plan on the implementation of the national 
HIV/AIDS strategy, the federal government recognises 
that transition from incarceration to life outside carries 
a special risk of overdose and stipulates that continuity 
of treatment should be ensured by the institution taking 
charge of the person released. People in prison with 
an expected high risk of relapse or mortality following 
release from prison can be enrolled in OST while still 
in prison. A naloxone project was launched in Bavaria, 
in which people in prison with current or past opiate 
use, or undergoing substitution treatment, were offered 
training on overdose risk and management, as well as 
first aid and the use of naloxone.
United Kingdom
In 2008, the Scottish government published a strategy 
to tackle health inequality entitled Equally Well. 
The document emphasises the need to provide 
interventions for people in prison who want to tackle 
their drug problems. Throughcare addiction services 
are offered to people who are being released from 
prison. According to the strategy, they should be able 
to gain access to addiction and health services within 
6 weeks of release from prison. In addition, in Scotland 
and Wales, take-home naloxone is widely available for 
people at risk of opioid overdose upon release.
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had already started it before imprisonment. Peer-to-peer 
interventions, which can play an important role in prison in 
supporting people who use drugs and informing them of 
available treatment options, are implemented in only one 
third of European countries.
There are many obstacles to implementing drug-related 
interventions in prison, including overcrowding, staff 
shortages and lack of resources. In addition, prisons are 
places of punishment. Public sentiment and political will, 
informed by perceptions of the deservedness of people 
in prison, may have an impact on the implementation 
in prison of interventions widely available outside. 
Furthermore, responding to needs arising from illicit 
behaviours is challenging in the community but all the more 
so in prison settings, where people may feel that disclosing 
their illicit activities carries a bigger risk of incurring 
additional penalties. Bearing this in mind, establishing 
trust between people in prison and healthcare staff is of 
core importance in these settings, as is implementing 
appropriate training.
The available data on drug-related interventions in prison, 
including availability, provision, coverage, quality and 
effectiveness, in Europe are scarce and largely of limited 
comparability. Improved documentation of the nature, 
quality, coverage and demand for drug-related interventions 
in prison would allow for a better understanding of the 
needs of people in prison and inform appropriate service 
planning for prison settings and linkages between prison 
and the community.
Despite existing obstacles, prison is a core setting in which 
otherwise hard-to-reach at-risk groups, such as people who 
use drugs, can be contacted and treated. Considering that 
people in prison are eventually returned to the community, 
interventions in prison are likely to have a significant impact 
on public health.
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Prisons are high-risk environments for the transmission 
of blood-borne virus and airborne infections (Altice et 
al., 2016). This is so for a number of reasons, including 
the over-incarceration of populations at greater risk of 
contracting HIV, hepatitis C and TB, such as people who use 
drugs; risky behaviour in prisons, such as unsafe injecting 
drug use; inadequate healthcare and late diagnosis of 
disease; substandard prison conditions and overcrowding; 
poor ventilation; and repeated prison transfers (Csete et 
al., 2016; Csete et al., 2018; Lazarus et al., 2018; Snow and 
Levy, 2018; Stone and Shirley-Beavan, 2018).
This chapter discusses the availability and provision 
of harm reduction interventions in prison. It includes 
interventions directly targeting drug use and drug-related 
problems, such as prevention and treatment of infectious 
diseases, and interventions that, while not directly 
addressing drug use, may be part of a package provided 
to people in prison, such as condom distribution and safe 
tattoo programmes, which seek to reduce the transmission 
of blood-borne viruses and sexually transmitted infections.
I  Harm reduction: reducing health-related harms of drug use
Harm reduction interventions are implemented in prison 
to reduce the health and social harms of drug use to the 
individuals and the prison community. A core principle of 
harm reduction is developing pragmatic responses to deal 
with drug use through a hierarchy of intervention goals that 
place a primary emphasis on reducing the health-related 
harm of continued drug use (EMCDDA, 2010).
A large proportion of people who inject drugs go through 
the prison system, many of whom are often hard to reach 
in the community and thus hard to treat (see Chapter 2). 
Prisons can be a core setting in which to reach them and 
provide harm reduction, counselling, testing and treatment 
services before they return to the community.
A range of measures are recommended to reduce drug-
related infectious diseases among people who inject drugs. 
These include the provision of OST (see Chapter 4), the 
distribution of sterile injecting equipment, vaccination, 
testing and treatment for infectious diseases as well as 
health promotion interventions focused on safer injecting 
behaviour and reduced sexual risk behaviour (EMCDDA, 
2018) (see also Chapter 6).
Many of these measures are available in European prisons, 
including testing for and treatment of infectious diseases, 
in particular hepatitis B and C, HIV and TB; hepatitis 
B vaccination; needle and syringe programmes, condom 
and lubricant distribution and provision of disinfectant 
materials; naloxone distribution; education; and 
counselling. However, information on the level of provision 
and on the modes of implementation of these interventions 
is scarce, and large differences seem to exist between 
countries, and within countries between different prisons. 
Information on the evidence available for the effectiveness 
of these measures is reported in Chapter 6.
I  Testing, vaccination and treatment of infectious diseases
People who inject drugs constitute a significant proportion 
of the population with blood-borne infections, particularly 
HIV and HCV (Stone, 2018) (Chapter 3). While prison is 
a core setting in which to reach this population, providing 
treatment in prison may be a considerable challenge 
to prison systems because of its costs, the need for 
collaboration with infectious disease and drug dependence 
specialists, and other factors such as structural barriers in 
the prison system.
CHAPTER 5
A focus on harm reduction 
interventions in prison
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EU-funded projects: HA-REACT
The Joint Action on HIV and co-infection prevention 
and harm reduction (HA-REACT) project, which took 
place between 2015 and 2019, addressed existing 
gaps in the prevention of HIV and other co-infections, 
especially TB and viral hepatitis, among people who 
inject drugs. Among the areas covered by the project, 
prison health is central. One of the HA-REACT project’s 
outputs, a toolbox on how to advance harm reduction 
in prison settings, is available on a dedicated web 
platform (hareact.eu). Among the tools available are 
information, education and practical implementation 
materials targeting healthcare professionals 
operating in prison settings, prison administration 
and other relevant stakeholders (e.g. community-
based organisations): materials are oriented towards 
implementing interventions such as OST and prison 
needle and syringe programmes, condom distribution 
and provision of take-home naloxone.
It is important that testing for infectious diseases is 
offered to people in prison but that it is not mandatory 
(EMCDDA, 2010; UNODC et al., 2013; ECDC and EMCDDA, 
2018). During the medical assessment on entry to prison, 
a radiographical examination may be performed if required. 
ECDC guidance suggests that early detection of TB may be 
followed by preventive measures such as isolating a patient 
during the infectious period to mitigate the risk posed 
by highly infectious airborne diseases in closed settings 
(ECDC and EMCDDA, 2018). Testing in prison for TB is 
available in prisons in most European countries; in Hungary 
it is mandatory for all new entrants to prison and annually 
for all those staying in prison (Tarján et al., 2019).
Testing for HIV, HBV and HCV is voluntary in all prisons 
in Europe and more often than not includes pre- and 
post-test counselling. In Austria, HIV testing is offered on 
a routine basis to all people entering prison, and testing 
for HIV, HBV and HCV is usually performed when an 
individual arrives in prison, a year after previous testing, 
or more frequently if medical necessity demands. For 
HCV, there are insufficient data available to distinguish 
whether tests and screening are conducted to detect 
antigens or antibodies. In most countries, a confidential 
health record is created during the health assessment 
on entry to prison and updated as needed during the 
person’s sentence. Electronic information systems and 
centralised databases are increasingly providing a system 
for monitoring the health of people in prison, even as 
they move between prison establishments. In Finland, 
infectious disease tests are recommended for all people 
in prison. The UK prison service has recently adopted an 
opt-out approach to testing: infectious disease tests are 
proactively offered to all those entering prison, who can 
accept or refuse the test. Tests are usually accompanied 
by educational interventions, which may be followed 
by structured counselling, as in Luxembourg, or by 
informative sessions, as in Hungary. At the European 
level, data on the coverage of testing are scarce and of 
limited quality.
Based on available data, HIV testing rates among people 
in prison in the last year (2017) in 13 EU Member States 
and the United Kingdom ranged from 2 % (in Hungary) to 
100 % (in Estonia). An estimate of HIV testing coverage (7), 
defined as the proportion of people in prison tested in the 
last year, was available from 16 countries, according to 
which five countries reported full coverage (> 95 %), two 
high coverage (61-95 %), one medium coverage (30-
60 %) and eight low coverage (< 30%) (Tarján et al., 2019) 
(Figure 5.1).
HCV testing is not always offered to or requested by people 
in prison. Because the infection is often asymptomatic, 
many people in prison are not aware of their status. 
HCV testing rates ranged between 5 % and 100 % in 11 
countries. Among the 15 countries reporting coverage, 
coverage of HCV testing in the last year was estimated to 
be full in three countries, high in one country, medium in 
three countries and low in eight countries (Tarján et al., 
2019) (Figure 5.1).
HBV testing rates among people in prison in the last year 
ranged between 4 % and 100 % in 11 countries. Full 
coverage was reported in three countries, high coverage 
in two countries and low coverage in 10 countries (Tarján 
et al., 2019). Positive results are commonly followed by 
post-test counselling. HBV vaccination in prison is available 
in 19 European countries (Tarján et al., 2019) (Figure 5.1).
Treatment of infectious diseases is available in prison in 
most European countries. It is mainly provided within a set 
of interventions that include counselling, post-exposure 
prophylaxis and linkage with external services during 
treatment in prison and upon release. Differences in how 
continuity of care is implemented are reported by country, 
prison and type of treatment. In general, there is no full 
provision of harm reduction interventions both in terms of 
number of prisons and of people in need.
HIV antiretroviral therapy is available to people in prisons 
in all countries for which information is available. Full 
(7) Estimated coverage was calculated on the basis of testing rate or, if that 
was not available, the coverage was estimated by experts. 
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coverage (> 95 % of people in prison in need are in 
treatment) is reported in seven countries and high 
coverage (60-95 %) in another seven countries out of 15 
for which this information was available (Tarján et al., 2019) 
(Figure 5.1). In some countries, such as Spain, treatment 
is provided inside prison, while in others, such as Croatia, 
patients are referred to external community services. In 
France, a prophylactic antiretroviral therapy is provided 
to people in prison and to prison staff after accidental 
exposure to blood. In Lithuania, since the 2016-2017 HIV 
outbreak in prison, special attention has been given to the 
quality of HIV treatment.
Antiviral therapy for HBV is reported to be available in most 
European countries. Belgium, Czechia, Luxembourg and 
Slovenia estimate that almost all people in prison in need 
are enrolled in treatment (Tarján et al., 2019).
Prisons are considered a very important setting for 
reducing the national burden of hepatitis C and eliminating 
prison-to-community and prison-to-prison spread of 
the infection (Winter and Hellard, 2018). A growing 
body of evidence shows that HCV treatment is feasible 
and effective in prison settings. Direct-acting antiviral 
treatments for HCV have high cure rates and are less toxic 
than previous interferon-based treatments. Because of the 
short treatment duration (8 or 12 weeks), it is now more 
feasible to treat infected people who use drugs during 
a prison stay.
Antiviral treatment for HCV in prison is available in most 
European countries. However, data on HCV treatment 
coverage in prisons in Europe are scarce and indicate that 
only a small proportion of those in need are treated. Only 
Belgium, Czechia, Luxembourg, Hungary and Slovenia 
report a full or high coverage of HCV treatment in prison 
(Tarján et al., 2019).
Treatment for TB is available in prisons in the majority 
of European countries. Only Czechia, Estonia, Spain, 
Lithuania, Luxembourg, the Netherlands, Portugal and 
Slovenia report data on coverage of TB treatment in prison, 
and they estimate that it is full coverage (Tarján et al., 
2019).
Referral after release from prison is essential to allow those 
leaving prison to continue HIV antiretroviral treatment: this 
is implemented, fully or partly, in the majority of countries. 
There is currently little information on the success rate of 
these referrals and the drop-out rate could be high (ECDC 
and EMCDDA, 2018; Tarján et al., 2019).
Little is known of people’s opportunity to continue antiviral 
treatment for HCV when they leave prison. Based on the 
available data, referral to HCV treatment is fully or partially 
available in 25 countries (see Table 4.1). Adequate supplies 
of medicines for the treatment of HCV are provided to 
individuals on their release in Spain, France, Italy and 
Portugal. Enough medication is provided to cover either 
the transition period until individuals are effectively linked 
with community services or the entire duration of treatment 
when direct-acting antiviral therapies are used, which is 
increasingly becoming the standard of care (Stöver et al., 
2019). The provision of prescriptions for these medications 
is the preferred option in the United Kingdom, combined 
Harm reduction interventions targeting 
infectious diseases in three European 
countries
Spain
The main objective of risk and harm reduction 
programmes in Spanish prisons is to reduce the 
harmful effects of drugs on health. Harm reduction 
programmes in prison include a set of interventions 
ranging from testing, vaccination and treatment of 
infectious diseases to syringe exchange programmes 
and the supply of bleach, aluminium foil and 
condoms. Overdose action programmes, methadone 
maintenance treatment programmes, and general 
health education and information are also available.
Croatia
Harm reduction programmes include training and 
counselling on drug-related health risks and the 
prevention of infectious disease. They aim to improve 
the health and general medical condition of people 
in prison who use drugs. Interventions include 
substitution therapy, testing for infectious diseases, 
treatment of viral hepatitis, a preparatory procedure 
for and referral to HIV/AIDS treatment, and motivating 
people who use drugs to enter maintenance, 
detoxification and psychosocial treatment.
Lithuania
In Lithuania, a specific HIV testing scheme, based on 
epidemiological and clinical recommendations and 
defined by national legislation, is applied in prison 
settings. Under the scheme, every person in prison 
is tested for HIV: once a year (if not tested for other 
reasons); 4 weeks after the last test; and when first 
arriving in prison or when moving between prisons or 
territorial police custody if more than 4 weeks have 
passed since the last test (Tarján et al., 2019).
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with active referral to a suitable service provider in the 
community.
I  Prison-based needle and syringe programmes
Interventions aiming to reduce the transmission of 
infectious diseases in prison settings include needle and 
syringe programmes and distribution of disinfectants, as 
well as other measures not specifically targeting people 
who use drugs, such as the distribution of condoms and 
lubricant, safe tattooing interventions and risk prevention 
strategies. These interventions may be implemented within 
a package of harm reduction measures, and often include 
a component of information and education. Methods of 
distribution may vary by country and by prison; for example, 
condoms and syringes may be distributed by healthcare 
staff or provided by machines; condoms may also be 
provided in the prison canteen and may be free of charge.
Needle and syringe programmes aim to provide sterile 
equipment for drug injection as a measure to prevent the 
risk of infection (WHO, 2004). Evidence shows that this 
intervention is effective in reducing the transmission of 
HIV among people who inject drugs in the community, 
and European public health guidance discusses the 
effectiveness of implementing needle and syringe 
programmes in prisons as part of a comprehensive set 
of harm reduction interventions (WHO, 2004; ECDC and 
EMCDDA, 2018) (see Chapter 6).
Prison-based needle and syringe programmes are available 
in only three European countries: Germany, Spain and 
Luxembourg. In Spain, needle and syringe programmes 
are implemented under central jurisdiction in all Spanish 
prisons where there are people injecting drugs, while in 
Luxembourg, the two prisons functioning in the country 
have implemented them. In Germany, a single programme 
exists in a women’s prison in Berlin. In France, the law 
authorises needle and syringe programmes in prison in 
the framework of harm reduction measures; however, the 
regulatory measures to allow implementation remain to 
be adopted (Table 5.1). Needle and syringe programmes 
in prison remain controversial in many countries, even 
in those where needle and syringe programmes have 
been a longstanding and successful intervention in the 
community (Stöver and Hariga, 2016).
Other countries have also made efforts in this regard. 
A pilot project launched in 2007 in Portugal was 
discontinued without distributing any syringes, because of 
the absence of demand for clean syringes; and in Romania 
Needle and syringe programmes, 
condom distribution and safe tattooing 
in prison in three European countries
Czechia
Since 2017, one Czech prison has been running 
a programme for condom distribution. Condoms 
are provided through dispenser machines and upon 
request. They are also available to purchase in all 
prison canteens. Free condoms are available only in 
prisons with rooms for non-standard visits, where the 
person in prison can be alone with their external visitor.
Spain
Since 1997, all 97 prisons have had the technical 
and legal conditions required for exchanging needles 
and syringes for people who are injecting drugs. The 
exchange kit includes a needle and syringe inside 
a transparent box, a disinfectant wipe, distilled water 
and condoms (photo).
Needle and syringe kit, Spain
Copyright: Vicedirectorate General of Penitentiary Health of Spain.
Luxembourg
In 2017, a structured safe tattoo programme was set 
up in one of Luxembourg’s two prisons. It is a peer-
to-peer project that provides the opportunity to have 
a tattoo in appropriate hygienic conditions, preventing 
the transmission of communicable diseases. The safe 
tattoo project is subject to strict regulations. People 
in prison who are interested may apply to become an 
official tattoo artist and can undergo specific training. 
Since 2018, the programme has trained 20 male and 
female tattoo artists. In total, 139 people have had 
a tattoo in prison since the implementation of the 
project.
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a needle and syringe programme operated in several 
prisons but was not sustained once external funding 
ended. In the Netherlands, prison-based needle and syringe 
programmes are not implemented, as there is no indication 
of injecting drug use in prison (Tarján et al., 2019).
I  Other interventions for preventing infectious diseases in prisons
Other harm reduction interventions may be offered in 
prison that do not directly address drug use but may be 
part of a package provided to people in prison. UNODC 
recommends 15 interventions as part of a comprehensive 
package for effective prevention of infectious diseases 
in closed settings such as prisons (UNODC et al., 2013), 
including condom distribution and safe tattoo programmes.
Condom distribution programmes are available in 21 
European countries, less than half of which also provide 
lubricant (Table 4.1). A small number of countries report 
the distribution of bleach or other disinfectants in prison 
(ECDC and EMCDDA, 2018; Tarján et al., 2019) (see 
Table 4.1).
Safe tattoo programmes in prison are aimed at preventing 
the transmission of infectious diseases. Ten countries 
report the availability of information interventions on the 
risks of tattooing and piercing in prison (Tarján et al., 2019). 
Safe tattoo programmes in prison, which aim to provide 
a safer alternative to clandestine tattooing, are available in 
Luxembourg. These programmes provide a tattoo parlour 
where trained tattooists offer tattoos free of charge applying 
safe tattooing materials and standards (Tran et al., 2018).
I Preventing overdose
The risk of overdose death for opioid users is particularly 
high in the first period after release from prison (Farrell 
and Marsden, 2008; Merrall et al., 2010) (see Chapter 3). 
In particular, the first one or two weeks after release have 
a greatly increased overdose death rate (Bukten et al., 
2017).
The main responses aiming to reduce opioid-related 
deaths both in the community and in prison involve a set 
of interventions geared towards preventing overdoses 
from occurring in the first place and those focusing on 
preventing death when overdoses do occur (EMCDDA, 
2017) (Figure 5.2).
A number of interventions are implemented with a view 
to reducing this risk, including pre-release counselling 
on overdose risk, training in first aid and overdose 
management, optimising referral to ensure continuity 
of drug treatment between prison and community, and 
distributing naloxone (Brummer et al., 2018). Information 
and education on overdose risks are available in most 
countries.
Naloxone is an opioid antagonist medication used in 
hospital emergency departments and by ambulance 
personnel to reverse opioid overdose (EMCDDA, 2016). In 
recent years, there has been an expansion of take-home 
naloxone programmes, which provide overdose training and 
make the medication available to those likely to witness an 
opioid overdose (EMCDDA, 2018).
People in prison are included in take-home naloxone 
programmes in Estonia, France, Norway and the United 
Kingdom. In Germany, a pilot project is under way in 
TABLE 5.1
Prison-based needle and syringe programmes in five European countries
Country Start date Overview Syringes/kits distributed
Germany 1996 4 dispensing machines, available in 1 prison (out of 181) N/A
Spain 1997
Available in all prisons 
Distributed by health staff 
Kit includes syringe, disinfectant wipe, distilled water, 
condom
2018: 3 233 syringes 
Since 1997: more than 214 000 
syringes
Luxembourg 2005
Available on request in all (2) prisons 
Provided by health staff 
Kit includes 2 syringes
2017: 23 kits distributed, and 1 372 
syringes exchanged
Portugal 2007




Operated in several prisons 
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Bavaria. In England, a study was conducted across 10 
prisons to analyse the perceptions of staff and people in 
prison regarding take-home naloxone programmes and 
to assess the barriers preventing the training of people 
in prison and the effective and timely distribution of kits 
(Sondhi et al., 2016). The findings highlighted the need 
for more training and information on a number of specific 
concerns, including the potential consequences of being 
found in possession of naloxone, lack of anonymity for 
people enrolled in the programmes, and logistical issues 
surrounding the training of people in prison and the 
distribution of kits at discharge.
I Conclusions
Many people in prison experience negative health and 
social consequences related to their drug use. Prisons 
are also high-risk environments for the transmission of 
infectious diseases for a number of reasons, including the 
over-incarceration of vulnerable and disadvantaged groups 
who carry a disproportionately high burden of disease and 
ill health. Nevertheless, the availability and provision of 
harm reduction interventions in European prisons remains 
limited and it is not comparable to the level of provision 
of such interventions in the community. Some services, 
largely implemented in the community, are still not available 
in most European prisons, despite evidence to support 
their effectiveness. For example, needle and syringe 
programmes, to prevent the transmission of blood-borne 
viruses, and take-home naloxone programmes, to prevent 
overdose death, are available in prison in fewer than 
a handful of countries. Information on the provision and 
effectiveness of harm reduction interventions in Europe is 
limited. The overview presented here provides a baseline for 
monitoring at the European level, while highlighting a need 
for improvements in data quality, comprehensiveness and 
coverage in order to provide a solid evidence base for future 
policy planning.
FIGURE 5.2
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The organisation and availability of drug-related 
interventions in prisons across Europe are mapped in 
Chapters 4 and 5. This chapter remains focused on 
interventions but shifts the emphasis on to the evidence. 
It provides an overview of existing scientific evidence for 
drug-related interventions in prison and identifies the 
main knowledge gaps. In addition, it focuses on some new 
developments in responding to drug problems in prison. 
The evidence presented in this chapter has been collected 
from various sources, including published systematic 
reviews, guidance documents and the EMCDDA’s Best 
Practice Portal.
Equivalence of care for people in prison is a well-
recognised international standard (Council of Europe, 
2006; United Nations General Assembly, 2015). The focus 
on provision may be insufficient for this population with 
complex health needs to achieve equity, and achieving 
equivalence of health outcomes may be a more appropriate 
objective to tackle (Charles and Draper, 2012). Thus, the 
main sections of this chapter report evidence on healthcare 
interventions targeting people who use drugs, and 
people who inject drugs, with a particular focus on health 
outcomes rather than on intervention type or time frame. 
More specifically, identified prison drug interventions have 
been categorised on their expected outcomes, with a major 
focus on three drug-related health outcomes: behavioural 
change, prevention of communicable diseases, and 
prevention of drug-related mortality.
Because of its relevance for different treatment phases 
and importance in achieving different outcomes, opioid 
substitution treatment (OST) in prison features under 
all three main health outcomes discussed here. Positive 
outcomes in the areas of social reintegration post release 
are also considered in this chapter. The available evidence 
of effectiveness of drug-related interventions in prison 
settings, using data extracted from the evidence database 
on the EMCDDA’s Best Practice Portal, is summarised in an 
appendix to the chapter (Table 6.6).
I  Behavioural change in people who use drugs: key evidence in prison settings
This first section investigates the evidence for interventions 
whose primary objectives are those of behavioural change 
(Table 6.1). Such interventions are generally aimed at 
changing one or more psychological determinants of 
behaviour to promote safer conduct. When considering 
the prison population with experience of drug use, such 
approaches are mainly directed towards preventing or 
reducing drug use and drug-related harm. A number of 
these interventions, including drug treatment programmes, 
have been developed and tested for effectiveness in 
community settings, generating a relatively robust body 
of evidence to support their implementation (ECDC and 
EMCDDA, 2011, 2017).
The treatment of addiction in prison includes several 
options, although information on the level and extent of 
provision of interventions conducted in prison and targeting 
drug dependence, addiction and drug-related problems 
is lacking (see Chapter 4). With the exception of OST, 
evidence derived from studies conducted in prison settings 
on most of these interventions is limited, or lacking, leaving 
substantial knowledge gaps regarding appropriate and 
tailored ways of implementing interventions in this setting.
I  Identifying health needs: healthcare assessment at entrance
Mental illness, substance use and infectious diseases 
such as TB, HIV infection, hepatitis B and hepatitis 
C may be under-reported by people in prison because 
of social stigma or low expectations of treatment in 
prison. Health screening on admission to prison allows 
the identification of health needs at an early stage. 
A thorough assessment of the health status and health-
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related needs of individuals being admitted into prison is 
a requirement of both European and international prison 
rules (Council of Europe, 2006; United Nations General 
Assembly, 2015). No scientific evidence is available on the 
benefits of performing such assessment nor on the most 
effective and acceptable approaches to implementing it. 
However, it is generally accepted that, upon admission 
to prison, a medical examination should be performed by 
a healthcare professional, which should cover the main 
areas such as physical health, including communicable 
diseases, alcohol and substance use, mental health, 
self-harm and suicide risk (Enggist et al., 2014). The NICE 
guidance document (NICE, 2016) provides practical advice 
on how to perform health assessments.
Healthcare assessment on entrance to prison may be of 
great relevance for individuals who have a history of drug 
use, including those who are receiving OST at the time of 
incarceration. While, in the first case, early identification 
of problem drug use and related health harms may lead to 
the development of an individualised support plan, in the 
latter, ensuring continuity of treatment is essential to avoid 
relapse and the resurgence of high-risk behaviour while in 
prison (ECDC and EMCDDA, 2018a,b,c).
I  Management of withdrawal: pharmacological interventions
There is very limited evidence on the effectiveness of 
pharmacological management of withdrawal in prison 
settings: one study performed in the United States reports 
an increase in drug-injecting behaviour following forced 
tapered withdrawal as an alternative to continuing OST 
(Rich et al., 2015). Anecdotal reports from a number of 
countries in Europe, such as Spain, Luxembourg, Portugal 
and the United Kingdom, suggest that voluntary and 
pharmacologically assisted withdrawal may be successfully 
implemented in prison. In Luxembourg, managing 
withdrawal symptoms is a requirement for enrolment in 
drug treatment in prison. However, according to recent 
systematic reviews on assisted withdrawal in community 
settings, there is no clear evidence on whether any of the 
medications, including naltrexone, is more effective than 
others in managing withdrawal nor in improving treatment 
TABLE 6.1
Overview of the evidence of the effectiveness of drug-related and other health and social interventions for behavioural 
change in prison settings
Intervention Details Evidence rating Desired outcome Reference
Pharmacological 
treatment
OST (with methadone) in prison to increase 
post-incarceration community treatment 
engagement
Beneficial
To retain patients in 
treatment
Moore et al., 2019
Pharmacological 
treatment
OST to reduce injecting risk behaviour in 
prison
Beneficial
To reduce risk 
behaviours




OST to reduce substance use in prison Beneficial
To reduce substance 
use




OST (with methadone) in prison to reduce 
post-release illicit opioid use
Beneficial
To reduce substance 
use
Moore et al., 2019
Pharmacological 
treatment
OST (with methadone) in prison to reduce 
post-release injection drug use
Beneficial
To reduce substance 
use
Moore et al., 2019
Continuity of 
treatment from prison 
to community
Continuity of care to improve post-release 
behavioural outcomes
Likely to be 
beneficial
To retain patients in 
treatment
ECDC and EMCDDA, 2018c
Needle and syringe 
programmes
Needle and syringe programmes in prison 
to reduce HIV and HCV transmission via 
shared injection equipment
Likely to be 
beneficial
To reduce infectious 
diseases; to reduce 
risk behaviours
ECDC and EMCDDA, 2018b
Provision of condoms 
and lubricant
Provision of condoms and lubricant in 
prison to reduce sexual risk behaviours
Likely to be 
beneficial
To reduce risk 
behaviours
ECDC and EMCDDA, 2018b
Therapeutic 
communities
Therapeutic communities in prison to 
reduce re-incarceration rates and drug 
misuse relapse





Galassi et al., 2015
Needle and syringe 
programmes
Needle and syringe programmes in prison to 




To reduce risk 
behaviours
ECDC and EMCDDA, 2018b
Pharmacological 
treatment
Pharmacological v. non-pharmacological 
treatment to reduce drug use and re-
offending among drug-using offenders
Unknown 
effectiveness
To reduce substance 
use; to reduce re-
incarceration rates
Perry et al., 2015
Evidence ratings are based on GRADE.
Source: Evidence database, EMCDDA Best Practice Portal.
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outcomes or minimising potential risks (Jarvis et al., 2018; 
Rahimi-Movaghar et al., 2018).
I Opioid substitution treatment
OST is an intervention of proven effectiveness in the 
treatment of opioid use in community settings; in prison 
it is used in the different phases of drug treatment. In 
the initial health assessment of individuals who have 
a history of drug use, OST can be used for managing 
withdrawal symptoms, and discontinuing medication for 
those who have been engaged in OST programmes before 
incarceration may be risky.
OST is also used in prison as a treatment intervention for 
those assessed as having an opioid problem. A systematic 
review of 21 studies conducted in prison settings, 
regarding the effectiveness of opioid maintenance 
treatment, concluded that the benefits of this treatment 
when provided in prison are similar to those obtained in 
community settings. OST was significantly associated with 
reduced heroin use, injecting and syringe sharing in prison 
if doses were adequate. Continuation of OST for those 
who were following this treatment before incarceration is 
essential to avoid relapse and the resurgence of high-risk 
behaviour while in prison (ECDC and EMCDDA, 2018a, 
2018b, 2018c). And pre-release OST was significantly 
associated with increased entry to treatment and retention 
after release if arrangements existed to continue treatment 
(Hedrich et al., 2012).
I Therapeutic communities in prison
Therapeutic communities have been defined as drug-free 
environments in which people with problem drug use 
live together in an organised and structured way, and 
the community is used as a method of addressing the 
substance abuse and social and psychological problems of 
the individuals (EMCDDA, 2014a). Based on the consistent 
findings of two literature reviews (EMCDDA, 2014a; 
de Andrade et al., 2018), therapeutic communities appear 
to be effective in reducing relapse into drug use and re-
incarceration. The effect on substance use after release is 
less durable, but evidence shows that it may be enhanced 
with appropriate aftercare interventions (de Andrade et al., 
2018). Evidence from qualitative studies from the Nordic 
countries indicate that prison staff working in therapeutic 
communities reported a good sense of professionalism, 
engagement with the intervention and good relationships 
with the people in prison (Kolind, 2015; Kolind et al., 2015; 
Kolind and Duke, 2016). A 2019 systematic review of 25 
studies on the effectiveness of prison-based behavioural 
treatment for people with drug- and alcohol-related 
problems suggests that the use of cognitive-behavioural 
therapy delivered in therapeutic community settings in 
prison is current best practice (Doyle et al., 2019).
I Individual or group psychological support
Interventions aimed at offering psychological support to 
people in prison who use drugs have been explored in the 
literature, mostly targeting specific population subgroups, 
such as women in prison and people with mental illnesses 
(EMCDDA, 2017). However, a narrative review analysing 
different interventions targeting female drug-using 
offenders or drug-using offenders with co-occurring mental 
illness reported no evidence of effect on drug use (Perry et 
al., 2015).
I Peer-to-peer interventions
Peer interventions, delivered to people in prison by 
people in prison, aim to improve health and reduce risk 
factors. Different modes of peer-to-peer activities have 
been identified, including peer education, peer support, 
peer mentoring and bridging roles (South et al., 2017). 
A systematic review explored peer-to-peer interventions 
in prison settings. Although most of the studies included 
were of poor methodological quality, the body of evidence 
suggests that peer education interventions are effective 
at reducing risky behaviours, are acceptable and have 
a positive effect on recipients. The review also concludes 
that being a peer deliverer is itself associated with 
positive effects on the individual (Bagnall et al., 2015). 
Peer-led interventions in prison may also be instrumental 
to research activities, such as situational analysis and 
information gathering, as exemplified by an analysis of 
the views and experiences of people in prison of new 
psychoactive substances in the United Kingdom (User 
Voice, 2016).
l  Prevention and control of communicable diseases in people who use drugs: key evidence in prison settings
Epidemiological data from EU and European Economic 
Area (EEA) countries indicate a higher prevalence of blood-
borne viruses, namely HBV, HCV and HIV, among people 
in prison and particularly among those with a history of 
INSIGHTS I Prison and drugs in Europe: current and future challenges
82
injecting drug use (ECDC, 2018). Furthermore, people 
who inject drugs are at increased risk of acquiring one or 
more such infections while in detention (Altice et al., 2016; 
Stone et al., 2017). Injection site infections and injuries 
among people who inject drugs are a recognised health 
issue (Health Protection Agency et al., 2012; Hope et al., 
2014) and may be of even more concern in prison settings, 
where clean injecting paraphernalia are mostly unavailable 
(Table 6.2).
I Active case finding
Early identification of infections is fundamental to 
implementing appropriate primary and secondary 
healthcare measures. Active case finding is a strategy 
for the systematic identification of individuals or 
groups suspected to be at risk of a particular disease; it 
involves the targeting of resources and the use of tests, 
examinations and other procedures to enable early 
diagnosis. A sizeable literature exists on active case-finding 
interventions implemented in prison settings (ECDC and 
EMCDDA, 2017). Most of the studies are focused on testing 
for blood-borne viruses on admission to prison; however, 
evidence covers additional diseases such as sexually 
transmitted infections and TB (ECDC and EMCDDA, 2017). 
According to the available evidence, universal active case 
finding, preferably upon admission, is the most effective 
approach, at least for blood-borne viruses and TB, provided 
that confidentiality and consent are ensured (ECDC and 
EMCDDA, 2017, 2018a).
I Opioid substitution treatment
OST is effective in targeting infectious diseases. When 
considering blood-borne virus prevention measures 
targeting people who inject drugs, scientific evidence 
TABLE 6.2
Overview of the evidence base on the effectiveness of drug-related and other health and social interventions for 
prevention and control of communicable diseases in prison settings
Intervention Details Evidence rating Desired outcome Reference
HBV, HCV and HIV testing upon 
admission to prison
HBV, HCV and HIV testing upon 
admission to prison to reduce 
transmission
Beneficial
To reduce infectious 
diseases
ECDC and EMCDDA, 
2018a,b
Health promotion and peer-
education on blood-borne virus 
testing
Health promotion and peer education 
to increase blood-borne virus testing 
uptake in prison
Beneficial
To reduce infectious 
diseases
ECDC and EMCDDA, 
2018a
Pharmacological treatment
OST to reduce injecting risk 
behaviour in prison
Beneficial
To reduce risk 
behaviours
ECDC and EMCDDA, 
2018b,c
Provision of HBV vaccination in 
prison
Provision of HBV vaccination in 
prison to reduce transmission
Beneficial
To reduce infectious 
diseases
ECDC and EMCDDA, 
2018b, c
Provision of HBV, HCV and HIV 
treatment in prison
Provision of HCV and HIV treatment 
in prison to reduce transmission
Beneficial
To reduce infectious 
diseases
ECDC and EMCDDA, 
2018b,c
Needle and syringe programmes
Needle and syringe programmes 
in prison to reduce HIV and HCV 
transmission via shared injection 
equipment
Likely to be 
beneficial
To reduce infectious 
diseases, to reduce 
risk behaviours
ECDC and EMCDDA, 
2018b,c
Pre- and post-exposure 
prophylaxis for HIV
Pre- and post-exposure prophylaxis 
for HIV in prison to reduce HIV 
acquisition
Likely to be 
beneficial
To reduce infectious 
diseases
ECDC and EMCDDA, 
2018b
Provision of condoms and 
lubricant
Provision of condoms and lubricant 
in prison to reduce sexual risk 
behaviours
Likely to be 
beneficial
To reduce risk 
behaviours
ECDC and EMCDDA, 
2018b
Needle and syringe programmes
Needle and syringe programmes 
in prison to reduce injecting risk 




To reduce risk 
behaviours
ECDC and EMCDDA, 
2018b
Pharmacological treatment OST to reduce HIV and HCV in prison
Unknown 
effectiveness
To reduce infectious 
diseases
EMCDDA, 2010
Safe tattooing and body piercing 
programmes
Safe tattooing and body piercing 
programmes to reduce blood-borne 
virus transmission in prison
Unknown 
effectiveness
To reduce infectious 
diseases
ECDC and EMCDDA, 
2018b
Evidence ratings are based on GRADE.
Source: Evidence database, EMCDDA Best Practice Portal.
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supports the use of OST to prevent transmission of 
infections among people who also use opioids during 
detention (ECDC and EMCDDA, 2018b), and another study 
links the high level of OST coverage in Scottish prisons 
with an observed reduced incidence of HCV infection in 
the prison population (Taylor et al., 2013). OST in prison 
is also relevant in tackling other health-related outcomes. 
However, studies inside prison are too few and insufficient 
to demonstrate its effectiveness in reducing seroconversion 
inside prison.
I Vaccination
According to the WHO, vaccination is a life course 
intervention to be provided through all stages of life, 
including adulthood (WHO Europe, 2013). Prison may offer 
a suitable location where vaccination coverage may be 
increased among individuals belonging to deprived and 
socially marginalised groups and where specific groups 
at higher risk, such as people who inject drugs, may be 
targeted.
While evidence on vaccination interventions in prison 
settings is extremely limited, it indicates that providing 
vaccination against HBV to all individuals upon admission 
ECDC and EMCDDA guidance on preventing blood-borne viruses in prison settings: key 
conclusions
The available scientific evidence, backed up by expert 
opinion, allows for the following key conclusions to be 
made:
Prevention
Offer a comprehensive package of preventive measures 
to people in prison that meet the same national 
standards as those recommended for community 
settings.
Evidence shows that also in prison settings, condoms 
and behavioural interventions promote safer sex.
Evidence shows that opioid substitution treatment 
reduces illicit opioid use and risks related to equipment 
sharing and, when continued on release, provides 
protection from death caused by overdose.
Evidence shows that the provision of clean drug injection 
equipment is possible in prison settings and can 
successfully contribute to a comprehensive programme 
to reduce blood-borne virus (BBV) transmission.
HBV vaccination
Offer HBV vaccination to people in prison with unknown 
or negative serology.
Evidence shows that using rapid schedules may result in 
a higher completion rate of the full schedule.
Testing for viral hepatitis and HIV
Actively offer BBV testing to all people in prison upon 
admission and throughout the time in prison.
Evidence shows that pro-active provision of BBV testing 
leads to a higher uptake; health promotion and peer 
education have been shown to increase HIV testing 
uptake.
Viral hepatitis and HIV treatment
Offer appropriate treatment to individuals diagnosed 
with HIV, HBV or HCV infection in prison settings, in 
line with the guidelines applied in the community 
and meeting the same provision standards as in the 
community.
Evidence shows that treatment of BBV infections is 
feasible and effective in prison.
Continuity of care
Actively support and ensure continuity of care between 
prison and community.
Evidence shows that release from prison is a key barrier 
to continuity and adherence to drug and infectious 
diseases treatment.
Evidence shows that collaboration and partnership 
between prison and community health-care services 
promote and facilitate uninterrupted care.
Evidence shows that active referral to external services 
improves treatment adherence.
Source: EMCDDA and ECDC, 2018b.
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into prison is beneficial (ECDC and EMCDDA, 2018b). 
Findings from a recent longitudinal study from Scotland 
suggest an association between the implementation of 
universal HBV vaccination in prison and an increasing 
level of coverage among people who inject drugs in the 
community (Palmateer et al., 2018). Hepatitis A virus 
vaccination, as already recommended in many EU/EEA 
countries (ECDC, 2016), could also be considered in 
prison settings for groups at high risk, such as people who 
use drugs and people who inject drugs, or with a high 
prevalence of hepatic disease (ECDC and EMCDDA, 
2018b).
Other vaccinations are under consideration in some 
European countries. Vaccination against flu for people in 
prison and prison staff may be considered an important 
preventive measure to avoid outbreaks in this setting during 
the flu season, as recent grey literature from England 
emphasises (O’Moore et al., 2018). A tetanus vaccination 
booster may be specifically relevant for people who inject 
drugs, given the higher risk of percutaneous injuries while 
injecting drugs.
In the early phases of the COVID-19 epidemic, WHO 
immunisation experts recommended as part of a values 
framework for the allocation and prioritisation of COVID-19 
vaccination (WHO, 2020) that social groups unable to 
physically distance, such as those in detention facilities, 
should be priority groups for COVID-19 vaccination. 
Subsequently, the European Commission has extended 
this recommendation to the EU Member States (European 
Commission, 2020).
I Treatment of blood-borne infections
Existing evidence on treatment for HCV and HIV in prison 
is substantial and suggests that it is feasible and beneficial 
in this setting (ECDC and EMCDDA, 2018b; Vroling et al., 
2018), whether it is self-administered or directly observed. 
Currently, no evidence has been identified on HBV 
treatment in prison settings (ECDC and EMCDDA, 2018b; 
Nakitanda et al., 2021).
I Needle and syringe programmes
The implementation of prison-based needle and syringe 
programmes in Europe is very limited, with the existence of 
ongoing programmes reported in three European countries: 
Germany (one prison), Spain and Luxembourg (ECDC 
and EMCDDA, 2018b). The scientific literature assessing 
the health outcomes for prison-based needle and syringe 
programmes is still scarce (ECDC and EMCDDA, 2018b). 
The strength of the evidence is too limited to demonstrate 
an effect on safe injecting practices; however, prison-based 
needle and syringe programmes are considered likely to be 
beneficial on the basis of reliable indirect evidence derived 
from community settings (Wiessing et al., 2014; EMCDDA, 
2017; ECDC and EMCDDA, 2018b; Lazarus et al., 2018). 
The available evidence on the effectiveness of prison-
based needle and syringe programmes suggests that this 
measure is likely to be beneficial in reducing blood-borne 
virus transmission among offenders who inject drugs 
(ECDC and EMCDDA, 2018b; Lazarus et al., 2018). Finally, 
existing evidence and anecdotal reports suggest a minimal 
risk of negative outcomes, such as increased violence, 
following the implementation of prison-based needle and 
syringe programmes (ECDC and EMCDDA, 2018b).
I Continuity of care
As individuals transition from prison to the community, 
continuity of care is essential in order to avoid disrupting 
treatment for disease and to prevent disease relapse or 
drug-resistant mutations (ECDC and EMCDDA, 2018b). 
Evidence shows that release from prison is the single most 
important factor associated with discontinuing treatment, 
in particular for HCV infection (Aspinall et al., 2016; ECDC 
and EMCDDA, 2018b). A number of interventions have 
been reported in the literature to promote continuity of 
care post release, including proactive referral and provision 
of drug prescriptions (for drug- and non-drug-related 
problems) (ECDC and EMCDDA, 2018b). In addition, the 
recent EU-funded project ‘My first 48 h out’ investigated 
continuity of care, in prison and upon release, for people 
who have used drugs for a long time, and the provision 
of case management with a focus on four EU countries 
(Belgium, Germany, France and Portugal). While identifying 
a number of strategies developed at national level, the 
project report recognises a number of barriers perceived by 
people who use drugs and professionals working in prison 
and community services (Stöver et al., 2019).
I Other prevention interventions
Evidence on more general blood-borne virus prevention 
interventions targeting people in prison is limited to a small 
number of measures such as distribution of condoms 
(Moazen et al., 2021), safe tattooing programmes and 
skills-building interventions. The available evidence is 
generally of low quality (ECDC and EMCDDA, 2018b). 
In the absence of prison-specific evidence on additional 
measures such as prevention of mother-to-child 
transmission, pre- or post-exposure prophylaxis and 
safe healthcare services, conclusive evidence derived 
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from community settings may be considered to support 
evidence-based interventions in the prison setting on the 
basis of the principle of equivalence of care (ECDC and 
EMCDDA, 2018b).
I  Prevention of post-release mortality among people who use drugs: key evidence in prison settings
Mortality post release is a major concern, particularly 
regarding people who inject opioids (see Chapter 3). 
High mortality rates in the months post release, peaking 
in the first 4 weeks, have been widely described in the 
literature (Farrell and Marsden, 2008; Binswanger et al., 
2016). Effective prevention of drug-related deaths includes 
providing OST for people dependent on opioids during 
detention, ensuring continuity of care after release and 
providing overdose response training combined with take-
home naloxone at the time of release (Table 6.3).
I Opioid substitution treatment
Accumulating evidence from the literature suggests 
that uptake of OST while in prison and continuation 
post-release has a protective effect against drug-related 
deaths (Hedrich et al., 2012; ECDC and EMCDDA 
2018b, 2018c). In particular, comparative studies show 
that uptake of OST during detention is associated 
with increased likelihood of continuation post-release, 
earlier enrolment in community services and reduced 
risk of relapse (ECDC and EMCDDA, 2018b). Two 
studies indicate that uptake of OST during detention 
was associated with a substantial reduction in all-cause 
mortality (75 %) and drug-related deaths (85 %) in 
the first month after release (Degenhardt et al., 2014; 
Marsden et al., 2017). Continuity of care for patients 
receiving OST after release is critical, as even short gaps 
in treatment may trigger relapse into illicit opioid use 
(ECDC and EMCDDA, 2018b, 2018c). In this context, 
ensuring appropriate referral to community services is of 
paramount importance (ECDC and EMCDDA, 2018b).
I Provision of take-home naloxone at release
Naloxone is an effective opioid antagonist medication 
used to reverse respiratory depression caused by opioid 
overdose. Take-home naloxone programmes combine 
overdose training with the distribution of naloxone (as an 
injectable solution in ampoules or pre-filled syringes or 
as a nasal spray) to potential bystanders of overdoses. 
Take-home naloxone programmes have been shown to 
be protective against overdose deaths (EMCDDA, 2017; 
Horton et al., 2017; McDonald et al., 2017; Horsburgh, 
2018). In particular, provision of take-home naloxone for 
people released from correctional settings has been shown 
to be feasible and acceptable (Bird et al., 2016; Horton 
et al., 2017; Parmar et al., 2017). Increased availability of 
naloxone through a nationwide take-home programme in 
Scotland has been linked to a reduction in overdose deaths 
after release (Bird et al., 2016). The wider availability of 
naloxone nasal spray may further increase acceptability 
and use (Mohammed et al., 2016; EMCDDA, 2016). An 
implementation guide for providing take-home naloxone 
at the time of release from prison has been developed in 
the framework of a project supported by the EU Justice 
Programme (Horsburgh, 2018).
TABLE 6.3
Overview of the evidence base on the effectiveness of drug-related interventions in prison for prevention of post-
release mortality
Intervention Details Evidence rating Desired outcomes Reference
Pharmacological treatment OST to reduce deaths in prison Beneficial To reduce mortality
Larney et al., 
2014
Continuity of OST from 
prison to community
Continuity of OST from prison to 
community to reduce post-release 
mortality








Naloxone training and prescription 
to reduce opioid overdose mortality 
after release from prison
Likely to be beneficial To reduce mortality Bird et al., 2016
Evidence ratings are based on GRADE.
Source: Evidence database, EMCDDA Best Practice Portal.
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I  Social reintegration: key evidence and evidence-based interventions
Policies and measures to support social reintegration 
form essential components of a comprehensive drugs 
strategy, and this is reflected in international and EU policy 
(EMCDDA, 2012). The success of social reintegration 
measures often relies on effective collaboration between 
different services, particularly when those measures are 
focused on people who are released from prison settings 
(Table 6.4). In particular, the EU-funded Throughcare 
project developed a dedicated toolkit to address 
throughcare services for offenders with problematic drug 
use (MacDonald et al., 2011). Such services are primarily 
concerned with assisting people in prison to prepare 
for release, helping them settle in the community and 
preventing reoffending.
It has been argued that a successful throughcare 
programme should be based on the general principle 
that care should be individualised and it should address 
four key areas of intervention, namely healthcare, family, 
finance and housing, and employment (MacDonald et al., 
2011). The importance of individual-based assessments 
has been further reiterated by the recent ECDC and 
EMCDDA guidance, and it is supported by some evidence 
showing that individual case management is associated 
with better post-release outcomes, such as engagement 
with harm reduction services (ECDC and EMCDDA, 2018b, 
2018c). A recent systematic review assessing re-entry 
programmes for people with problematic drug use and 
mental health disorders as they transition from prison to 
the community found that three main factors contributed to 
successful throughcare: the structural context, supportive 
relationships with staff, and continuity of care, including 
pre-release planning. Housing and employment were 
identified in all included studies as the most critical forms 
of practical support to reduce recidivism (Kendall et al., 
2018). In contrast, targeted interventions such as skill-
building vocational training for women in detention have 
been shown to have no clear benefits on employment 
outcomes and criminal recidivism (EMCDDA, 2012). 
However, research on interventions, including reintegration 
activities, for women with drug-related problems in prison 
is extremely scarce and there may have been changes in 
recent years.
I Extended-release naltrexone
Used to prevent relapse in opioid-dependent individuals, 
extended-release naltrexone is a sustained-release 
monthly injectable formulation of the full mu-opioid 
TABLE 6.4
Overview of the evidence base on the effectiveness of drug-related interventions in prison for social reintegration outcomes
Intervention Details Evidence rating Desired outcome Reference
Pharmacological treatment
OST (with methadone) in prison to increase 
post-incarceration community treatment 
engagement
Beneficial
Retain patients in 
treatment
Moore et al., 2019
Pharmacological treatment
OST (with methadone) in prison to reduce post-




Moore et al., 2019
Pharmacological treatment
OST (with methadone) in prison to reduce post-




Moore et al., 2019
Continuity of treatment from 
prison to community
Continuity of care to improve post-release 
behavioural outcomes
Likely to be 
beneficial





Naltrexone v. non-pharmacological treatment 
to reduce criminal activity (re-incarceration) in 
drug-using offenders





Perry et al., 2015
Therapeutic communities
Therapeutic communities in prison to reduce 
re-incarceration rates and drug misuse relapse




rates; to reduce 
relapse
Galassi et al., 2015
Educational and vocational 
training interventions
Vocational training to develop skills on 















Moore et al., 2019
Pharmacological treatment
Pharmacological v. non-pharmacological 







Perry et al., 2015
Evidence ratings are based on GRADE.
Source: Evidence database, EMCDDA Best Practice Portal.
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EU-funded projects: Throughcare
The project Throughcare aimed to research existing 
approaches to throughcare and aftercare services 
for people with problematic drug use returning to 
the community from prison. It also aimed to explore 
people’s needs for the services identified, with the 
main focus on women, young people, people from 
ethnic minorities and those with mental health issues. 
The project developed a toolkit to support countries in 
designing and implementing interventions for effective 
engagement and concerted action between prison 
authorities, community services and civil society to 
ensure continuity of care during transition from prison 
to the community. The toolkit is divided into sections 
to cover assessment of needs and planning to meet 
them, collaborative working practices, training and 
information needs, and monitoring. The toolkit is 
enriched by national case studies collected during the 
project.
Women in prison and the ROSE 
network in Italy
In Italy, women in prison constitute about 4-5 % of 
the prison population. This population subgroup is 
characterised by a prevalence of substance abuse, 
HIV, viral hepatitis and sexually transmitted infections 
often higher than that in the male prison population. 
In addition, a significant proportion of women in 
prison refuse treatment despite having considerable 
healthcare needs. To address this problem, in 2016 
a multidisciplinary network was established within the 
Italian national society for prison health (SIMSPe): the 
RoSe network (sanitapenitenziaria.org) or Rete Donne 
SIMSPe, aiming to achieve full coverage of the Italian 
prison system and to include women and transgender 
populations. The purpose of the RoSe network is to 
collect relevant information of the health status and 
healthcare needs of women in detention in Italy, with 
the ultimate goal of engaging prison institutions and 
prison health services in delivering appropriate care 
for this vulnerable population, including enhancing 
screening, linkage to care and support for adhering to 
treatment.
receptor antagonist (Lee et al., 2016). While in general 
there is limited evidence, a 2018 systematic review of 34 
studies found that providing extended-release naltrexone 
on release from prison, compared with providing non-
pharmacological treatment, is likely to be beneficial in 
reducing re-incarceration in drug-using offenders (Perry et 
al., 2015).
I  Legal and structural contexts: key evidence and evidence-based interventions
The national legal and structural context has a major 
influence on prison and drug policies and their 
implementation in European countries, and currently 
there is much heterogeneity in the way in which evidence-
based prison healthcare is integrated into national and 
local policies (and the way these policies are translated 
into practice). While this is a broad and relatively complex 
subject, only two approaches are presented here: 
alternatives to punishment and governance of health 
services in prison.
I Alternatives to coercive sanctions
Diverting offenders with problem drug use towards 
rehabilitative measures and away from incarceration 
has a number of positive effects, such as avoiding 
the damaging effects of detention and contributing to 
reducing the costs of the prison system. It is also in line 
with the rehabilitative objective to stop the ‘revolving 
door’ of recidivism by a rationale other than deterrence 
(White, 2017). Under the EU drug strategy (2013-2020), 
alternatives to punishment are referred to as ‘alternatives 
to coercive sanctions’, and the state of play around 
Europe was reported in 2016 by a project funded by the 
European Commission (Kruithof et al., 2016). Although the 
expression ‘alternatives to prison’ is rather ambiguous and 
may refer to punitive or rehabilitative programmes outside 
prison, ‘alternatives to coercive sanctions’ are broadly 
defined as measures that have some rehabilitative element 
and are used instead of punishment. The measures 
covered range from attending a brief intervention 
instead of paying a fine, receiving a suspended sentence 
conditional on attending drug treatment or agreeing 
to undergo treatment in prison that shortens the 
incarceration period. They may also include responses that 
constitute non-intervention, such as deciding not to charge 
or prosecute (Kruithof et al., 2016).
INSIGHTS I Prison and drugs in Europe: current and future challenges
88
Several different approaches to alternatives to coercive 
sanctions are implemented within the European Union, yet 
the evidence base for these programmes is limited, as few 
programme evaluations have been conducted. Evaluations 
that do exist have mostly had rather weak designs, and 
more robust evaluations have usually been conducted 
outside the region in a different context (EMCDDA, 2015; 
EMCDDA, 2017). The recent Commission-funded study 
concluded that the evidence favouring alternatives to 
coercive sanctions is promising but equivocal, as there are 
few studies of good quality.
Outcome evaluations have also been weak in this area, 
possibly because process evaluations, supported by the 
results of the study questionnaire, have shown there 
are several barriers to the use of alternatives to coercive 
sanctions in practice (Kruithof et al., 2016). These include 
lack of awareness of the existence of options for alternatives 
to coercive sanctions; members of the judiciary’s personal 
beliefs about the effectiveness or otherwise of rehabilitative 
interventions; judicial performance monitoring systems 
not designed to treat non-punishment as an acceptable 
outcome; administrative factors such as lack of treatment 
resources, requirements for apparently onerous judicial 
monitoring of the treatment process, or lack of coordination 
between judicial and rehabilitative agencies; legislative 
factors that limit the number and type of offenders that may 
receive such alternatives; and contextual factors including 
a change in political or public mood towards drug-using 
offenders (Kruithof et al., 2016).
One of the most studied interventions in this area has 
been the drug courts. These are courts that specialise in 
dealing with drug-related offences and drug-dependent 
offenders. Their primary objective is to reduce offending 
behaviour and support reintegration by referring offenders 
to drug treatment (EMCDDA, 2012), while retaining the 
deterrent threat of administering a criminal sanction, 
including a prison sentence. The European Commission 
study (Kruithof et al., 2016) noted that drug courts are 
better described as mechanisms for offering alternatives 
to coercive sanctions rather than alternatives to coercive 
sanctions in their own right. Research shows that 
drug courts might be potentially effective in improving 
employment outcomes and reducing criminal recidivism 
(see Table 6.5). Although studies have questioned their 
efficiency when compared with other alternatives to 
coercive sanctions, drug courts are considered most cost-
effective when dealing with the more problematic offenders.
I Governance of prison healthcare services
In 2013, the WHO published guidance for policymakers 
advocating that the management and coordination of all 
relevant agencies and resources contributing to the health 
and well-being of people in prison should be a shared, i.e. 
whole-of-government, responsibility and that ministries of 
health should provide and be accountable for healthcare 
services in prison settings (WHO Europe, 2013). Since the 
end of the 1990s, governance of prison healthcare has 
been moved to ministries of health in a growing number 
of countries (see Chapter 4). Yet, obtaining evidence that 
this transition results in better prison healthcare is not 
easy. Mainly, this is due to a widespread lack of baseline 
health data and to methodological and implementation 
challenges linked to designing and conducting evaluations 
of such system-wide transfer processes (WHO Europe, 
2013). Individual Member States have reported benefits 
such as improved resources and funding for key prison 
health issues, and the inclusion of people in prison in 
major public health initiatives (WHO Europe, 2013). 
Recent evidence from the region suggests an improvement 
in the performance of prison health services following 
their transfer to health ministries (Leaman et al., 2017). 
Furthermore, such transfers may favour the development of 
prison health indicators, service performance assessments 
and integration of prison health data into national health 
statistics (WHO Europe, 2013). A 2019 Council of Europe 
publication emphasises the need for this transfer of 
responsibilities as a way to enhance the implementation 
of the principle of equivalence of care for people in prison, 
although it is necessary to consider the potential difficulties 
and critical issues related to the transfer (Pont, 2019).
TABLE 6.5
Overview of the evidence base on the effectiveness of drug court programmes
Intervention Details Evidence rating Desired outcome Reference
Drug court programmes
Drug court programmes on employment-
related outcomes (employed, enrolled in 
school, etc.)





Drug court programmes Drug court programmes to reduce recidivism




Mitchell et al., 2012
Drug court programmes







Evidence ratings are based on GRADE.
Source: Evidence database, EMCDDA Best Practice Portal.
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I Conclusions
Supporting quality improvement in prison healthcare and 
addressing equivalence of care requires transparency, 
high-quality data collection and performance monitoring 
(Leaman et al., 2017), all of which may contribute to 
a better understanding of the burden of disease within 
the prison population (and the related health needs) and 
create the basis for adequate resource allocation. Despite 
the accumulating evidence on healthcare interventions in 
prison settings, and the new initiatives mentioned above, 
important gaps exist. Notwithstanding the challenges of 
conducting research in prison settings, discussed at the 
start of the report, these gaps need to be addressed with 
more and better targeted studies to promote the adoption 
of evidence-based prison healthcare policies on a broader 
scale.
When it comes to researching healthcare provision in 
prison settings, innovative methodological approaches, 
tailored to the features of particular prison systems, would 
be extremely valuable. Many research studies on prison 
healthcare interventions are focused on limited and often 
poorly defined outcomes. While the body of evidence may 
be well developed in community settings, and reliable 
analogies could be drawn, the specificities of the prison 
environment need to be taken into account (Stone, 
2018). This is also the case for research on behavioural 
interventions. Such challenges affect the process of 
evidence collation and synthesis, ultimately hampering the 
opportunities to use findings to inform policy.
The effectiveness of some interventions, including 
drug-free wings and prevention of drug use initiation in 
prison, has been little researched to date. Future efforts 
to fill this gap will need to adopt rigorous methodological 
approaches, including the identification and definition of 
relevant outcomes, in order to avoid the pitfalls highlighted 
above.
Although randomised clinical trials are considered the 
gold standard in health research, it is well recognised 
that this study design may not always be applicable or 
feasible. Other methodological approaches, such as cluster 
trials or well-designed comparative studies, may suffice 
to produce sound and reliable evidence to inform policy. 
Research projects would need to be designed thoroughly 
to address controversial issues such as the implementation 
of prison-based needle and syringe programmes. While 
this is a particularly sensitive topic, given the implications 
of illicit substance use in a prison environment, it would 
benefit from a comprehensive research approach to assess 
behavioural and health-related outcomes (e.g. infectious 
disease transmission), as well as operational aspects (e.g. 
syringe distribution, acceptability among staff).
In general, more operational research would be beneficial, 
as it could provide pragmatic indications of how 
interventions could be better implemented in prison 
settings. For example, it would be useful to investigate 
effective approaches for providing treatment and 
throughcare services. Again, such research should be 
oriented to achieve well-defined outcomes and describe 
operational aspects in sufficient detail.
Timeliness of research is important, in particular in the case 
of issues such as providing treatment for HCV with new 
direct-acting antiviral treatments in prison settings. While 
robust evidence could be derived from community settings 
on this specific topic, prison-based research is needed to 
prove the potential impact of certain interventions not only 
on the prison population but also on the wider community. 
A similar consideration could be given for the provision 
of take-home naloxone in the context of release from 
a correctional setting. Although its feasibility has been 
established, there is a need for rigorous research into the 
health outcomes and implementation of such programmes.
Understanding the costs of drug-related measures 
is important for both policy development and policy 
evaluation. However, the information available on drug-
related public expenditure in Europe, at both local and 
national level, remains sparse and heterogeneous. 
Nevertheless, estimates suggest that less than 10 % of 
the prison budget is spent on healthcare, even though it is 
known that residential prison treatment reduces the costs 
associated with lost productivity due to imprisonment 
and is cost-effective, especially when offenders attend 
treatment post release (EMCDDA, 2014b; NIDA, 2014; 
Sridhar et al., 2018). The systematic and standardised 
collection of programme data on healthcare provision 
in prison settings could also contribute to addressing 
research gaps. Such data would be a major source of 
information for comparing the potential costs and benefits 
of healthcare interventions, ultimately supporting informed 
and evidence-based decision-making and resource 
allocation.
Information presented in this chapter shows that 
over the past decade high-quality research assessing 
the effectiveness of harm reduction interventions in 
prison settings has remained scarce while, during the 
same period, research in community settings strongly 
consolidated the knowledge about the effectiveness of 
these interventions. Therefore, the validity of effective 
interventions in prison settings should be considered in 
view of the need to give people in prison standards of care 
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equivalent those provided for people in the community. 
Furthermore, as prison health is public health, investment 
in prison health yields a health dividend beyond prison 
walls.
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This chapter focuses on the supply of drugs in European 
prisons. It describes how drug markets operate inside 
prison and the main supply chains. It also presents the 
main supply reduction measures implemented in European 
countries, with a particular focus on drug testing in prison.
I Dealing drugs in prison
Understanding why people become involved in drug 
dealing in prisons is important if drug supply in prison is 
to be tackled. The reasons reported often relate to efforts 
to maintain access to a supply for personal use by sharing 
and swapping drugs. Supplying drugs also allows people 
in prison (whether or not they use drugs) to generate the 
income needed to make prison life more comfortable, to 
support partners and family or simply to make a profit. 
Coercion is also reported.
Prohibited commodities fetch higher prices in prison 
than in non-prison environments. The profit that can 
be generated by drug sales in prisons is reported to 
be up to four times greater than that in the community 
(Crewe, 2006). Some drugs, such as new psychoactive 
substances, may offer an even greater profit margin. In 
the United Kingdom, several studies report that the cost 
of new psychoactive substances in prison can be much 
higher than their cost outside prison, even as much as 
30 times (CSJ, 2015; Ralphs et al., 2017). Such inflated 
profit margins are likely to have attracted the attention 
and increased the involvement of organised crime groups 
in servicing prison drug markets. A few countries have 
also reported cases in which people are believed to have 
deliberately breached their (parole) licence in order to take 
advantage of the high profits afforded by supplying drugs in 
prison (EMCDDA, 2018).
I Drugs seized in prison
Evidence on the types, amounts and availability of drugs 
in prison is scarce. Although no overall European data on 
drug seizures inside prison are available, there is some 
information at national level. For example, in 2017 in 
England and Wales, according to prison services data 
provided to the British media (BBC News, 2018), drugs 
were found 13 119 times in prisons; in Spain over 4 700 
seizures were reported. The most commonly seized drug 
in general in European countries is cannabis; this is 
consistent with the epidemiological data available from 
national surveys on drug use among people in prison.
FIGURE 7.1











Source: EMCDDA Reitox monitoring data.
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Another example is Portugal, where data on seizures inside 
prison are available. Data for 2014-2019 on the quantities 
seized inside prison reported by the Portuguese prison 
directorate show no clear trends in seizures of cannabis, 
cocaine or heroin (Figure 7.1). Changes reported in the 
quantities of drugs seized may, however, reflect fluctuations 
in the availability of drugs inside prison, drug prevalence 
inside and outside prison, supply reduction interventions in 
prison, the number and type of people imprisoned and their 
related patterns of drug use, and other unknown factors.
I  Drug supply to prison: main routes and methods
Contraband is part of daily life in prisons, even if 
considerable effort is needed to breach prison security. 
There are six main routes to taking illicit drugs into prison 
(Blakey, 2008), many of which are similar to those used to 
smuggle other goods (such as mobile phones): external 
visits; postage; prison staff; over prison walls; people 
entering or returning to prison; and new technologies.
Information about which routes are most commonly used 
is not provided by prison services, but it may be inferred to 
some extent from supplies that are intercepted or routes 
that are disrupted.
Technological advances over the last decade have affected 
how drugs are transported into prison. For example, rather 
than simply throwing drugs over prison walls, drones have 
been used to carry items into prison grounds. Different 
routes may be used simultaneously, and in combination, 
in order to prevent detection and maintain supply. New 
technologies are also put to use in efforts to restrict supply, 
such as the introduction of new scanning technology to 
examine the contents of post.
I External visits
It is important that people in prison maintain their social 
support networks through regular contact with family 
and friends (by phone, post or visits). People in prison 
are therefore routinely allowed social visits in most 
prison systems. Research has shown how visits can 
be used to take illicit drugs into prison to be used, sold 
or exchanged for other goods and services (Penfold et 
al., 2005; Tompkins, 2016; EMCDDA, 2018; Trestman 
and Wall, 2018). In some cases, drugs are wrapped in 
small packages and concealed internally, in clothing or 
in other goods (Figure 7.2); the packages are passed to 
the person in prison either mouth to mouth or concealed 
in items (e.g. food and drink). The person in prison will 
have to conceal the package internally to avoid detection 
on a post-visit search. Specific supply methods for 
smuggling synthetic cannabinoids and synthetic opioids 
are reported: these substances can be easily dissolved 
in a solvent, such as acetone, and can be sprayed onto 
paper and tobacco or impregnated into textiles (Ford and 
Berg, 2018).
Many prisons have surveillance and prevention strategies 
in place that seek to deter visitors from taking illicit goods 
into prisons and people from putting pressure on family 
and friends to do so. The opportunities to receive drugs 
through visits vary across countries, but also within the 
same country different prisons can have different rules 
and procedures regulating social visits. For example, some 
prisons have strict limits on what people can receive from 
visitors, and all items are routinely scanned; others may 
have fewer restrictions and no scanning. The level of risk 
attached to individuals will also influence the security 
measures surrounding their visits: high-risk people may 
not be allowed direct contact with visitors or to receive 
items. Measures tightening the security surrounding social 
visits include the use of low-level fixed furniture in visiting 
rooms (allowing for better control of interactions), video 
surveillance, drug detection dogs and, where appropriate, 
imposing closed visits or visitor bans (Wheatley, 2016; 
Trestman and Wall, 2018).
FIGURE 7.2
Drugs concealed in footwear, seized during an external 
visit
Source: Italian Penitentiary Department, Prison Office for Inspection and 
Control.
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I Postage
People in prison often report receiving drugs in parcels or 
letters (Penfold et al., 2005; Tompkins, 2016; EMCDDA, 
2018; Trestman and Wall, 2018). There are many ways 
to conceal drugs in prison post, including under stamps, 
in envelope flaps and sprayed on to letters; between the 
pages of books or magazines; and concealed in clothing or 
other items posted.
Only small amounts of particular types of drugs can be 
smuggled in this way. Some drugs, such as cannabis, 
are too bulky to conceal in post but others, such as new 
psychoactive substances, lend themselves to this method 
of importation (Ralphs et al., 2017; EMCDDA, 2018). 
A number of countries, including Germany, Lithuania, 
Hungary, Poland, Finland, Sweden and the United 
Kingdom, have reported detecting postal packages and 
letters sprayed with new psychoactive substances sent to 
people in prison in their jurisdictions. This method carries 
particular health risks, as it is prone to the occurrence of 
so-called ‘hot spots’, that is, areas of the paper containing 
a high concentration of the active compound, which are 
linked to an elevated risk of overdose. It has prompted 
some prisons across the United Kingdom to provide people 
with photocopies rather than the original letters sent to 
them (Allison and Hattenstone, 2018).
I Staff
There is a wide range of staff working in prison, performing 
different tasks and belonging to different professional 
groups (officers, health staff, education staff, and so on); 
some become involved in trafficking drugs into prison 
(EMCDDA, 2018; Trestman and Wall, 2018). Often the 
motivation is personal financial gain, but it may also be 
driven by coercion or blackmail; once a member of staff has 
been persuaded or coerced into taking any contraband to 
prison, they become vulnerable to blackmail and may find it 
difficult to stop their involvement. A freedom of information 
request by the British press found that between 2011 and 
2017, 341 prison staff in England and Wales had been 
dismissed, excluded, convicted or cautioned by police 
for contraband in drugs, mobile phones and weapons 
(Yeung, 2018). Very limited information is available for 
other countries. Among the potential contributing factors 
rendering prison staff vulnerable to corruption are a lack 
of appropriate training and pressures arising from staff 
cuts (Yeung, 2018; Trestman and Wall, 2018). It has been 
argued that large amounts of drugs can be brought into 
prison in this way (Crewe, 2006).
The use of external subcontractors has also been identified 
as an enabler for the supply of drugs in prison: cleaning 
companies, waste disposal trucks and canteen suppliers 
have been reported by countries as sources of supply. 
Distribution through the prison canteen was reported as 
a common route: pre-sealed food packages, such as coffee, 
instant noodles or crackers, may be used to conceal drugs 
(EMCDDA, 2018). Some prisons have reacted by allowing 
only approved suppliers and vendors of items to people in 
prison to be used (Wheatley, 2016).
I Over the prison walls
Drugs can be thrown over the prison walls, but this method 
is largely dependent on the prison design and its location 
(Figure 7.3). When thrown over the walls, drugs may be 
concealed in various ways, including inside tennis balls, 
dead animals such as birds or rats, or other objects (The 
Economist, 2013; BBC News, 2019). New technology 
allows for more sophisticated means: drones, for instance, 
are widely available and have been used to smuggle drugs, 
mobile phones and other goods over the perimeter fences 
or walls of prisons (EMCDDA, 2018; Trestman and Wall, 
2018). Several measures may be used to counteract drug 
supply over prison walls, including the use of high fences 
and nets, as well as restricting the access of people in 
prison to the inner periphery of the prison.
I People returning to prison
There is a constant turnover of people in prison, with many 
people entering prison, or re-entering after court visits or 
periods of release. Before entering prison, people may 
conceal drugs internally, rendering them hard to detect. 
Drug-using offenders wishing to have a supply of drugs for 
their initial days in prison, either to cope with withdrawal or 
to trade for other items, frequently undertake this practice. 
Non-users may also take drugs into prison to secure 
a source of income (Penfold et al., 2005; Tompkins, 2016).
FIGURE 7.3
People throwing objects over a prison wall
Source: Stewart (Sam) MacLeod.
INSIGHTS I Prison and drugs in Europe: current and future challenges
102
In England, the large profits afforded by the sale of 
synthetic cannabinoids in prison is reported to have 
prompted the deliberate use of licence recall to smuggle 
these drugs into prison (Ralphs et al., 2017). English policy 
stipulated that individuals who have served more than 
1 day in prison may be released on a minimum 12-month 
licence or parole with certain associated conditions. 
Offenders who break the terms of the licence or commit 
another offence during this period can be recalled to serve 
further time in custody. In some instances, it has been 
reported that offenders released on licence concealed 
synthetic cannabinoids in their bodies and intentionally 
broke the terms of the licence to be taken back to prison 
to sell them. Most prison systems will have their own set 
of operational procedures aimed at detecting drugs upon 
entry (see the section ‘Tackling drug supply’ for more detail 
on possible responses).
I New technologies
The use of drones to take illicit drugs into prison has 
already been mentioned. Drones use radio frequencies 
produced by a standard mobile phone. The use of drones 
in supplying drugs to prison requires good organisation 
and coordination between people in prison and those 
outside, for example using diversionary tactics to breach 
the perimeter security. This route often carries a high risk 
of detection because of video surveillance focusing on the 
prison perimeter and other routine security checks in place 
(Figure 7.4). Anti-drone technology that interferes with 
the drone signals may also be used: there are a variety of 
methods available ranging from simple to highly technical 
solutions, yet little is known about their effectiveness 
(Hegranes, 2018).
Very small mobile phones manufactured with 
nanotechnology are a concern for prison services, as they 
are easy to hide and smuggle into prison. Mobile phones 
are important for contacting outside partners in managing 
drug supply in prison (EMCDDA and Europol, 2019).
I  Drug distribution inside prison: mechanisms and actors involved
I Drug trade in prison
Getting drugs into prison is only one step in the supply 
chain. The next one is navigating the distribution systems 
inside prison walls (Dillon, 2001; Penfold et al., 2005; 
Crewe, 2006; Tompkins, 2016). There are several ways 
through which the prison drug market can operate, and 
these are affected by the actors involved (those supplying, 
distributing, selling and buying drugs) but also by the 
particular structure, regime and physical environment of 
the prison itself. Drug distribution is a dynamic process 
that can adapt and change in response to these influencing 
factors.
Networks, often established between people in prison who 
knew each other before imprisonment, are an integral part 
of the supply chain. Several studies describe how a degree 
of reciprocity, that is, gifting or sharing drugs with others, 
is a feature of prison markets. This is primarily, however, an 
effort to ensure the establishment of a network of people 
who use drugs on whom one can draw if the supply dries 
up or becomes scarce (Turnbull and Stimson, 1994; Dillon, 
2001; Penfold et al., 2005; Crewe, 2006; Mjåland, 2014). 
It has been argued that sharing is a very effective form 
of drug supply because there is a strong obligation to 
reciprocate once a person in prison accepts drugs gifted 
by another. Gender-specific differences are reported in 
the supply of drugs into prison: a recent study in Germany 
found that there were fewer organised structures for drug 
trafficking in women’s prisons, but reciprocity still played an 
important role.
Substitution medications are sometimes diverted to and 
trafficked inside prison, either by the people supposed to 
take the medication who conceal it and re-sell it inside 
prison or by using goods, such as fruit, injected with 
methadone.
Drugs can be directly traded in prison for money or other 
goods and services, but exchanges between buyer and 
FIGURE 7.4
A drone seized in prison grounds
Source: Stewart (Sam) MacLeod.
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seller may also be mediated through a third party inside 
prison who receives payment in drugs (Crewe, 2006). More 
unusual is external mediation, whereby the supplier and 
the purchaser have a third party outside prison through 
whom they organise payment in the community. This is 
a useful mechanism for the seller, as money has limited 
use inside a prison (Penfold et al., 2005), and for the buyer, 
as gaining access to resources to pay for drugs in prison 
may be difficult.
There are a number of people involved in the supply and 
distribution of drugs in prisons (see box ‘Roles and actors 
in the supply and distribution of drugs in prison’).
Actors involved in drug trafficking inside prison can be 
large-scale suppliers, dealers or members of organised 
crime groups. Some are continuing the business they ran 
before imprisonment, while others take advantage of the 
circumstances in which they find themselves and trade 
their own small supplies.
The available data suggest that there is rarely one source of 
drugs or one main dealer exercising control over the prison 
market. This is partly due to the mostly transient nature of 
the prison population (Penfold et al., 2005). In addition, 
relying on one source in prison may be a high-risk strategy 
given the level of security and the potential for detection. 
Therefore different levels of the market can operate 
simultaneously in order to sustain supplies in prison 
(Crewe, 2006; Mjåland, 2014; Tompkins, 2016).
Drug supply in the community is often described variously 
as hierarchical, horizontal or disorganised. Hierarchical 
supply describes a classic pyramidal structure, with 
a main dealer at the top, a number of mid-level dealers 
and a large number of low-level sellers or runners within 
a specific market or geographical area (Hough and 
Natarajan, 2000). Horizontal supply is characterised by 
a large number of financial transactions, drug exchanges 
and connected networks organised around a small number 
of key personnel (Pearson and Hobbs, 2003). The third 
type, disorganised, refers to small, flexible networks and 
partnerships of free-trading entrepreneurs (Reuter and 
Haaga, 1989). Recent developments, probably triggered 
by the rise of the internet and other factors such as 
globalisation, suggest that drug markets are becoming 
more ‘disorganised’, with increasing numbers of actors and 
entrepreneurs at all levels (EMCDDA and Europol, 2016, 
2019).
In prison, different types of drug markets often co-exist 
and operate largely independently of each other (Penfold 
et al., 2005; Crewe, 2006; Tompkins, 2016). Taking the 
three levels of drug markets described above, in prison 
the low level includes mutual supply among people who 
use drugs — an important practice within the prison 
environment (Penfold et al., 2005; Crewe, 2006; Mjåland, 
2014; Tompkins, 2016). Various methods are used to 
exchange drugs between people in prison. In France, for 
instance, walks and ‘yoyos’ (i.e. exchange through windows 
between people housed on different floors) are two of the 
preferred methods for exchanging substances (Chantraine, 
2004). Mid-level dealing has been described as a way to 
make prison life more comfortable as well as maintaining 
individual user-dealers’ access to drugs: drugs are 
exchanged for other goods and services such as cigarettes, 
food, toiletries, haircuts and clothing. Goods and services 
are the currency of choice, as cash has limited value within 
prison walls.
While low- and mid-level dealers in prison make use of 
resourceful skills and entrepreneurial methods, high-level 
dealing requires a greater degree of organisation, contacts 
and resources. Because they were often dealers in the 
community, high-level dealers have the contacts and 
resources required to ensure a continuous supply of larger 
quantities of drugs into a prison, through either social visits 
or other routes. In addition to networks that extend outside 
the prison, this level of dealing often involves the use of 
mobile phones smuggled into prison and the employment 
Roles and actors in the supply and 
distribution of drugs in prison
Prison supplier: an outsider who systematically 
supplies drugs to prison. These can be established 
individual drug suppliers based in the community, or 
organised crime groups.
Importer: a person who takes drugs into prison. 
Importers can be prison visitors, staff, friends and 
family of the people in prison, or people new to prison 
or re-entering prison.
Seller: an insider who sells or trades drugs. Sellers 
can be prison dealers with larger supplies and a range 
of importation sources or user-sellers with limited 
supplies and fewer sources.
Runner: an insider who moves drugs and goods 
around the prison, enabling transactions, most often 
a person in prison.
User-sharer: a person in prison with limited individual 
supplies entering into reciprocal sharing of drugs with 
other people in prison.
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of a number of people. High-level dealers pay other people 
in prison, usually in drugs or goods, to receive drugs on 
visits, hold drugs in their cells or elsewhere, make deliveries 
and collections, provide protection and ‘collect’ debts in 
much the same way that they operate in the community.
I Transactions, payments and violence
How to initiate and complete a transaction to purchase 
drugs inside prison may be dependent on various factors, 
including length of time in prison, extent of existing 
network of contacts, and availability of financial resources. 
For example, dealers need to secure suppliers, establish 
contact with buyers, negotiate deals, resource and arrange 
for payment, and organise transactions (with either 
suppliers or buyers). Each transaction with a new actor will 
demand careful organisation; subsequent ones will often 
require less effort. For the most part, however, dealers 
or sellers and buyers already know each other or will be 
introduced through a common acquaintance (Penfold et al., 
2005; Tompkins, 2016).
The exchange of or payment for drugs can occur in various 
places and settings within a prison, including canteens 
while queuing for food, the gym, multi-faith chapels and 
prayer rooms, prison workshops, by cell doors, in education 
settings, during association (i.e. when people in prison can 
move around the common areas and socialise with each 
other) or during visits (Penfold et al., 2005).
The role played by people in prison trusted by officers with 
prison work (e.g. serving food, cleaning, or working in the 
kitchen or the laundry), as well as of staff monitoring people 
in prison during external visits, is reported to be essential 
to the success of drug transactions. Often these trusted 
people in prison are able to move freely around the prison 
facilities and may thus act as runners; they may deliver 
drugs and take payment, conduct transactions at cell 
doors when other people in prison are not allowed out, and 
enable the movement of drugs between different wings 
and parts of the prison (Penfold et al., 2005; Crewe, 2006; 
Tompkins, 2016).
In Spain, people in prison are reported to make use of 
a post office immediate transfer system to pay for drugs in 
prison. The immediate transfer system, called giro, allows 
any person at any post office to transfer money in few 
minutes to any other person, who can collect it at any post 
office in the country. Using this system, the drug dealer 
provides the buyer with the name of the person collecting 
the giro payment; the buyer forwards the contact details 
(along with the amount to be transferred) to a relative or 
friend outside who goes to the post office to transfer the 
stipulated amount. A similar system is in place in France, 
involving prepayment via credit card or telephone (Protais 
and Jauffret-Roustide, 2019).
As with many other illegal markets, there is a level of 
threatened and actual violence in drug dealing in prison 
(Crewe, 2006). But, unlike settings in the community, 
prisons are closed punitive environments that lend 
themselves to the rapid escalation of violence; small 
disputes may easily turn into serious confrontations 
with severe consequences. The prison environment may 
also distort the market; for instance, there is a lack of 
opportunity to raise resources, there is a higher risk of 
detection attached to drug supply and distribution, and 
demand may suddenly outstrip supply. Tensions may arise 
from the need or desire to have drugs, the lack of resources 
to pay for them or the accumulation of debt. The recent 
rise in the use of new psychoactive substances in some 
prisons across Europe has led to concerns about how 
these substances may contribute to prison violence, not 
only through increased violent behaviour when under the 
influence, but also on account of the high profits that they 
can generate (Ralphs et al., 2017). The profit margin of new 
psychoactive substances in prison is of such a scale that 
organised crime groups have become closely involved in 
this segment of the prison drug market (EMCDDA, 2018).
I Tackling drug supply
Tackling drug supply in prison is a difficult task (Trestman 
and Wall, 2018). There are a range of supply reduction 
interventions currently in place in prisons across 
Europe that seek to detect, deter and disrupt drug 
supply; however, it remains unclear which measures, or 
combinations of measures, are effective (Dastouri et al., 
2012; Wheatley, 2016). There are few studies available, 
and differences between countries, prisons and prison 
management may render it more difficult to define what 
is the most appropriate approach to take. It is accepted, 
however, that a strategy is more likely to succeed if it 
comprises a combination of demand reduction, treatment, 
enforcement and security measures (Tompkins, 2016).
I Supply reduction interventions
Supply reduction strategies in prison are implemented 
differently across countries: they can be implemented 
at institutional level (i.e. prison level) or coordinated at 
national level. The government body responsible for 
implementing strategies is generally the national ministry 
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responsible for running the prison services, but the national 
body responsible for drug-related interventions may also 
play a role.
The most common enforcement and security measures 
directly addressing drug supply in prison consist of 
operational procedures to detect drugs and related 
paraphernalia, including body searches and searches of 
cells, furniture, personal belongings and common spaces, 
such as yards and workshops. Searches and screening 
are often extended to all those entering prison, including 
staff, visitors and service providers. Trained dogs are often 
used to conduct searches. Also used in some prisons is 
the so-called ‘electronic nose’. It is a portable electronic 
instrument, based on commercially available metal oxide 
gas sensors, that can be used to detect various types of 
drugs (Haddi et al., 2011). Detection instruments based on 
infrared or Raman spectroscopy may also be used. Other 
technologies used in search and monitoring include CCTV 
(closed-circuit television) and X-ray machines (Wheatley, 
2016). However, their effectiveness needs to be assessed 
further.
Interventions aimed at deterring and detecting drug 
supply in prison can be complemented with interventions 
seeking to disrupt the supply and distribution of drugs in 
prison. Enforcement and security measures used to detect 
illegal communications about drug trafficking may include 
monitoring and controlling the communications of people 
in prison, including random monitoring of post and phone 
conversations and the use of PIN (personal identification 
number) technology allowing only approved numbers to 
be dialled by people in prison (Wheatley, 2016). The last 
two may be of limited use if there is a high level of mobile 
phone contraband (or may even encourage it).
Other interventions involve circulating information (posters, 
leaflets, and so on) on the implications of drug supply, 
which may vary from criminal charges to loss of benefits, 
such as banning or limiting visits (Wheatley, 2016). There 
is, however, limited evidence on the effectiveness of 
sanctions in reducing drug supply in prison (Trestman and 
Wall, 2018).
One strategy to reduce drug supply in prison focuses on 
addressing drug demand. Drug treatment, for example, can 
work to reduce the pressure on, and desire of, individuals 
to seek out drugs (see Chapters 4 and 5). People who use 
drugs in prison often report that, if appropriate treatment 
were available in prison, they would be likely to seek it, 
listing as their motivation not having to face the challenges 
and risks of maintaining a supply of illicit drugs in prison 
(e.g. detection, debt, bullying and violence). However, many 
prison systems have limited treatment opportunities, which 
may in turn result in drug-seeking behaviour.
Drug testing programmes in prison are often implemented 
with the dual purpose of addressing drug supply and 
supporting drug treatment in prison; these will be 
discussed in some detail later in this chapter.
I Challenges to supply reduction in prison
There are many challenges to supply reduction in 
prison. Prisons are closed environments but ones with 
a considerable number of people, services and goods 
coming through the gates every day. Addressing drug 
supply in prison demands some understanding not only of 
the main routes and systems of supply and distribution in 
a particular prison but also of the possible implications of 
disrupting them.
Supply reduction and security measures may have 
unintended consequences. Disturbing one supply route 
may set off the flow of traffic to others. Security measures 
may result in increased pressure on people entering prison, 
including intimidation and robbing of those believed to 
have imported drugs into prison. They may also lead some 
people in prison to switch to drugs that are less likely to 
be detected, such as heroin, or to more harmful patterns 
of use, such as injection, with the consequent associated 
risks (Gore and Bird, 1996; EMCDDA, 2012; Ralphs et al., 
2017). One of the main reasons reported for the increased 
use of synthetic cannabinoids in prison was their initial 
undetectability in routine urine testing (User Voice, 2016). 
Policy initiatives resulting in tightened security do not 
always lead to a more stable environment. There is a risk 
that they may disrupt the current state of affairs and could 
potentially result in increased tension between people in 
prison and staff (Penfold et al., 2005).
There are issues of resources and capacity, with many 
prisons across Europe experiencing overcrowding, 
understaffing (or staff with limited training) and restricted 
budgets, all of which limit their scope for action. New 
technologies, for instance, are effective in tracing small 
amounts of many substances, or concealed items, but they 
are costly and staff may need specific training to operate 
them (Dastouri et al., 2012). Photocopying people’s post 
may seem simple enough but it can be a resource-intensive 
task, and it may infringe policies protecting personal 
privacy. Trained dogs are commonly used and are very 
efficient, but they can only work for a short time at each 
turn. Weaknesses in prison design may hinder efforts to 
reduce supply, but structural improvements can be costly 
and lengthy (Dastouri et al., 2012; Wheatley, 2016).
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There are also tensions between the need to maintain 
safety and security in prison and the need to uphold other 
aims of incarceration such as preparation for re-entry to the 
community at the end of the sentence. For example, there 
is an inherent conflict between controlling external visits 
and the rehabilitative role of maintaining family relations 
(Keene, 1997; Trestman and Wall, 2018). These challenges 
point to the complexity of the issue in hand. They show how 
drug supply may be better understood not in isolation but 
in relation to drug demand and treatment, the overall aims 
of imprisonment, the specific circumstances of each facility 
and the legal framework of its jurisdiction.
I Drug testing in prison
Drug testing programmes, mainly conducted through 
the analysis of collected urine, have been introduced in 
many European prisons as interventions to reduce both 
supply and demand since the 1990s. There is some 
evidence suggesting that mandatory drug testing may have 
a deterrent effect on drug use in some people in prison 
(Singleton et al., 2005). It is also believed that testing 
can support change or recovery as part of a treatment 
or therapeutic intervention and may reduce the levels of 
cannabis use (Dolan and Rodas, 2014). Drug testing may 
push some people to switch from using drugs that are 
detectable to using undetectable drugs, as in the case of 
the spread of new psychoactive substance use in prison, or 
it may have other unintended negative consequences, such 
as the increasing awareness of the availability and potential 
use of drugs (see Chapter 2).
Urinalysis offers a specific window for detecting 
substances, making test scheduling an important issue 
in many situations. When a drug is smoked or injected, 
absorption is almost instantaneous and excretion in urine 
begins almost immediately. Absorption is slower when 
a drug is administered orally and excretion may be delayed 
for several hours.
In general, cannabis is the most commonly detected drug 
because of its high prevalence of use in prisons but also 
the long period of detection after its use (up to several 
weeks), especially among more frequent users. The high 
levels of cannabis detection in prison may also be because 
it is the drug with the highest prevalence in the general 
population, and many people entering prison may have 
used shortly before they are tested on entry to prison. 
There may also be a bias related to the high rate of people 
re-entering on short sentences (Dolan and Rodas, 2014). 
Concerns have been raised that drug testing may lead 
people in prison to switch to more harmful substances 
and/or patterns of use that are more difficult to detect 
(Gore and Bird, 1996; EMCDDA, 2012; Ralphs et al., 2017).
Information from drug testing can provide useful 
epidemiological data and, when combined with other 
information sources, such as surveys of people in prison, 
may contribute to a comprehensive picture of the 
prevalence and patterns of drug use inside the prison. As 
a security measure, drug testing facilitates the detection 
of use and can work to deter use, yet, without specific 
follow-up such as treatment and counselling programmes, 
it can also increase tension inside prison and deflect 
attention from other important issues (MacDonald, 
1997). Professional medical ethics and international 
recommendations advise against healthcare providers 
being involved in drug testing when it is conducted for 
security and control purposes (UN, 2016).
Table 7.1 provides an overview of the use of drug testing 
programmes in a number of European countries using 
data collected from the EMCDDA’s legal correspondents 
in the EU Member States, Norway, Turkey and the United 
Kingdom and its Reitox network of national focal points in 
2018.
In three countries (Greece, France and Cyprus), drug 
testing is not available in prison. In most countries where 
drug testing exists, it has the dual purpose of supporting 
treatment and prison security, but in eight countries it is 
focused exclusively on security issues and in four its sole 
aim is to support drug-related treatment.
Where drug testing is mandatory, the person tested is 
obliged to provide urine, breath, saliva, sweat, blood or hair 
samples, on request, unless there are medical or similar 
reasons for their not doing so. Mandatory drug testing 
programmes are expensive, and can result in days added to 
sentences, in prison systems that are already overstretched 
with large numbers of people in prison and limited budgets 
(Singleton et al., 2005).
In most countries, drug testing is administered by 
healthcare staff, but in some it is administered by prison 
staff or by both prison and healthcare staff, and several 
countries mentioned testing on entry and exit from prison, 
testing on suspicion of use, and random testing. This also 
depends on the main aim of the test: treatment or security.
The extent to which drug testing is used and the occasions 
and circumstances that trigger it also vary across 
jurisdictions, but data are generally scarce. For example, 
Finland reported 46 000 tests performed in 1 year (in 
a prison population of around 3 000), while in Luxembourg 
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TABLE 7.1
Drug testing in prisons in the EU Member States, Norway, Turkey and the United Kingdom (situation in 2019 or most 
recent information available)
Country Aim Context Administration
Belgium Treatment Drug-free programme No information
Bulgaria Security Suspicion of use (not applied extensively) Healthcare staff
Czechia Security and treatment
On entry, suspicion of use, random, drug-free zone, treatment 
(OST, mandatory treatment, voluntary treatment)
Healthcare staff
Denmark Security and treatment
Suspicion of use, external visits, random control, drug-free 
zone, voluntary treatment
Prison staff
Germany Security and treatment
The system is not nationwide. In some prisons it is conducted 
in cases of suspicion of new psychoactive substance use
Prison officers
Estonia Treatment Random testing No information
Ireland (Security and treatment)
Currently planning the introduction of drug testing in prisons, 
to be applied in the context of OST
No information
Spain Security and treatment
As a control for the granting of permits — before, during or 
upon return — based on a prior commitment with the person 
in prison; preparation for release (up to 7 days for people with 
specific requirements)
Linked to the therapeutic process in methadone treatment 
programmes; to adjust doses in OST or cessation 
programmes. In the case of positive controls, efforts are 
made to prevent relapse; expulsion from the programme is 
avoided
Healthcare staff
Croatia Security and treatment
On entry, suspicion of use, transfer to another prison, if 
person is part of treatment programme, on return after each 
temporary stay outside the prison
Prison officers, healthcare staff
Italy Security and treatment On entry Healthcare staff
Latvia Security Suspicion of use Prison staff
Lithuania Security Suspicion of use Prison officers
Luxembourg Security Suspicion of use (rarely applied) Prison staff or healthcare staff
Hungary Security and treatment
Mandatory monthly testing in drug-free wings, upon 
admission to drug-free wings, and in cases of suspected 
drug use. Not mandatory but can occur: when returning from 
outside prison
Healthcare staff
Malta Security Random testing Healthcare staff
Netherlands Security
Transfer to other institutions. Mandatory testing before going 
on leave
No information
Austria Security and treatment OST Healthcare staff
Poland Security Suspicion of use Prison officers
Portugal Treatment
Random testing
Testing required to access prison privileges
On entry screening if suspicion of use
Healthcare staff
Romania Security and treatment
For inclusion in a treatment programme and whenever 
necessary during the programme, on suspicion of use
Healthcare staff
Slovenia Security and treatment
Random, if there is reasonable suspicion of being under the 
influence of drugs, OST/other treatment (Law on Execution 
of Criminal Sanctions)






In 2016 there were 46 000 tests conducted; positive tests 
result in penalties
No information
Sweden Security (treatment) On request, to ensure no intoxication
Prison officers (or healthcare 
staff if blood involved)
Norway Security and treatment Suspicion of use
Healthcare staff for body cavity 
inspection, blood samples
Prison officers for urine 
samples
United Kingdom Security/treatment Large random testing programme in England and Wales Prison officers, healthcare staff
Drug testing in prisons is not available in Greece, France, Cyprus. Information on drug testing in prisons is not available for Turkey.
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drug testing is triggered only by suspicion of use, and even 
then it is rarely applied.
I Conclusions
Prisons present a unique set of circumstances and 
challenges for those involved in drug markets and those 
trying to prevent drug supply. Despite their illegality, 
drugs enter prison and are used by people who are in 
prison, as evidenced by data on drug seizures and the 
prevalence of use in prison. Those using or trading in drugs 
have established routes of supply and mechanisms of 
distribution in prison, which are adapted to their particular 
circumstances but flexible enough to be adjusted to make 
use of new technologies or to overcome new challenges, 
such as increasing security measures and attempts by 
prison authorities to deter drug use.
Prison authorities have introduced a wide variety of 
measures to deter, detect and disrupt the supply and 
distribution of drugs in prison. There is limited information, 
however, about the impact of these measures, each 
presenting its own set of advantages and disadvantages. 
The challenge facing those tackling drug supply in prison 
lies in reaching a balance between care and control and in 
understanding that measures introduced to control drug 
supply may have positive and negative consequences for 
other elements of prison life.
More studies are needed on the efficacy of different supply 
reduction interventions in prison, both individually and 
combined (Dastouri et al., 2012). Research on the roles 
and motivations of the various actors involved in drug 
supply in European prisons is also likely to contribute to 
better informed policies and practices seeking to deter 
engagement with the prison drug market. Finally, a better 
understanding of how drug supply and drug treatment and 
demand intersect in prison settings may go a long way 
towards a more sustainable and cost-effective deployment 
of drug-related interventions in prison.
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This EMCDDA Insights report has gathered together 
contributions from a variety of sources to provide 
a comprehensive overview of the current knowledge and 
the latest developments in the field of drug use and prison 
in Europe. The report has set out what is known about drug 
use and drug-related harms among people in prison and 
the responses available to address them. This concluding 
chapter brings together and discusses a number of 
important emerging issues in the context of future 
challenges in the field.
This chapter also draws on the insights and expert opinions 
conveyed at the technical meeting ‘Prison and drugs in 
Europe: future challenges’, hosted by the EMCDDA in 
Lisbon in January 2019. The meeting brought together 
experts from a variety of fields (including academia, public 
institutions, people with lived experience, prison security 
staff, health and drug services, and prison administration) 
to discuss the future challenges in the field and how these 
can be understood within a larger societal context. The 
meeting also focused on what policymakers, treatment 
providers, prison administrations and practitioners in 
health and social interventions may need to improve the 
conditions of people in prison who experience drug-related 
problems and the communities they will return to.
I  Prison populations and social vulnerability
Prison populations are diverse, complex, highly dynamic 
and characterised by an increased prevalence of multi-
morbidity. Offending and drug use share a number of risk 
factors that, although not easily disentangled, reveal how 
drug use is often just one of many vulnerabilities of people 
in prison; this is particularly so in the case of women.
In recent years, attention has been devoted to how risk 
factors for drug use and imprisonment often relate to 
multiple and cumulative adverse childhood experiences 
that may have an intergenerational effect. These include 
experiences such as sexual abuse, violence, neglect 
and dysfunctional (and often drug-using) families. The 
development of interventions targeting this group must 
take into consideration the impact of such multiple adverse 
experiences on the behavioural and cognitive development 
of children (Fuentes, 2014; Jones et al., 2018).
Other groups of people in prison which may have particular 
health needs include foreign nationals, older people and 
LGBT (lesbian, gay, bisexual, transgender) people. Some 
of these groups (elderly, foreign nationals) are growing or 
have become more visible (LGBT) inside prison in recent 
years, yet little is known of their health and social care 
needs, which may be exacerbated when combined with 
drug-related problems.
In the future, there may be cumulative benefits from paying 
specific attention to targeted population groups when 
implementing drug-related interventions in prison. Women 
in prison, for example, report high levels of infectious 
disease and exposure to repeated trauma, particularly 
domestic violence and child abuse (Fuentes, 2014). 
Women who use drugs are particularly vulnerable, and 
their prison experiences, drug use and needs in terms of 
treatment need to be better understood.
Foreign nationals represent 11 % of the prison population 
in Europe (Aebi and Tiago, 2020) and, while there are no 
data specific to their healthcare needs (Tomita, 2019), 
several studies indicate that foreign nationals in prison 
face language and cultural barriers resulting in isolation 
and difficulties in expressing concerns about their health 
and accessing services, and that they may experience high 
levels of anxiety over their uncertain immigration status 
and family separation (Singh Bhui, 2007; Bosworth et al., 
2016). Studies also suggest that this group is likely to suffer 
from untreated mental health problems and is particularly 
vulnerable to suicide and self-harm (Borrill and Taylor, 2009).
LGBT people face complex problems inside prison, and 
the experiences of transgender people in this setting have 
been shown to be difficult. There is no or little information 
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about drug use by this group and their prison experience or 
the indicated treatment options, but there is evidence of an 
elevated risk of substance use and substance use disorders 
and a high prevalence of HIV infection among LGBT people 
in the community (Glynn and van den Berg, 2017).
There are also specific concerns related to older people 
who use opioids in Europe, many of whom have had 
some experience of incarceration. Older people who 
use drugs are characterised by a history of poor health, 
long-term drug use, chronic tobacco and alcohol use, 
and age-related deterioration of the immune system, all 
contributing to increased susceptibility to chronic health 
problems such as cardiovascular and lung conditions. The 
cumulative effects of drug use and drug-related problems, 
including experience of non-fatal overdoses and infections, 
accelerate physical ageing among this group, which often 
has major implications for treatment and social support 
services (EMCDDA, 2010; Pirona et al., 2015).
While outside the scope of this report, young people in 
prison and juvenile prisons also represent a key population 
with particular needs. For this group, indicative prevention 
interventions have aimed to reduce drug problems and 
their negative consequences in individuals with behavioural 
or psychological problems, who are predicted to have 
a higher risk of substance use problems later in life 
(Carapinha et al., 2016; EMCDDA, 2019).
Addressing the needs of these groups in prison represents 
a challenge that the prison services in Europe will 
increasingly have to face in the coming years.
I Prison and community
The need for a closer link between prison and the 
community has been repeatedly highlighted in national 
and international principles and recommendations guiding 
the provision and governance of health and social care 
in prison. The prison and the community are not discrete 
environments; they connect and intersect as people move 
between one and the other. This is particularly so in the 
case of people who use drugs. As the average duration 
of a prison sentence for this group is a few months, it 
is a dynamic population with regular contacts with the 
community, and this has implications for public health. 
Chapters 2 and 3 highlight how the prevalence of drug 
use and drug-related problems among people in prison is 
generally high. Providing continuity of care as people move 
between prison and the community is key to achieving 
sustainable and effective treatment outcomes.
Considering that people in prison come from and 
eventually return to the community, interventions in 
prison are likely to have a significant impact on public 
health. Interventions in prison may play a key role upon 
release in facilitating the continuity of treatment and 
in preventing drug-related deaths, and they may have 
a significant impact on morbidity, mortality, public health 
and recidivism. This not only benefits prisoners themselves 
but also delivers a community dividend (O’Moore, 2015). 
By addressing drug-related problems in prison settings, the 
health of people living in prison and in the community they 
return to can be improved, producing an overall societal 
benefit.
In addition, while prison conditions can negatively affect 
the already impaired health of people who use drugs, these 
are also settings that may facilitate the provision of health 
services. It is often in prison that people deemed hard to 
reach by health services in the community first come into 
contact with all-important prevention, treatment and harm 
reduction services to address their drug use and drug-
related problems.
Closer coordination between health and social services 
outside and inside prison may require adjusting some 
professional practices, listening to the needs of people 
in prison, improving collaboration between professionals, 
reinforcing the diffusion of harm reduction measures in 
prison and supporting innovative programmes including 
alternatives to imprisonment. New technologies, such 
as e-health, can contribute to improving the linkage and 
continuity of care between services in and outside prison. 
Practical applications of e-health in the provision of drug 
treatment have been implemented in some Spanish 
prisons with encouraging results (EMCDDA, 2019; Morel-
Darleux, 2019; Usieto, 2019).
People in prison retain their fundamental right to enjoy 
good health and are entitled to a standard of medical care 
that is at least the equivalent of that provided in the wider 
community. The smoking ban introduced in British prisons 
in 2015 sought to apply to prison the same preventive 
measures implemented in the community, and in doing so 
it addressed a significant health inequality among prison 
populations affected by a high prevalence of tobacco 
smoking and second-hand exposure. Assessments of 
the impact of the smoking ban in prison have, to date, 
shown no evidence of a negative impact on mental 
health or a decrease in safety or an escalation of violence 
(Maddalena, 2019). However, an ongoing study carried 
out by an English peer-to-peer organisation highlighted 
the need to address the difficulties experienced by a large 
proportion of people in prison with intensive and long-term 
tobacco smoking behaviours caused by stopping smoking 
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and the need to provide appropriate support for smoking 
cessation both inside prison and on release (User Voice, 
2016).
As many people in prison come from vulnerable population 
groups, equivalence of care may not result in the same 
level of health as that enjoyed by the general population; 
therefore, additional interventions in prison may be needed 
to achieve equivalence of health outcomes. For the most 
part, however, people in prison are faced with a limited 
range of treatment options, and equivalence and continuity 
of care remain unachieved principles in the majority of 
countries in Europe.
Most interventions that have proved effective in the 
community have been implemented in prison but following 
some delay and with insufficient coverage (Chapter 4). OST 
in prison, for instance, while implemented in all reporting 
countries but one, remains available to only a small 
proportion of the people who need it. This is so despite its 
proven effectiveness in the treatment of opioid use and 
in reducing transmission of blood-borne viruses, as well 
its protective effect on drug-related deaths post release. 
Testing and treatment of infectious diseases among 
people in prison has an important impact on public health 
(Meroueh, 2019; Stöver et al., 2019b). Although testing 
and treatment of HIV, HCV and HBV are available in many 
COVID-19 and drugs in prison: the impact of a ‘double lockdown’
Prisons, as closed and tightly populated environments, often overcrowded, represent a challenge in controlling the 
spread of infectious diseases, including COVID-19. Furthermore, prison populations suffer from poor health compared 
with their peers in the community (Enggist et al., 2014). International organisations and NGOs were quick to publish 
guidance and recommendations for preventing the spread of COVID-19 in prison settings, and prevention and 
containment measures have been implemented in European countries since March 2020. In most prisons in Europe, 
external visits, services from external providers and group activities were interrupted; staff and, whenever possible, 
people in prison started to use personal protective equipment; and increased attention was given to hygiene, education 
and training on COVID-19 (EMCDDA, 2020). People with suspected COVID-19 were quarantined in designated 
spaces, and diagnosis, surveillance and treatment were implemented (WHO Europe, 2020). Furthermore, to reduce 
overcrowding, as an important risk factor for the spread of the disease, several European countries introduced 
regulations for the early release of some detainees, which resulted in a reduction of around 10 % in the prison 
populations in some European countries (Council of Europe, 2020; Europris, 2020).
Based on two EMCDDA studies conducted in May 2020 and in February 2021, those measures have had an important 
impact on drug issues in prison settings, including drug availability and drug use, drug-related harms and the provision 
of drug services (EMCDDA, 2020, 2021).
The interruption of external visiting appears to have disrupted one of the ways that drugs are smuggled into prison 
settings. Although this route is reported to have been partly replaced by an increase in the use of other methods, such 
as throwing drugs over the walls or using drones for drug trafficking, the overall drug availability in prisons is reported 
in many cases to have declined. According to experts, this has contributed to a more general reduction in the use of 
illicit drugs in prisons. Despite some fluctuations since March 2020, overall drug use appears to have remained at lower 
levels than in the pre-COVID-19 period.
The implementation of containment measures has also caused a disruption in the provision of drug services in prison, 
including services that involved people gathering in groups, such as psychosocial and peer-led interventions, and 
services provided by external suppliers.
In this context, efforts have been made to maintain the provision of services in a closed setting, which is subject to 
multiple limitations; innovations were introduced to address those obstacles, including increased use of telemedicine. 
Specific efforts were made to maintain the provision of OST in prison and the prevention and treatment of drug-related 
infectious diseases. Increases in mental health needs of people in prison, including those with drug problems were 
reported.
The emergence of COVID-19 has made the drug-related problem inside prison more visible and the need to address it 
more urgent (Montanari et al., forthcoming).
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prisons across Europe, little is known about the levels of 
coverage and the numbers of people needing treatment. 
Needle and syringe programmes to prevent transmission 
of blood-borne viruses, which are widely implemented in 
the community across Europe, are available in prison in 
only three EU Member States. Considering that prisons are 
high-risk environments for the transmission of blood-borne 
infections, a comprehensive approach to harm reduction 
in prison is expected to play a significant role in the health 
of people in prison and in the community (UNODC et al., 
2013; Michel et al., 2015; Stöver and Hariga, 2016; Stöver 
et al., 2019a).
Compared with the early 2000s, the availability and levels 
of provision of health and social care services targeting the 
needs of people in prison who use drugs have improved 
in several European countries, yet much remains to be 
done to enable prison health services in Europe to provide 
treatment and care in conditions comparable to those 
enjoyed by people in the community.
Obstacles to implementing drug-related interventions 
in prison include prison overcrowding, staff shortages 
and lack of resources. In addition, prisons are places of 
punishment. On the one hand, responding to needs arising 
from illicit behaviours is challenging in the community 
but all the more so in prison settings, where people may 
feel that disclosing their illicit activities carries a bigger 
risk of incurring additional penalties; establishing trust 
between people in prison and healthcare staff is of core 
importance in these settings. On the other hand, public 
sentiment and political will, informed by perceptions on the 
deservedness of people in prison, may negatively affect the 
implementation in prison of interventions widely available 
outside (Stöver et al., 2019a).
Developing a strong evidence base for drug-related 
interventions in prison, through sound operational research 
and programme evaluations that assess the impact on 
people in prison and on the wider community, may work to 
support arguments for allocating resources in this field.
I Care and control
Prison authorities are responsible for the care of the 
people in their custody. They are also responsible for 
maintaining good order and security in prison, including 
tackling the drug supply and violence. Violence in prison 
is often linked to drug use and drug supply, and it is at 
least in part a reflection of both the individuals involved 
and the prison environment. As detailed in Chapter 7, 
a particular challenge when tackling drug supply in prison 
lies in reaching a balance between care and control, and 
understanding that measures introduced to control drug 
supply may have positive and negative impacts on other 
elements of prison life. People in prison can swiftly adopt 
new drug-using practices (EMCDDA, 2018).
The rapid expansion in the use of new psychoactive 
substances has had implications for how prison services 
operate. These substances are easier to conceal than other 
drugs and more difficult to detect through existing security 
systems, and their use in prison has been associated with 
increased paranoia, aggressive behaviour and drug-related 
deaths (EMCDDA, 2018). Since 2014, there have been 
increasing reports of people in prison using synthetic 
cannabinoids as a result of the peculiarity of the prison 
drug market.
Open discussions about new psychoactive substances 
with people in prison are jeopardised by fears of disclosing 
illicit behaviour. A survey conducted in English prisons 
found that over 50 % of people in prison would not seek 
support for fear of potentially incurring penalties and felt 
that prison officers were more concerned with punishment 
than support (User Voice, 2016; Johnson, 2019). In this 
context it is possible that interventions led by peers would 
help to overcome barriers to trust and offer positive role 
models for people in prison. Peer-to-peer interventions can 
also have a broader social impact by building social capital 
and resilience within deprived communities (Fletcher, 
2012; Johnson, 2019). In addition, these interventions may 
facilitate earlier access to information on new drugs or 
drug-using behaviours, which in turn can assist prison and 
healthcare staff in responding in a timely and appropriate 
manner, developing targeted interventions and providing 
relevant information to people in prison. Early identification 
of new patterns of drug use through general screening 
could also facilitate early responses.
Prison authorities have introduced a wide variety of 
measures to detect, deter and disrupt the supply and 
distribution of drugs in prison. New techniques, such as 
drones, new drug testing machines and ‘electronic nose’-
type devices, among others, have been introduced in some 
prisons to support the traditional operational searches 
of people, personal belongings, cells and other spaces, 
and the monitoring and control of people in prison’s 
communications (Chapter 7). There is limited information, 
however, about the impact of these measures, and more 
research is needed to inform policies and practices 
seeking to deter engagement with the prison drug market. 
Drug treatment can work to reduce the pressure on, and 
desire of, individuals to seek out new drugs. A better 
understanding of how drug supply and drug treatment and 
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demand intersect in prison settings may go a long way 
towards a more sustainable and cost-effective deployment 
of drug-related interventions in prison.
The role of prison officers in the delivery of drug treatment 
and harm reduction interventions differs across European 
prisons and has been the subject of some discussion 
(Kolind, 2015). Because prison officers work in close 
proximity with people in prison, they are well placed to 
understand the everyday challenges of life in prison and to 
provide support when needed. Conflicts of duty are likely 
to arise, as prison officers’ responsibility for maintaining 
good order and security may be at odds with their efforts to 
develop trusting and supportive therapeutic relationships. In 
addition, people in prison may hesitate to disclose their illicit 
behaviour to prison officers (Kolind, 2019; Torsten, 2019).
An increasing number of countries are seeking a clear 
demarcation between the delivery of health services and 
the everyday running of prison life, in order to limit potential 
conflicts of duty between providing care and maintaining 
control. The clinical independence of healthcare staff is 
considered important to the provision of good healthcare 
in correctional settings, where the relationship between 
patients and caregivers is not based on free choice and 
where the punitive setting can present challenges for 
providing optimal medical care (Pont et al., 2018). Clinical 
independence also allows healthcare staff to refuse to be 
involved in implementing punitive measures.
Such concerns are one of the factors that have led 
a number of European countries to move the responsibility 
for healthcare in prison from the justice or interior 
ministries to the health ministry. However, while the 
early results from such transfers of the responsibility for 
healthcare are promising, it remains to be further assessed 
and confirmed whether these measures can contribute 
and have contributed to improving the health of people in 
prison and how structural changes can be improved.
I  Drugs and prison: alternative approaches
For a person with experience of illicit drug use in the 
community, a period of imprisonment may be associated 
with a number of negative consequences, including 
encouraging new patterns of drug use, exposure to 
infectious diseases, disruption of drug treatment and 
isolation from support networks. In addition, after 
release, the stigma of a criminal conviction may limit 
job opportunities and reduce the likelihood of social 
rehabilitation.
Several measures have been discussed and implemented 
in European countries that could potentially affect 
imprisonment rates, reducing the number of people 
serving prison sentences or other forms of punishment for 
drug use and other drug-related offences. These include 
decriminalising drug use, abolishing short-term sentences 
of less than 12 months (Gjersing, 2019) and providing 
alternatives to coercive sanctions.
A recent study modelled the effects of possible drug 
policy scenarios in Norway. It found that abolishing 
incarceration for use and possession of illicit drugs would 
result in an 18 % reduction in incarceration episodes, 
but that abolishing incarceration for all drug-related 
crimes (those committed to support drug use, offences 
for drug use regardless of quantity, production and drug 
trafficking) would result in a reduction of almost 60 % of 
incarceration episodes (Gjersing, 2019). Other studies 
have argued that diverting offenders with problematic drug 
use patterns towards rehabilitative measures and away 
from incarceration may have a number of positive effects, 
such as avoiding the damaging effects of detention and 
contributing to reducing the costs of the prison system 
(White, 2017).
Alternatives to prison are a specific type of alternative to 
coercive sanctions, meant as a measure with a retributive 
aim, taking place outside prison. While ‘alternatives to 
conviction or coercive sanctions’ emphasises the aim of 
the policy response, ‘alternatives to prison’ emphasises 
the setting. Alternatives to prison include receiving 
a suspended sentence conditional on attending drug 
treatment or agreeing to undergo treatment in prison that 
shortens the incarceration period (Kruithof et al., 2016).
Alternatives to coercive sanctions have been implemented 
in many countries in Europe, with a particular focus 
on high-risk drug users. The policy arguments for 
implementing these measures run along two lines: 
reducing harm to the individual and society caused by 
high-risk drug use; and addressing the structural burdens 
on the justice system arising from low-risk drug users, that 
is, to reduce the burden on the criminal justice system 
by avoiding prosecuting some drug offences, such as 
possession. The lack of clarity in choosing one of the two 
objectives often creates ambiguity and may lead to a loss 
of political support for rehabilitative measures. While it is 
widely agreed that the general deterrent of punishment 
has little effect on consumption levels of illicit drugs, drug 
use and its associated problems continue to be considered 
primarily a criminal justice matter by many, and measures 
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moving away from punitive sentencing continue to meet 
with some resistance.
Few countries in Europe have chosen to adopt widespread 
rehabilitative approaches. Where such policies are 
adopted, they are often implemented without robust 
monitoring or evaluation, despite the fact that investment 
in these could show dividends in the long run by providing 
information that can be used to improve the efficiency 
and effectiveness of the programmes. But, even if the 
resulting evidence is not strong, the key to success seems 
to be having a range of interventions available that can 
be matched appropriately to the needs of individuals with 
different types and levels of drug problems (EMCDDA, 
2015). Studies are needed to improve the evidence base 
around alternatives to coercive sanctions, with particular 
attention being paid to the groups that can benefit most 
from them and to the stages of the criminal justice process 
at which they are best applied.
I Implications for policy and practice
European countries have a unique opportunity to 
understand and tackle the impact of the intersection 
between drugs and prison by adopting a pragmatic and 
evidence-based approach to the health and social care 
needs of people in prison with drug-related problems. 
A number of key issues with implications for policy and 
practice are highlighted below.
• The principles of equivalence of care and continuity of 
care require the provision of the same range of evidence-
based interventions for people with drug problems 
who are in prison as in the community, provided by 
staff properly qualified for treating addiction (whether 
prison staff or outside professionals), and mechanisms 
to ensure continuity of treatment; this is especially 
important for those incarcerated for short periods.
• International institutions provide recommendations 
for a whole-of-government responsibility in the 
management of health care in prison (WHO guidance) 
and provision of harm reduction measures in prison 
(UN/WHO guidance).
• Health and social care responses in prison may have 
a significant impact on the morbidity and mortality of 
the prison population, and on the community outside 
prison, with a significant overall public health benefit. 
First, by engaging people with drug-related problems 
in treatment, their drug use and risk behaviours in 
prison and overdose risks on release may be reduced; 
and second, by offering testing for infectious diseases 
to everybody on entry to prison and following up with 
treatment as needed, the prevalence of infectious 
disease in prison population, including among those 
with drug problems can be reduced.
Key interventions addressing drug-related problems in 
prisons include:
• health assessments on entry to prison, including 
an assessment of drug use and related problems;
• targeted prevention of the risk factors common 
to both drug use and imprisonment, including 
interventions that address multiple adverse 
childhood experiences;
• a full range of drug treatment interventions, 
including OST for those with opioid use problems;
• interventions targeting risk behaviours and 
infectious diseases, including harm reduction 
measures and the prevention and treatment of 
infectious diseases — offering infectious disease 
testing to every person on entry to prison would 
be an important starting point;
• tackling the risk of overdose associated 
with release from prison through a range of 
interventions in preparation for release, including 
continuity of treatment and referral to outside 
services, and overdose prevention activities with 
consideration given to the provision of take-home 
naloxone;
• preparation for release that includes activities to 
support the social reintegration of people with 
drug problems.
• Alternatives to coercive sanctions are implemented 
in several countries for people with high-risk patterns 
of drug use who commit criminal offences. It is widely 
recognised that punishment is not a deterrent to drug 
use and some studies have shown a potential effect 
of such alternative measures on reducing offending 
and drug use (Kruithof et al., 2016). More studies 
are needed to improve the evidence base on the 
effectiveness of these measures.
• It is important to increase the transfer of best 
practices by collecting and disseminating best practice 
interventions and existing guidance on effective drug-
related interventions in prison.
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• It is necessary to scale up effective interventions 
and aim for the full implementation of drug-related 
interventions in prison for which the evidence for 
effectiveness is strong.
• Improving the evidence on health and social care 
interventions in prison, and on the needs of people in 
prison with drug-related problems, including minority 
groups such as women, LGBT people and foreign 
nationals, is important. Data on the various issues 
surrounding drugs and prison in Europe can inform 
needs assessment, service planning and treatment 
organisation and offer a window to the profile and 
needs of people with drug-related problems in the 
community.
• Enhancing monitoring and research in prisons is 
an essential requirement to generate the evidence 
needed for the provision of appropriate interventions 
on prison and drugs. Harmonisation of data collection 
across European countries, especially regarding 
data comparability, is important if the value of the 
information collected is to be realised. This is true for 
comparing experiences, issues and solutions between 
countries, and for facilitating the exchange and 
promotion of best practice in drug-related interventions 
in Europe. Increasing the synergies between 
international organisations will help to avoid duplication 
and ensure the validity of data.
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I Abbreviations
ADHD attention deficit-hyperactivity disorder
BBV Blood-borne virus
CPT European Committee for the Prevention of Torture
ECDC European Centre for Disease Prevention and Control
ECHR European Convention of Human Rights
ECtHR European Court of Human Rights
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EQDP European questionnaire on drug use among people living in prison
HA-REACT Joint Action on HIV and Co-infection Prevention and Harm Reduction
HBV hepatitis B virus
HCV hepatitis C virus
HIPED Health in Prisons European Database
HIPP health in prison programme (WHO)
HIV human immunodeficiency virus
LGBT lesbian, gay, bisexual and transgender
NGO non-governmental organisation
NICE National Institute for Health and Care Excellence (UK)
OST opioid substitution treatment
SDG (UN) Sustainable Development Goal
SMR Standard Minimum Rules for the Treatment of Prisoners
TB tuberculosis
UNODC United Nations Office on Drugs and Crime
Wephren Worldwide Prison Health Research and Engagement Network
WHO World Health Organization

GETTING IN TOUCH WITH THE EU
In person
All over the European Union there are hundreds of Europe Direct 
Information Centres. You can find the address of the centre nearest 
you at: http://europa.eu/contact
On the phone or by e-mail
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service 
  by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge 
for these calls), 
  at the following standard number: +32 22999696 or
  by electronic mail via: http://europa.eu/contact
FINDING INFORMATION ABOUT THE EU
Online
Information about the European Union in all the official languages of 
the EU is available on the Europa website at: http://europa.eu  
EU Publications
You can download or order free and priced EU publications from 
EU Bookshop at: http://bookshop.europa.eu. Multiple copies of free 
publications may be obtained by contacting Europe Direct or your 
local information centre (see http://europa.eu/contact)
EU law and related documents
For access to legal information from the EU, including all EU law 
since 1951 in all the official language versions, go to EUR-Lex at: 
http://eur-lex.europa.eu
Open data from the EU
The EU Open Data Portal (http://data.europa.eu/euodp/en/data) 
provides access to datasets from the EU. Data can be downloaded 
and reused for free, both for commercial and non-commercial 
purposes.
About this series
EMCDDA Insights are topic-based reports that bring 
together current research and study findings on a 
particular issue in the drugs field. This publication 
provides an overview of current knowledge and the 
latest developments in the field of drug use and 
prison in Europe. The report explores in depth the 
epidemiology of drug use and drug-related problems 
among the prison population, the available social and 
health service responses to drug-related problems 
in prison, including the most recent evidence of 
effectiveness, and the drug supply and markets inside 
prison. It also discusses recent and future challenges in 
this area. The report will be of interest to policymakers 
and their advisors, specialists and practitioners, 
researchers and scientists and all those concerned with 
the issue of prison and drugs. 
About the EMCDDA
The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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